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Abstract 
Detergent-free solubilisation using a polymer of styrene maleic acid (SMA) has proven useful in 
the study of membrane proteins. SMA was employed to solubilise G-protein-coupled receptors 
(GPCRs) from mammalian cells, into SMA lipid particles (SMALPs). Optimal SMALP-
solubilisation conditions were determined to be 2 % (w/v) SMA, at 37 °C for 1 h retaining wild-
type (WT)-like pharmacological profiles and conferring improved stability on GPCRs over 
detergent micelles. 
Endoplasmic reticulum (ER)-retention motifs –KDEL and –KHILFRRRRRGFRQ were found not 
to be applicable to all proteins. Study of SMALP-solubilisation of intracellular membranes was 
prevented by the inability to retain the adenosine 2a receptor (A2aR) in the ER. A cysteine-nul 
A2aR construct was produced containing two reporter groups and behaved as WT-A2aR. This 
construct is ready for use in fluorescence studies to further understanding of A2aR and the use of 
SMALPs in biophysical techniques. 
A range of GPCRs, from different GPCR subfamilies, were SMALP-solubilised with retention of 
ligand binding capability. Methods were successfully developed to reduce non-specific binding 
arising from ionic interactions of ligand and SMA. Finally, in a world first, the SMA analogue 
styrene maleimide, was shown to solubilise GPCRs with retention of ligand binding capability. 
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Throughout this thesis, abbreviations are used as recommended by the Journal of Biological 
Chemistry. In addition, the following abbreviations have been used: 
A1R   adenosine 1 receptor 
A2aR   adenosine 2a receptor 
A2bR   adenosine 2b receptor 
A3R   adenosine 3 receptor 
Amy1-3   amylin receptor 1-3 
AVP   [arginine8]vasopressin 
BSA   bovine serum albumin 
bp   base pairs 
cAMP   cyclic 3’-5’-adenosine monophosphate 
CD   circular dichroism 
cDNA   complementary DNA 
CHS    cholesteryl hemisuccinate 
CTR   calcitonin receptor 
CXCR1  chemokine receptor type 1 
DAG   diacylglycerol 
DDM    n-dodecyl β-D-maltoside 
ECL   extracellular loop 
E.coli    Escherichia coli 
EDTA   ethylenediaminetetraacetic acid 
EGTA   ethyleneglycoltetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
ER   endoplasmic reticulum 
FRET   Förster resonance energy tranfer 
G-protein  guanine nucleotide binding protein 
GDP   guanosine diphosphate 
GPCR   G-protein-coupled receptor 
GTP   guanosine triphosphate 
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HA   haemagluttinin 
HRP    horseraddish peroxidase 
IAEDANS  5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic  
   acid 
ICL   intracellular loop 
InsP3   inositol 1,4,5-trisphosphate 
M1R   muscarinic acetylcholine receptor 1 
MT-cells  mock transfected cells 
MW   molecular weight 
Nanodiscs  apolipoprotein stabilised nanodiscs 
NECA  n-ethylcarboxamidoadenosine 
NDI   nephrogenic diabetes insipidus 
NMR   nuclear magnetic resonance 
NMS   n-methyl scopolamine 
OT   oxytocin 
OTR   oxytocin receptor 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PEI   polyethylenimine 
RAMP   receptor activity modifying protein 
sCT   salmon calcitonin 
SDS   sodium dodecyl sulphate 
SMA   styrene maleic acid 
SMALP  styrene maleic acid lipid particle 
SMI   styrene maleimide 
SMILP  styrene maleimide lipid particle 
TM   transmembrane 
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TMD    transmembrane domain 
V1aR   vasopressin 1a receptor 
V1bR   vasopressin 1b receptor 
V2R   vasopressin 2 receptor 
WT   wild-type 
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α2c-AR   α2c adrenergic receptor 
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1 CHAPTER 1: INTRODUCTION 
1.1 G-protein-coupled receptors 
Coded for by approximately 4 % of the entire human genome there are over 800 distinct 
types of G-protein-coupled receptors (GPCRs), making them the largest family of 
membrane proteins (Fredriksson et al., 2003). GPCRs have become an important target for 
the pharmaceutical industry due to their abundance and role in a wide range of biological 
processes. Currently around 40 % of all clinically available drugs target GPCRs (Rask-
Andersen et al., 2011). 
1.2 G-proteins 
GPCRs are primarily identified through their ability to signal through heterotrimeric 
guanine nucleotide binding proteins (G-proteins). G-proteins consist of three subunits: Gα, 
Gβ and Gγ. Gα is the largest of the subunits and contains the guanine nucleotide binding 
site with intrinsic GTPase activity. In the inactive state, Gα is GDP-bound. The Gβ and Gγ 
subunits are tightly linked to each other and non-covalently bound to the Gα subunit in the 
inactive state. Active GPCRs induce GDP exchange for GTP in the Gα subunit. The 
mechanisms by which this occurs have been elucidated from crystallographic data, 
including a Gα subunit (Gαs) coupled to the β2 adrenergic receptor in an active confromation 
(Oldham and Hamm, 2008, Rasmussen et al., 2011b, Chung et al., 2011). GTP binding at 
the Gα subunit results in dissociation of the functional subunits Gα and Gβγ to mediate their 
effects through effector molecules. G-protein signalling continues until GTP is hydrolysed 
by the intrinsic GTPase activity of the Gα subunit, driving reassociation of GDP-bound Gα 
with Gβγ. 
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There are 16 known Gα subtypes which are classified into 4 main families: Gαs, Gαi, Gαq/11 
and Gα12 (Simon et al., 1991). Gαs and Gαi stimulate and inhibit, respectively, adenylyl 
cyclase. Adenylyl cyclase produces cyclic-adenosine 3’-5’-monophosphate (cAMP) to 
regulate cAMP-dependent protein kinases and some guanine nucleotide exchange factors. 
Gαq stimulates phospholipase C to produce: inositol 1,4,5-trisphosphate (InsP3), stimulating 
calcium release from the endoplasmic reticulum (ER) and diacylglycerol (DAG) for 
activation of protein kinase C. Gα12 subunits produce their effect through Rho family 
GTPases involved in cytoskeletal rearrangements. The activation and intracellular effects of 
G-proteins are summarised in figure 1.1 (Ritter and Hall, 2009). 
1.3 GPCR classification 
Across the superfamily, GPCRs share a characteristic 7 transmembrane (7TM) helical 
bundle connected by alternating intracellular and extracellular loops (ICL and ECL 
respectively). They also possess an extracellular amino (N-) terminus and intracellular 
carboxyl (C-) terminus (shown in figure 1.2). Despite the conservation of overall structure, 
there is little sequence homology across the GPCR superfamily. However, groups of GPCRs 
do share some sequence homology and characteristic motifs. This has allowed for GPCRs 
to be subcategorised by the family A-F system (Kolakowski, 1994). Human GPCRs can be 
further subcategorised by the GRAFS system into: glutamate, rhodopsin-like, adhesion, 
frizzled/smoothened and secretin-like (Fredriksson et al., 2003). 
Families A-C are the three major GPCR subfamilies. Ligand binding at family A and B 
GPCRs involves an orthosteric ligand binding site at the TM core. However, as 
demonstrated in figure 1.3, family C GPCRs possess a long N-terminal sequence (~ 580 
residues), structured to form a “Venus flytrap” orthosteric binding site for the endogenous   
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Figure 1.1. G-protein signalling pathways. GPCR activation of G-proteins resulting in 
functional Gα and Gβγ subunits that produce signals through effector molecules. Gαs and 
Gαi stimulate and inhibit adenylyl cyclase respectively, responsible for cAMP production. 
Gαq stimulates phospholipase C to produce InsP3 and DAG. Gα12/13 modulate Rho GTPases. 
The second messenger molecules are involved in protein activation, calcium homeostasis 
and cytoskeletal arrangement. Image taken from Ritter and Hall, 2009. 
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Figure 1.2. Schematic representation of the general structure of a GPCR. The 7 
transmembrane helices, characteristic of GPCRs, are shown in blue, numbered 1-7 and 
connected by alternating intracellular loops (ICL1-3) and extracellular loops (ECL1-3). The 
GPCR is embedded in the membrane with the extracellular N-terminus connected to TM1 
and intracellular C-terminus connected to TM7. 
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ligand (Pin et al., 2003). Family C includes the metabotropic glutamate receptors (mGluR) 
1-5. The structure of the TM domain of mGluR1 has recently been solved through x-ray 
crystallography (Wu et al., 2014) and was shown to possess similar architecture to family 
A and B GPCRs. This common architecture, exemplified in figure 1.4, has each helix tilted 
differently in relation to the membrane bilayer and several kinked helices (Krebs et al., 
2003). Also, despite the ECLs being regions of low sequence homology within and between 
subfamilies, there is a highly conserved Cys-Cys disulphide bridge tethering ECL2 to the 
top of TM3 (Wheatley et al., 2012, Wu et al., 2014). The conserved architecture is likely to 
be important to the fundamental mechanisms of signal transduction, resulting in GPCR 
signalling through G-proteins. However, with so little sequence homology across the GPCR 
superfamily, the residues and motifs employed to maintain this structure differ between 
subfamilies. 
1.3.1  Family A GPCRs 
Family A is comprised of > 700 GPCRs, making it by far the largest of the GPCR 
subfamilies. As a result of the number of distinct GPCRs, there is a wide range of ligands 
that interact with, and produce their effect through family A. Although the size and type of 
ligand can vary, from small biogenic amines to peptides (Strader et al., 1994), the ligand 
will bind the orthosteric binding site in the TM core of the GPCR. For small molecule 
ligands the orthosteric binding pocket is deep in the TM core. As a result small molecule 
ligands do not form interactions with ECLs (Tota and Strader, 1990). Peptide ligands 
however, are larger than small molecule ligands such as biogenic amines. As a result they 
form interactions with the TM core and the extracellular domains to promote their effect. 
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Figure 1.3. The difference in N-terminal domains and orthosteric binding sites from 
family A-C. Family A GPCRs typically contain the shortest N-terminus of families A-C 
and the orthosteric binding pocket for ligands is in the TM core with some contacts at the 
ECLs. Family B, with a larger N-terminus than family A, has more ligand contacts in the 
N-terminus but the orthosteric binding site is at the TM bundle. Family C possess the largest 
N-terminus of the 3 families which is the orthosteric binding site for ligands, with only small 
molecule ligands binding the allosteric site in the TM bundle. Adapted from Wu et al., 2014. 
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Figure 1.4. Crystal structure of the dopamine D3 receptor. Transmembrane helices, 
yellow, labelled with roman numerals, are connected by annotated ICLs and ECLs. At the 
centre is the dopamine receptor antagonist eticlopride bound to the orthosteric binding 
pocket of this family A GPCR. Image taken from (Chien et al., 2010). 
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The conformational changes induced by ligand binding to family A GPCRs are controlled 
through a series of highly conserved residues and motifs that typify family A GPCRs 
(Mirzadegan et al., 2003). Highlighted in figure 1.5 are highly conserved motifs (in blue) 
and the most highly conserved individual residues of each TM helix (in red). Identification 
of the latter has allowed a common numbering system for residues across family A GPCRs. 
This allows the comparison of similarly positioned residues between family A GPCRs 
(Ballesteros and Weinstein, 1995). In the Ballesteros-Weinstein numbering system, the most 
highly conserved residue in each TM-helix is a reference point denoted as X.50 (where X is 
the TM number). Residues following X.50 are denoted as an increase from 50 and preceding 
residues as a decrease from 50. For example 3 residues before the most highly conserved 
residue of TM1 (1.50) would be referred to as 1.47. 
The E/DRY motif is one of the most highly conserved motifs across family A. R3.50, located 
at the bottom of TM3 interacts with an acidic residue in TM6(6.30) (Scheer et al., 1996, 
Palczewski et al., 2000). This is referred to as the “ionic lock” as it constrains GPCRs in an 
inactive conformation. Upon GPCR activation, the ionic lock is broken and R3.50 forms 
interactions with Y5.58 (Park et al., 2008), allowing movement of TM6 away from TM3. 
This movement is based around the CWxP motif and is the basis for GPCR signal 
transduction to G-proteins. P6.50 in CWxP induces a pronounced kink in TM6, modulated 
by W6.48, termed the “rotamer toggle switch”. This allows the extracellular side of TM6 to 
move towards TM3 upon agonist binding. The result is the intracellular side of TM6 moves 
away from TM3, opening the G-protein binding pocket (Shi et al., 2002, Ruprecht et al., 
2004, Schwartz et al., 2006). Stability of active conformations is thought to be based around 
the NPxxY motif in TM7. N7.49 of NPxxY is believed to stabilise the active conformation 
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Figure 1.5. Schematic representation of a family A GPCR. Transmembrane helices are 
numbered with roman numerals (I-VII). The most highly conserved residues of each helix 
are displayed in red with their Ballosteros-Weinstein number displayed (Ballesteros and 
Weinstein, 1995). Highly conserved motifs are displayed in blue. Conserved Cys-Cys 
disulphide bridge is demonstrated by a thick red line. Zig-zag black lines indicate 
palmitoylation and black branches indicate sites of glycosylation. 
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through interactions with N1.50 and D2.50 (Govaerts et al., 2001, Urizar et al., 2005). Upon 
activation Y7.53 causes Y5.58 to move into the helical bundle, allowing its interaction with 
R3.50 (Fritze et al., 2003, Standfuss et al., 2011). 
1.3.2  Family B GPCRs 
Family B GPCRs have a characteristic N-terminus of ~100-160 residues. This is a large N-
terminus in relation to family A GPCRs, but not as large as family C GPCRs (~580 
residues). The increased size of the family B N-terminus is required for identification of 
their large peptide ligands (~30-40 residues). Family B are receptors for 15 peptide 
hormones that are grouped into 5 subfamilies. Peptide ligands bind to family B GPCRs via 
a two-domain model (Hoare et al., 2004). Initially, the C-terminus of the peptide ligand 
binds the large N-terminus of the GPCR. This then orientates the N-terminus of the ligand 
to bind to the top of the TM domain (TMD). The extracellular surface of the TMD is held 
in a chalice-like conformation, as determined through two solved structures of family B 
GPCR TMDs (Hollenstein et al., 2013, Siu et al., 2013).  
Family B GPCRs contain a largely different set of conserved residues and motifs. One 
residue, Y7.53 of family A, has an equivalent tyrosine in TM7 of family B GPCRs that 
occupies a similar position. No crystal structures of an agonist bound active family B GPCR 
have been published so it is unknown whether it has a similar role in receptor activation. 
However, as family B GPCRs do not contain the E/DRY ionic lock motif, it is unlikely to 
perform an identical role in family B. There is an alternative ionic lock mechanism in some 
family B GPCRs, which stabilises an inactive state by tethering TM2 to TM3. Sequence 
homology has shown a conserved GWGxP motif in TM4 of family B GPCRs. The role for 
this GWGxP motif is believed to be structural, based around the kink formation of proline 
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residues in a helix. However, the exact role for this motif is unclear as the two crystal 
structures of inactive family B TMDs show this motif in different conformations. 
Some family B GPCRs have the ability to interact with receptor activity modifying proteins 
(RAMPs) (McLatchie et al., 1998). RAMPs are a small family of 3 proteins (named 
RAMP1-3) which consist of an N-terminus (~90-103 residues), a single transmembrane 
spanning helix (~22 residues) and a short C-terminus (~9 residues). RAMPs form 
complexes with some family B GPCRs to produce an altered receptor pharmacology. The 
structured N-terminus of RAMPs is the main site of interaction with GPCRs and the main 
determinant of the pharmacology of the resulting complex (Fraser et al., 1999, Zumpe et al., 
2000). Spontaneous hetero-dimerisation with RAMPs, ubiquitously expressed in all cell 
types studied (Sexton et al., 2001), has introduced extra complexity to the study of family 
B GPCRs. 
1.4 Post-translational modifications 
There are several post-translational modifications that are conferred to GPCRs. Their effect 
on structure and function seems to vary between GPCRs. Palmitoylation of cysteine residues 
in the C-terminus can lead to the formation and anchoring of an 8th helix to the membrane, 
as seen in some crystal structures (Palczewski et al., 2000). This has been shown to play a 
role in structure and function of some GPCRs (Hawtin et al., 2001). Ubiquitination is the 
application of ubiquitin to the intracellular domains of GPCRs. Ubiquitin is a determinant 
of GPCR fate upon endocytosis, presence of ubiquitin targets the GPCR to lysosomes for 
degradation (Ciechanover, 2010). 
Most GPCRs undergo glycosylation of their extracellular domains before trafficking to the 
cell surface. Glycosylation involves the addition of an oligosaccharide to the Asn or Ser/Thr 
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of an NxS/T motif. There are two forms of glycosylation: in N-linked glycosylation, 
performed initially in the ER and refined in Golgi apparatus, the oligosaccharide is linked 
to the nitrogen of asparagine; O-linked glycosylation, performed in the Golgi apparatus, is 
rare in GPCRs but can occur as oligosaccharides are linked to hydroxyl groups of serine or 
threonine. Glycosylation can result in a variety of oligosaccharide chains being attached to 
the GPCR. Different oligosaccharide chains, created from different combinations of 
saccharides, can be applied. This results in unpredictable molecular weights of glycosylated 
proteins (Wheatley and Hawtin, 1999). The role of glycosylation varies depending on the 
GPCR. It has been demonstrated that glycosylation is largely important for correct protein 
folding and transport to the membrane (Zhang et al., 1995, Davidson et al., 1996). For some 
receptors glycosylation has been shown to be important in correct protein function, as 
demonstrated by ligand binding and G-protein interaction (Rands et al., 1990). Other 
receptors have no known functional implications of glycosylation (van Koppen and 
Nathanson, 1990, Piersen et al., 1994, Kimura et al., 1997). 
1.5 Models for GPCR activation and signalling 
The idea that GPCRs were inactive until agonist bound, at which point coupling and 
signalling through G-proteins was permitted, is insufficient to explain the complex nature 
of GPCR signalling. Models of GPCR activation have been proposed and extended as the 
complexity of GPCR signalling has been elucidated from experimental data. The original 
ternary complex model explained the ability of a GPCR to bind an agonist, leading to 
signalling via an intracellular intermediary (De Lean et al., 1980). This was found to be 
insufficient when constitutively active GPCRs were observed. The extended ternary 
complex incorporated constitutive activity to explain agonist independent signalling via G-
13 
 
proteins. This investigation also elucidated the effect of G-protein pre-coupling to GPCRs, 
increasing agonist affinity of GPCRs (Samama et al., 1993). A progression on the extended 
ternary complex model was the cubic ternary complex model (Weiss et al., 1996). This 
explained the ability of receptors to form complexes with G-proteins, without signalling, in 
the presence of an inverse agonist. 
The basis for each of the ternary complex models is that GPCRs signal only through G-
proteins. However, it has also been shown that GPCRs signal through G-protein 
independent pathways. This has been well documented to involve β-arrestin. It has long 
been understood that β-arrestins prevent GPCR:G-protein coupling. According to previous 
models, this should decrease GPCR agonist affinity, instead the opposite was observed 
(Gurevich et al., 1997). β-arrestins act as protein scaffolds, by drawing together different 
components of signalling pathways within close proximity of each other, they facilitate 
GPCR signal transduction without G-proteins (DeWire et al., 2007). Since the discovery 
that GPCRs signal via different pathways than just G-proteins, agonists have been identified 
that can preferentially signal through specific pathways. The ability of “biased agonists” to 
signal through specific pathways is facilitated by the close proximity of the GPCR and the 
appropriate transducer as a result of β-arrestin acting as a protein scaffold (Strachan et al., 
2014). Although precise mechanisms underlying biased agonism are not fully understood, 
there is great interest from pharmaceutical companies to design and create biased agonists. 
The ability to signal through one pathway, while antagonising others, thus reducing side-
effects from low specificity, could lead to the discovery of much safer drugs (Whalen et al., 
2011, Kenakin, 2012). 
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1.6 Inactivation of GPCR signalling 
GPCR signal regulation is essential and can be effected through several mechanisms. 
Signalling via second messenger molecules: cAMP, InsP3 and DAG is stopped by: cAMP 
phosphodiesterases (cleavage of cAMP into phosphate and adenosine), phosphatidylinositol 
phosphatases (cleavage of InsP3 into inositol and phosphates) and diacylglycerol kinases 
(applies phosphates to diacyglycerol) respectively (Luttrell, 2008). Regulation of signalling 
can occur upstream of second messengers. The inherant GTPase activity of the Gα subunit 
can be increased, deactivating the G-protein and preventing its signalling through 
reassociation with Gβγ (Ross, 1995, Ross and Wilkie, 2000). Regulation of the GPCR upon 
agonist binding is presented in figure 1.6. Within seconds of agonist exposure the GPCR is 
desensitised, preventing GPCR:G-protein coupling. Initially, serine and threonine residues 
on the intracellular loops and C-terminus of the GPCR are phosphorylated by G-protein-
coupled receptor kinases (GRKs). This has been shown to uncouple GPCR:G-protein 
interactions in some cases (Pitcher et al., 1992). GPCR:G-protein coupling is completely 
prevented when arrestin molecules interact with the phosphorylated residues of the GPCR 
and occupy the TM-core (Gurevich and Gurevich, 2004, Shukla et al., 2013, Shukla et al., 
2014). Longer-term regulation of GPCR signalling involves sequestration. Arrestins contain 
a C-terminal motif that binds to clathrin and β2-adaptin of the adaptin complex AP-2 
(Goodman et al., 1996, Laporte et al., 1999). The GPCR then undergoes clathrin-coated pit 
mediated endocytosis. Upon endocytosis the GPCR faces one of two fates: dissociation from 
arrestin and subsequent recycling to the cell surface or lysosomal degradation as a 
GPCR:arrestin complex (Oakley et al., 1999). 
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Figure 1.6. Mechanisms of GPCR inactivation. Agonist binding to GPCRs results in G-protein mediated intracellular signalling. Phosphorylation 
of GPCR intracellular domains by G-protein-coupled receptor kinases (GRK) is followed by arrestin recruitment, preventing GPCR:G-protein 
coupling leading to GPCR desensitisation. Arrestin targets the GPCR to clathrin-coated pits and is sequestered by endocytosis to be either lysosomally 
degraded or recycled back to the cell surface. Image taken from Ritter and Hall, 2009. 
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1.7 Adenosine 
Adenosine is a small molecule with an approximate molecular weight (MW) of 267 Da. A purine 
nucleoside, adenosine is often produced as a result of the breakdown of adenine nucleosides and 
adenosine phosphates. In the human body, in cells and tissue fluid, adenosine is present at 10-200 
nM as a resting concentration, this rises to ~30 μM under biological stress (Fredholm, 2010). First 
identified as a signalling molecule in 1929 (Drury and Szent-Gyorgyi, 1929), adenosine is the 
endogenous ligand for a subsect of family A GPCRs known as adenosine receptors. 
1.7.1  Adenosine receptors 
The ability of adenosine receptors to bind adenosine and stimulate or inhibit cAMP production 
was first identified in 1979 (van Calker et al., 1979). Since then, sequence homology and the 
ability of adenosine receptor subtypes to produce different responses has lead to the identification 
of 4 distinct adenosine receptors (Londos et al., 1980, Bruns et al., 1986, Zhou et al., 1992). The 
major roles of adenosine receptor subtypes A1 (A1R), A2a (A2aR), A2b (A2bR) and A3 (A3R) are 
summarised in table 1.1. The overall role of adenosine receptors is for cytoprotection (Fredholm, 
2007). A2aR is one of the most thoroughly studied GPCRs. The structure of A2aR has been solved 
9 times in inactive (Dore et al., 2011) and active (Xu et al., 2011) conformations. Interest in 
adenosine receptors is high due to their cytoprotective nature. Development of better drugs at 
adenosine receptors is believed to aid treatment of: cardiac arrest (by targeting A1R), 
neurodegenerative disorders Alzheimer’s disease and Parkinson’s disease and 
immunosuppression for graft versus host disease (A2aR), nociception (A2bR) and inflammation 
associated with immune response (A3R). 
There exists a library of well characterised ligands with defined specificities for each adenosine 
receptor. Among the vast library of adenosine receptor ligands there are adenosine analogues such   
17 
 
 
 
 
 
 
 
Adenosine receptor 
subtype 
G-protein Major physiological roles 
A1R Gi Bradychardia and antinociception 
A2aR Gs 
Vasodilation, inhibition of platelet aggregation and 
ischaemic damage limitation 
A2bR Gs 
Monocyte and macrophage inhibition and vascular 
smooth muscle relaxation 
A3R Gi Promotes mediator release from mast cells 
 
Table 1.1. Physiological roles of adenosine receptor subtypes. Physiological roles affected by 
adenosine receptor subtypes and the G-protein they are mediated through. 
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as NECA, which have been developed as agonists (figure 1.7). Regadenoson is an agonist at A2aR 
that has FDA approval for use in medical studies of the heart. Xanthine analogues such as caffeine, 
approved for use in treatment of Parkinson’s disease, and ZM241385 are adenosine receptor 
antagonists (figure 1.7). Other antagonists of adenosine receptors that have FDA approval for use 
in Parkinson’s disease treatment are theophylline and istradefylline, both of which are caffeine 
analogues. 
1.8 Neurohypophysial hormones 
Oxytocin (OT) and [Arg8]vasopressin (AVP) (figure 1.8) are the canonical neurohypophysial 
hormones. OT and AVP are structurally similar nonapeptides containing a Cys1-Cys6 disulphide 
bond. The two hormones differ in sequence in two positions: Ile3 and Leu8 of OT are Phe3 and 
Arg8 in AVP. Synthesised in the hypothalamus, they are released into the blood stream to travel 
to their receptors and effect their response. 
1.8.1  Neurohypophysial hormone receptors 
Upon OT binding, the oxytocin receptor (OTR) stimulates contraction of the uterus during labour 
and lactation from mammary glands (Soloff et al., 1979). OTR is a family A GPCR that signals 
through the Gq-coupled pathway. OTR binds OT with high affinity but also binds AVP with high 
affinity, however OT behaves as a full agonist, while AVP acts as a partial agonist, displaying 
reduced efficacy compared to OT (Wootten et al., 2011).  
AVP acts as a full agonist at three receptor subtypes: vasopressin 1a, 1b and 2 receptors (V1aR, 
V1bR and V2R respectively) (Michell et al., 1979). Each of the three vasopressin receptor subtypes 
is a family A GPCR. V1aR is responsible for the majority of the effects of AVP. AVP binding to 
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Figure 1.7. Ligands for the adenosine receptor family of GPCRs. (A) adenosine, the 
endogenous ligand for adenosine receptors, is constructed of the purine adenine and ribose. (B) 
NECA is a synthetic adenosine analogue that is an agonist at the adenosine receptors. (C) caffeine 
is one of the most commonly used drugs in the world and acts as an antagonist at adenosine 
receptors. (D) ZM241385 is a synthetic inverse agonist at adenosine receptors. 
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Figure 1.8. Structure of oxytocin and AVP. Structure and peptide sequence of the nonapeptides oxytocin and AVP are displayed on the left and 
right respectively. 
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V1aR results in: contraction of smooth muscle (Penit et al., 1983); increased glycogenolysis 
(Howl et al., 1991); modulation of insulin secretion (Dunning et al., 1984) and platelet 
aggregation (Filep and Rosenkranz, 1987). V1aR signals via the Gq-coupled pathway, as does 
V1bR responsible for adrenocorticotropic hormone release (Gillies et al., 1982). V2R is 
expressed predominantly in the kidneys where it plays a key role in antidiuresis (Jard et al., 
1975), signalling via the Gs-coupled pathway. 
1.9 Acetylcholine and muscarinic receptors 
Acetylcholine is a small molecule that acts in signal transmission across synapses. 
Acetylcholine is a low affinity agonist at muscarinic receptors which are expressed throughout 
the central and peripheral nervous systems. Members of GPCR family A, the muscarinic 
acetylcholine receptors have 5 subtypes: muscarinic acetylcholine receptors 1-5 (M1-5R) 
(Peralta et al., 1987, Bonner et al., 1988). M2R and M4R both signal via the Gi-coupled 
pathway, whereas M1R, M3R and M5R signal through the Gq-coupled pathway. Muscarinic 
acetylcholine receptors have been implicated in several diseases, such as: Alzheimer’s disease, 
schizophrenia and diabetes (Wess et al., 2007), making them popular targets for drug 
development. Structure-based drug design will have been aided by the solved crystal structures 
of: antagonist-bound M2R (Haga et al., 2012) and M3R (Thorsen et al., 2014) as well as 
agonist-bound M2R (Kruse et al., 2013). 
1.10 Calcitonin and amylin 
Calcitonin is a peptide of 32 residues involved in protection of the skeleton during periods of 
high calcium requirement (Wimalawansa, 1997). As a member of the calcitonin gene peptide 
superfamily, calcitonin is closely related to calcitonin gene-related peptide (involved in 
vasodilation) and amylin. Amylin is secreted from pancreatic cells and works to decrease the 
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requirement of insulin by slowing the influx of glucose into the bloodstream following a meal 
(Pittner et al., 1994). 
The calcitonin receptor (CTR) is a family B GPCR that signals through the Gs-coupled 
pathway. The endogenously expressed calcitonin subtype in humans will only bind to CTR in 
the absence of RAMPs (Hay et al., 2005). CTR interaction with RAMPs creates high affinity 
amylin receptors named AMY1-3 based on the RAMP they associate with (Armour et al., 1999). 
This has made study of CTR difficult as all cell types express at least one form of RAMP 
(Sexton et al., 2001). However, the unique pharmacological profiles of each amylin receptor in 
comparison to each other and CTR can allow identification of specifc heterodimeric 
complexes. Expression of specific AMY receptors and CTR can be achieved through 
expression in carefully selected cell types (Christopoulos et al., 1999). This can allow study of 
this pharmaceutically relevant class of receptors that have already been identified as drug 
targets for bone disorders and diabetes (Henriksen et al., 2010, Younk et al., 2011). 
1.11 Biophysical analysis of GPCRs 
In drug development, understanding of the structure and dynamics of target proteins can 
provide insights into how to create more specific drugs, or identify new binding sites for new 
drugs. Biophysical analysis allows detailed information, at a molecular level, of the structure, 
function and dynamics of proteins. However, a prerequisite for many of these techniques is that 
the protein is soluble in aqueous solution. Solubilisation of hydrophobic membrane proteins is 
commonly achieved through use of surfactants, often referred to as detergents. 
1.11.1 Detergents 
Detergents are amphipathic molecules which possess hydrophobic and hydrophilic groups. In 
aqueous solution they are driven to form detergent micelles in which the polar head groups 
confer solubility on the micelle, while the hydrophobic hydrocarbon chains are shielded from 
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solution. When introduced to cell plasma membranes, detergents readily incorporate into the 
outer layer of lipid. Curvophilic detergents introduce a curvature to the membrane, 
unfavourable for the close- packing of curvophobic lipids (Stuart and Boekema, 2007).The 
smaller detergent molecules, such as Triton X-100 (Alonso et al., 1987), are able to rapidly 
change, “flip-flop”, between the two layers of lipid (Kragh-Hansen et al., 1998). When the 
detergent has saturated both layers of the membrane, the membrane will fully solubilise into 
detergent micelles. The flip-flop of these smaller detergents allows solubilisation to occur 
quickly. Larger detergents, such as n-dodecyl β-D-maltoside (DDM), are unable to flip-flop 
between lipid layers. Instead these detergents continue to saturate only the outer layer of the 
membrane, resulting in a curvature that is unfavourable for lipid packing. When the detergent 
concentration in the membrane outer layer is high enough, the induced curvature causes 
perturbations in the lipid packing, allowing detergent access to the other layer (de Foresta et 
al., 1989). This ultimately allows sections of membrane to be solubilised in detergent micelles. 
Inablity to flip-flop means the larger detergents are slower at solubilising membranes. 
However, the reduced speed of solubilisation does appear to increase the stability of the 
solubilised proteins (de Foresta et al., 1989, Kragh-Hansen et al., 1998, Stuart and Boekema, 
2007). Cholesterol is also routinely added during detergent solubilisation, in the form of 
cholesteryl hemisuccinate (CHS), to further increase the stability of the extracted protein (Toro 
et al., 2009, Attrill et al., 2009). 
Detergent-solubilisation of membranes results in fragments of the membrane being 
incorporated into detergent micelles. This includes membrane proteins, which hydrophobically 
interact with the detergents, creating molecularly dispersed proteins that are soluble in aqueous 
solution and able to be studied in a wide range of biophysical techniques. For each protein to 
be solubilised, many detergents are investigated to identify which detergent will extract the 
protein while retaining protein structure and function. For GPCR solubilisation with detergents, 
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DDM is known to extract GPCRs with better retention of protein function than most other 
detergents. However, the solubilised membrane protein sample never retains 100 % functional 
activity. This is thought to be a result of the induced membrane perturbations caused by high 
detergent concentration in the outer lipid layer causing membrane protein structural defects 
(Pantaler et al., 2000).  
Detergent micelles are constantly changing in order to minimise the volume of solvent 
contained in their centre. As a result, the presence of curvophobic lipid molecules are 
minimised in detergent micelles. This effectively strips membrane proteins of their lipid 
annulus (lipid which immediately surrounds the protein), which has been shown to contribute 
towards membrane protein stability and function (Sixl and Watts, 1983, Gibson and Brown, 
1993, Lee, 2004). The detergent micelle that forms around the membrane protein is a poor 
mimic of the native lipid annulus. There is a subsequent change in lateral pressure exerted on 
the membrane protein, resulting in an altered protein conformation (Marsh, 2007). As a result 
of this, detergent-solubilised proteins are known to be unstable, often irreversibly aggregated 
and generally require use within hours of preparation. Detergents are therefore able to 
solubilise membrane proteins, but the detergent-solubilised protein may not be in a native 
conformation or behave as in its native lipid environment. Furthermore, irreversible 
aggregation of detergent-solubilised proteins can render the protein unviable for use in 
downstream analyses. 
1.11.2 Alternatives to detergents 
Despite the knowledge of membrane proteins detergents have provided, their inherent 
disadvantages have necessitated the search for alternative means of stabilising solubilised 
membrane proteins in aqueous solution. Among the most successful alternatives to be 
investigated are: apolipoprotein stabilised nanodiscs; fluorinated surfactants and amphipathic 
polymers. High density lipoprotein apoA-1-stabilised nanodiscs (herein referred to as 
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nanodiscs), pioneered by the Sligar group, are one of the most thoroughly investigated systems 
to date (Bayburt et al., 1998). There have been a range of different membrane proteins that 
have been studied using nanodiscs, including one of the canonical family A GPCRs β2 
adrenergic receptor (Leitz et al., 2006). Nanodiscs provide a defined lipid bilayer, surrounded 
by a belt of apolipoproteins, as shown in figure 1.9, with defined diameters between 10 and 20 
nm (Nath et al., 2007). The defined nature of the nanodisc allows for specific lipid 
environments, displaying phase transitions similar to those observed in lipid bilayers (Shaw et 
al., 2004, Denisov et al., 2005). Although it is possible for more than one protein to exist in 
each individual nanodisc, aggregation of proteins between nanodiscs is prevented by the 
apolipoprotein belt. This allows for predominantly monodisperse membrane protein 
preparations with little variation between samples that have displayed increased thermostability 
to membrane proteins in detergent micelles (Banerjee et al., 2008). 
Nanodisc assembly involves incubation of detergent-solubilised proteins with a desired lipid 
and the apolipoprotein. These reagents then assemble to form the apolipoprotein-belted, 
defined nanodiscs, in which the membrane protein is surrounded by a native-like lipid annulus 
(Leitz et al., 2006, Nath et al., 2007). The major problem with nanodiscs as a method of 
stabilising membrane proteins in aqueous solution is the initial requirement for detergent 
solubilisation. All structural defects created by detergent solubilisation of membrane proteins 
are introduced before stabilisation of the protein by nanodiscs. The lipid environment inside 
the nanodisc can only be “native-like”. Although providing a better mimic than detergents for 
the native membrane environment, it lacks the diversity of lipids that constitutes the native 
lipid annulus. Finally, the apolipoprotein belt is constructed of α-helical proteins. This prevents 
the use of nanodiscs for the study of membrane proteins in several biophysical techniques, 
including nuclear magnetic resonance (NMR) and circular dichroism (CD).  
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Figure 1.9. Representation of the β2 adrenergic receptor in an apolipoprotein stabilised 
nanodisc. The family A GPCR β2 adrenergic receptor, displayed in green, as it may look in a 
nanodisc. Native-like lipid bilayer, displayed in red, surrounds the GPCR and stabilised by the 
apolipoprotein belt (purple) surrounding the nanodisc. Image taken from Leitz et al., 2006. 
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Fluorinated and hemifluorinated surfactants are structurally similar to detergents, but contain 
fluorine in the alkyl chains. The presence of fluorine causes the alkyl chains to adopt a more 
rigid conformation than detergents. This has reportedly improved membrane protein stability 
in small, well-defined complexes and has not impeded membrane protein studies (Chabaud et 
al., 1998, Breyton et al., 2004). However, as with nanodiscs, fluorinated surfactants are unable 
to solubilise membrane proteins (Chabaud et al., 1998) and rely on an initial detergent-
solubilisation step. Proteins are stabilised by fluorinated surfactants due to: less favourable 
partitioning of lipids and other hydrophobic membrane components; low affinity of fluorinated 
alkyl chains for the lipophilic transmembrane regions of proteins, allowing retention of 
protein:protein interactions (Popot, 2010). These properties prevent any part of the lipid 
annulus to be retained with the solubilised protein, affecting receptor function. They have also 
been shown to drive protein aggregation, limiting their use in biophysical analyses (Chabaud 
et al., 1998, Der Mardirossian et al., 1998). 
Amphipols are short amphipathic polymers that can associate with the lipophilic TM region of 
membrane proteins (Popot, 2010). Use of detergents prior to membrane protein stabilisation is 
a major disadvantage for most of the systems that have been investigated for protein 
stabilisation, and this is the case for the majority of amphipols (Zoonens et al., 2007, Gohon et 
al., 2008). However, some amphipathic polymers have been shown to solubilise proteins 
directly from membranes, in the absence of detergents (Popot et al., 2003). The non-peptide 
nature of the amphipols has allowed biophysical analysis of proteins through Förster resonance 
energy transfer (FRET) (Zoonens et al., 2007) and NMR (Zoonens et al., 2005) which would 
not be possible with the protein-based nanodisc system. However, even when proteins can be 
solubilised directly from membranes, the association of amphipols with the TM regions of 
membrane proteins prevents the solubilisation of much of the annular lipid. Protein structure 
and function is therefore still altered upon solubilisation. Protein aggregation is still a problem 
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seen through use of amphipols (Popot, 2010), limiting their use in biophysical analyses. The 
alkyl chain of amphipols has also been shown to interact with the hydrophobic core of 
solubilised receptors, preventing their use in studies requiring ligand binding (Popot, 2010). 
1.12 Styrene maleic acid 
Styrene maleic acid (SMA) is an amphipathic polymer consisting of hydrophilic maleic acid 
and hydrophobic styrene repeating subunits (displayed in figure 1.10). SMA can exist as 
polymers of styrene:maleic acid subunits at different ratios, providing different characteristics 
to the resulting polymer. SMA has been used to confer improved heat and impact resistance to 
several plastics, as well as paint emulsifiers and production of glossed paper. Other than its 
applications in the plastics industry, SMA has also been used in the cosmeceutical industry, by 
Malvern cosmeceuticals, and has passed phase II clinical trials for use as a reversible male 
sterilising agent (Guha et al., 1997). SMA has also been used as a drug delivery system 
specifically targeting tumours (Greish et al., 2005, Parayath et al., 2015). In recent years SMA 
has been identified as a means of solubilising membrane proteins without the use of detergents 
(Knowles et al., 2009). 
Most alternative methods of stabilising solubilised membrane proteins have required an initial 
detergent solubilisation step. This is detrimental to protein structure and function as a result of 
the detergent solubilisation of membranes, and removal of annular lipid from membrane 
proteins. The ideal method of protein solubilisation would not require the use of detergents at 
any stage, and solubilise proteins with their lipid annulus intact. SMA was found to 
spontaneously incorporate fragments of membranes, including membrane proteins, without the 
need for prior solubilisation (Knowles et al., 2009, Jamshad et al., 2011). SMA is a 
hydrophobically associating polymer (Tonge and Tighe, 2001) which partitions into the lipid 
bilayer of a membrane, driven by the hydrophobic styrene groups.  
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Figure 1.10. Structure of styrene maleic acid. SMA polymer is comprised of repeating 
subunits of maleic acid and styrene. The ratio of styrene:maleic acid can produce a more 
(increased styrene) or less (increased maleic acid) hydrophobic polymer. 
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Although the exact mechanism of membrane solubilisation with SMA has not been fully 
elucidated, it is believed that in the membrane SMA chains undergo spontaneous 
polymerisation to form longer chains. This spontaneous polymerisation in the membrane 
allows for SMA discs of different diameters. Once a disc has been formed there is a re-
orientation of the styrene and maleic acid groups around the highly flexible, carbon-carbon 
single bond, backbone. This allows the lipophilic styrene groups to interact with lipids and 
membrane proteins (Postis et al., 2015), while the hydrophilic maleic acid groups orientate to 
the outside of the disc conferring a strong negative charge, and solubility in aqueous solution, 
to the discs (Scheidelaar et al., 2015). SMA lipid particles (SMALPs) are then freely dispersed 
in aqueous solution, displayed in figure 1.11. This has allowed analysis through a range of 
biophysical techniques including CD (Knowles et al., 2009) and electron paramagnetic 
resonance (Orwick-Rydmark et al., 2012) which would not be available in systems such as the 
nanodiscs. 
Since the initial study, interest in the SMALP-solubilisation technique has grown. Although 
some studies have used the more hydrophobic 3:1 styrene:maleic acid (molar ratio) polymer 
(Orwick-Rydmark et al., 2012, Long et al., 2013, Bell et al., 2015); SMA in a 2:1 styrene:maleic 
acid molar ratio has been the more commonly studied form of SMA. It has been demonstrated 
that SMALPs have no preference for any lipid type investigated and that proteins can be 
SMALP-solubilised and reconstituted into lipid bilayers in a functional state (Dorr et al., 2014). 
SMALP containing only lipids have an average size of approximately 10-12 nm in diameter 
(Knowles et al., 2009, Scheidelaar et al., 2015). However, presence of one or more proteins 
within the SMALP has been shown to increase the diameter of the SMALP up to 24 ± 5 nm 
(Paulin et al., 2014). This allows for incorporation of large proteins and complexes which 
would not be possible in the restricted nanodisc system (Postis et al., 2015).  
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Figure 1.11. SMALP-solubilisation of a GPCR. A membrane bound GPCR (left, blue) is 
extracted directly from the membrane by SMA, without the use of detergents. The resulting 
SMALP-solubilised GPCR (right) is still surrounded by its lipid annulus and is soluble in 
aqueous solution with the SMA belt surrounding it (light blue). Image taken from Jamshad et 
al., 2011. 
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1.13 Aims of this study 
This study aims to determine the utility of SMALPs in the solubilisation and subsequent study 
of the pharmaceutically relevant GPCR superfamily from mammalian cells.  
The SMALP technique was first investigated for its ability to extract the pharmaceutically 
relevant GPCR A2aR from mammalian cells. SMALP-solubilised A2aR was further probed for 
retention of function through radioligand binding. The additional stability conferred to the A2aR 
through SMALP-solubilisation with its lipid annulus intact was investigated for a series of 
challenging conditions. 
The ability of SMA to solubilise plasma membranes has been well documented. However, the 
ability of SMA to solubilise from intracellular membranes has not been thoroughly explored. 
To probe this in mammalian cells, A2aR constructs were engineered with ER-retention motifs 
to prevent plasma membrane expression and provide a tool to study the ability of SMA to 
solubilise intracellular membranes. 
The ability of SMALPs to be used in spectroscopic studies has been documented. Based on 
previous studies on β2 adrenergic receptor, an A2aR construct was developed. Introduction of 
suitable residues for derivatisation by fluorescent probes and removal of other derivitisable 
sites would allow fluorescence studies of A2aR. 
The need to identify different detergents for solubilisation of different proteins is a long and 
expensive process. The ability of SMA to be used in the solubilisation, and subsequent study 
of, a range of different GPCRs, from different GPCR subfamilies, was explored. 
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2 CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1  Antibodies 
Polyclonal, rabbit, anti-Gs primary antibody (catalogue number: SC-823) was purchased from 
Santa Cruz Biotechnology (Texas, U.S.A). Monoclonal, mouse clone HA-7, anti-
haemagglutanin (HA) (catalogue number: H9658) was purchased from Sigma (Dorset, UK). 
Horseraddish peroxidase-conjugated: anti-mouse (catalogue number: 70765) and anti-rabbit 
(catalogue number: 7074P2) secondary antibodies were purchased from New England Biolabs 
(NEB) (Hitchin, UK). 
2.1.2  Cell tissue culture 
Cell culture plasticware was purchased from Greiner Bio One (Gloucestershire, UK). 
Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from Scientific Laboratory 
Supplies (SLS) (Hessle, UK). Foetal Bovine Serum (FBS) was purchased from Sigma (Dorset, 
UK). Linear polyethylenimine (PEI) (catalogue number: 9002-98-6) was purchased from 
Polysciences Inc. (Eppelheim, Germany). 
2.1.3  Molecular biology reagents 
Custom oligonucleotides (synthesised to 0.2 µmole scale) and pcDNA3.1(+) mammalian 
expression vector were purchased from Invitrogen/Life technologies (Paisley, UK). 
Deoxyribonucleotides triphosphates (dNTPs) and Isolate II plasmid mini prep kit were 
purchased from Bioline (London, UK). Axyprep DNA gel extraction kit was purchased from 
Fisher scientific (Loughbourough, UK). Pfu DNA polymerase and Pureyield plasmid maxiprep 
kit were purchased from Promega (Southampton, UK). DpnI, ApaI and XbaI restriction 
enzymes and T4 DNA ligase were purchased from NEB (Hitchin, UK). 
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2.1.4  Radioligand binding reagents 
N-(2-aminoethyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-
acetamide, Xanthine Amine Congener (XAC); 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-
a][1,3,5]triazin-5-yl-amino]ethyl)phenol (ZM241385); 1-(6-amino-9H-purin-9-yl)-1-deoxy-
N-ethyl-β-D-ribofuranuronamide, 5’(N-ethylcarboxamido)adenosine (NECA); 3,7-dihydro-
1,3-dimethyl-1H-purine-2,6-dione (theophylline); (RS)-(8-Methyl-8-azabicyclo[3,2,1]oct-3-
yl) 3-hydroxy-2-phenylpropanoate (atropine); Sephadex G-15, G-25, G-50 and G-75 were 
purchased from Sigma (Dorset, UK). [Arginine8]vasopressin (AVP) and oxytocin (OT) were 
purchased from Bachem (Weil am Rhine, Germany). Adenosine deaminase was purchased 
from Roche (Burgess Hill, UK). Tritiated ZM241385 ([2-3H]-4-(2-[7-amino-2-[2-
furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol), specific activity (SA): 50 
Ci/mmol, was purchased from American Radiolabelled Chemicals (Royston, UK). Tritiated 
AVP, [Phe-3,4,5-3H]AVP, SA: 67.7-69 Ci/mmol; tritiated oxytocin, [Tyr2,6-3H]oxytocin, SA: 
49.9 Ci/mmol, and tritiated N-methyl scopolamine, [N-methyl-3H] NMS, SA: 70-87 Ci/mmol, 
soluene®-350 and optiphase Hisafe™ 3 scintillant were purchased from PerkinElmer 
(Stevenage, UK). 
2.1.5  Solubilisation reagents 
Styrene maleic anhydride was purchased from Cray Valley (Pennsylvania, U.S.A). n-dodecyl 
β-D-maltoside (DDM) and cholesteryl hemisuccinate (CHS) were purchased from Sigma 
(Dorset, UK). 
2.1.6  Substrates 
Sigma-fast o-phenylenediamine dihydrochloride (OPD) was purchased from Sigma (Dorset, 
UK). 
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2.1.7  Western blotting reagents 
Tetramethylethylenediamine (TEMED) and ammonium persulphate (APS) were purchased 
from Sigma (Dorset, UK). Hyperpage protein ladder was purchased from Bioline (London, 
UK). Nitrocellulose membrane was purchased from GE healthcare (Amersham, UK). 30% 
acrylamide 0.8% bisacrylamide and EZ-ECL chemiluminescence detection kit were purchased 
from Geneflow (Staffordshire, UK). 
2.2 Methods 
2.2.1  Site-directed mutagenesis 
Mutagenic primers were designed to contain the desired mutation flanked by sequences 
complementary to the template DNA (pcDNA3.1(+) coding for A2aR). Reaction mixtures were 
made to a final volume of 50 µl in 1 x Pfu buffer, containing: 100 ng of template DNA; 10 
pmol of sense and antisense primers; dNTP mix (dATP, dCTP, dGTP, dTTP) at final molarity 
of 0.4 mM and 2-3 units of Pfu DNA polymerase. 
Reaction conditions: Initial 95 °C for 1 min; denaturation at 95 °C for 30 sec; annealing at 55 
°C for 1 min and elongation at 68 °C for 14 min. denaturation, annealing and elongation steps 
were repeated 11 times. 
2.2.2  Polymerase-chain reaction (PCR) 
Reaction mixtures were set up as above. Reaction conditions were: initial 95 °C for 1 min; 
denaturation at 95 °C for 1 min; annealing at 55 °C for 30 sec; elongation at 72 °C for 2.5 min; 
denaturation, annealing and elongation were repeated for 30 cycles before a final 72 °C 
elongation step for 5 min. 
2.2.3  Restriction enzyme digest 
Samples incubated at 37 °C for minimum of 1 h with 20 units of restriction enzyme in 1 x 
restriction enzyme buffer. 
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2.2.4  Gel electrophoresis 
Samples from site-directed mutagenesis, PCR and restriction enzyme digests were examined 
by gel electrophoresis for identification of products. Samples were mixed with 10 x running 
buffer (0.25 % (w/v) bromophenol blue, 10 mM Tris, 1mM EDTA and 30 % (v/v) glycerol) 
9:10. Samples were run on 1 % (w/v) agarose gels, containing 0.5 µg/ml ethidium bromide, in 
TAE buffer (40 mM Tris, 20 mM acetic acid and 1 mM EDTA) at approximately 80 mV for 1 
h. Gels were observed using an ultraviolet light transilluminator. 
2.2.5  Transformation 
Chemically competent E.coli XL-10 gold cells were made as previously described (Sambrook, 
1989). 30 µl of XL-10 gold cells were incubated with cDNA samples on ice for 20 min. 
Samples were heatshocked at 42 °C for 45 sec and incubated on ice for 2 min. Samples were 
recovered in lysogeny broth (LB-Lennox) (10 g/L peptone, 5 g/L NaCl and 5 g/L yeast extract) 
for 1 h at 37 °C. Cells were sedimented through centrifugation (9,500 x g, 5 min) and spread 
on LB agar plates containing 100 µg/ml ampicillin. Agar plates were incubated at 37 °C 
overnight. Individual colonies were picked to inoculate 15 ml LB-Lennox containing 100 
µg/ml ampicillin and incubated, shaking, overnight at 37 °C. 
2.2.6  Plasmid cDNA extraction and purification 
Isolate II plasmid mini-prep kit was used as per manufacturers instructions to extract and purify 
approximately 5 µg of cDNA from E.coli. Mini-prep cDNA sequence was confirmed by 
automated fluorescence cDNA sequencing. cDNA production was scaled up using Pureyield 
plasmid maxiprep kit as per manufacturers instructions. This yielded approximately 0.5 mg of 
cDNA. Precise concentrations of cDNA solutions were calculated by use of a nanodrop 2000 
U.V.-Vis spectrophotometer. 
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2.2.7  Automated fluorescence DNA sequencing 
All DNA sequences were confirmed by automated fluorescence DNA sequencing (functional 
genomics, proteomics and metabolomics facility, University of Birmingham, UK). 
2.2.8  Cell tissue culture 
HEK 293T cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10 
% (v/v) foetal bovine serum (FBS) (hereon referred to as DMEM) and incubated at 37 °C, 5 % 
(v/v) CO2. Cells were routinely passaged during log phase (~80 % confluence) every 3-4 days. 
Cell stocks in 90 % (v/v) FBS and 10 % (v/v) DMSO were stored in liquid nitrogen. 
HEK 293T cells were seeded at a density of: ~5 x 105 in a 92 mm diameter dish for membrane 
harvesting and whole cell SMALP-solubilisation; ~1 x 105 per well of a 24-well plate for 
enzyme-linked immunosorbent assays (ELISAs); and ~2.5 x 104 per well of a 96-well plate for 
cAMP alphascreen assays. Cells were incubated at 37 °C, 5 % (v/v) CO2 for 48 h (membrane 
harvesting) or 24 h (ELISAs and cAMP alphascreen assays) before transfection. 
2.2.9  PEI transfection 
5 % (w/v) glucose solution (sterile filtered) and 0.8 mg/ml (32 μM, based on average MW of 
linear PEI polymer) PEI solution (sterile filtered) were added to DNA samples. These were 
allowed to complex for 30 min at room temperature (16 °C) before addition of fresh DMEM 
and applied to cells. 
Transfection solutions for membrane harvesting and SMALP-solubilisation consisted of: 1 ml 
glucose solution; 48 µg PEI; and 5 µg of DNA per 92 mm dish. Transfection solutions for use 
in ELISAs: 30 µl glucose solution, 2 µg PEI; 0.5 µg DNA; and 500 µl DMEM per well. 
Transfection solutions for use in cAMP alphascreen assays: 7.5 µl glucose solution; 0.8 µg 
PEI; 0.125 µg DNA; and 125 µl DMEM per well. 
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2.2.10  Cell membrane harvesting 
As previously reported (Wheatley et al., 1997). Briefly: 48 h after transfection, cells were 
washed with 5 ml ice cold PBS. Cells were scraped from dishes in harvesting buffer (20 mM 
HEPES, 1 mM EGTA, 10 mM magnesium acetate, pH 7.4) containing 250 mM sucrose and 
0.1 mg/ml bacitracin. Cells were sedimented through centrifugation (4500 x g, 5 min). Cells 
were resuspended in harvesting buffer containing 0.1 mg/ml bacitracin and incubated on ice 
for 20 min. Membranes were sedimented through centrifugation (4500 x g, 5 min) and 
resuspended in harvesting buffer containing 250 mM sucrose. Membranes were stored at -20 
°C. 
2.2.11  SMA preparation 
As previously described (Knowles et al., 2009). Briefly: 10 % (w/v) styrene maleic anhydride 
was dissolved in 1 M NaOH overnight before heating under reflux for 2 h. SMA/NaOH 
solution was dialysed against dialysis buffer (20 mM HEPES, 1 mM EGTA, 1 mM magnesium 
acetate, pH 7.4). SMA was stored at 4 °C. 
2.2.12  SMALP-solubilisation of mammalian cells 
Unless stated otherwise, SMALP-solubilisation was performed as follows: 48 h after 
transfection, cells were washed with ice cold PBS. Cells were scraped from dishes in SMALP 
buffer (20 mM HEPES, 1 mM EGTA, 10 mM magnesium acetate, 2 % (w/v) SMA, pH 7.4) 
containing 5 units/ml of benzonase and protease inhibitors. Samples were incubated at 37 °C 
for 1 h before centrifugation at 100,000 x g for 1 h. Supernatants were saved and insoluble 
material was resuspended in initial volume of harvesting buffer (20 mM HEPES, 1 mM EGTA, 
10 mM magnesium acetate, pH 7.4). Samples were stored at -20 °C. 
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2.2.13  Detergent-solubilisation 
Mammalian cell membranes were prepared as above. n-dodecyl β-D-maltoside (DDM) and 
cholesteryl hemisuccinate (CHS) were added to harvested membranes to a final concentration 
of 2.5 % (w/v) and 0.5 % (w/v) respectively. Samples were incubated rotating at 4 °C for 3 h 
with protease inhibitors. Samples centrifuged at 100,000 x g for 1 h and supernatants used 
immediately. 
2.2.14  BCA protein concentration assay 
Approximate protein concentrations were obtained using the Pierce BCA assay kit (life 
technologies, Paisley, UK), as per manufacturer’s instructions. Briefly: Reagent A (containing 
bicinchoninic acid) was mixed with reagent B (cupric sulphate) 50:1. 1 ml was added to BSA 
standards and samples and incubated for 30 min at 37 °C. Absorbance readings were taken at 
562 nm. 
2.2.15  Alphascreen cAMP assay 
Performed as per manufacturer’s instructions (PerkinElmer, Stevenage, UK). Briefly: 48 h after 
transfection cells were incubated for 1 h, 37 °C, with stimulation buffer (Hank’s balanced salt 
solution, 0.1 % (w/v) BSA, 5 mM HEPES, 50 μM rolipram and cilostamide, pH 7.4). Cells 
expressing A2aR constructs were stimulated for 20 min with 1 x 10
-4 M NECA. Stimulation 
solutions were removed through aspiration before 100 % ethanol was added and allowed to 
evaporate. Cell lysis buffer (5 mM HEPES, 0.1 % (w/v) BSA, 0.3 % TWEEN20, pH 7.4) was 
added and incubated at room temperature, shaking, for 15 min. Samples were frozen at – 20 
°C. Samples were thawed and transferred to opaque, white, ½ area 96 well plates and 0.5 units 
of acceptor beads added per well. After 30 min incubation at room temperature, 1.5 units of 
donor beads containing biotinylated cAMP were added. Samples were incubated overnight at 
room temperature and read using a Mithras LB 940 (Berthold, Bad Wildbad, Germany). 
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2.2.16  Competition radioligand binding assay for membrane-bound receptors 
Reaction mixtures composed of: tritiated ligand; competing ligand at stated final 
concentrations; and harvested membrane-bound protein sample containing 25-50 µg protein, 
were made up to 500 µl using binding buffer (20 mM HEPES, 1 mM EGTA, 10 mM 
magnesium acetate, pH 7.4) containing: 0.1 % (w/v) BSA for peptide ligands; 0.1 units of 
adenosine deaminase for A2aR constructs. Non-specific binding was defined in the presence of 
a saturating concentration of competing ligand. Reaction mixtures were incubated at 30 °C 
until equilibrium was established (30-90 min). Centrifugation at 9,500 x g for 10 min separated 
bound from free ligand. Membranes were superficially washed and solubilised in 50 µl Soluene 
350. 1 ml Hisafe3 liquid scintillation cocktail was added and samples counted using Tri-carb 
2810 TR liquid scintillation analyser (PerkinElmer, Stevenage, UK) for 3 min. 
2.2.17  Competition radioligand binding assay for soluble receptors 
Reaction mixtures were prepared as above, containing 20-60 µg of soluble protein in a final 
volume of 100 µl. Non-specific binding was defined in the presence of a saturating 
concentration of competing ligand. Equilibrium was established at 30 °C (30-90 min). 
Separation of bound from free ligand was achieved by centrifugation (1000 x g, 4 min) of 50 
µl reaction mixture through Sephadex packed spin columns. Void volumes were collected and 
1 ml of Hisafe3 liquid scintillation cocktail was added to samples. Counting was performed on 
Tri-carb 2810 TR liquid scintillation analyser (PerkinElmer, Stevenage, UK) for 3 min. 
2.2.18  Thermostability experiments 
Protein samples were stored at set temperatures for 30 min. After 5 min on ice, specific binding 
was determined using the equation: 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 = 𝑇𝑜𝑡𝑎𝑙 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 −  𝑁𝑜𝑛 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 
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Where: total binding was defined as DPM recorded in the absence of competing ligand; Non-
specific binding was defined as DPM recorded in the presence of saturating concentrations of 
competing ligands. 
2.2.19  Cell-surface ELISA 
48 h after transfection: cells expressing A2aR constructs for internalisation investigations were 
stimulated with 1 x 10-4 M NECA for 1 h at 37 °C. Cells were fixed with 3.7 % (v/v) 
formaldehyde in PBS for 15 min at room temperature. Cells were washed 3 times with PBS 
and incubated in block solution (1 % (w/v) BSA in PBS), shaking, for 45 min at room 
temperature. Primary antibody was added to cells, at a dilution of 1:4000 in block solution, and 
incubated for 1 h, shaking, at room temperature. Cells were washed as before and incubated 
with block solution  for 15 min. HRP-linked secondary antibody was added, at a dilution of 
1:4000 in PBS, and incubated for 1 h (shaking at room temperature). Cells were washed 3 times 
in PBS and allowed to develop in the dark with 250 µl of OPD substrate (made as per 
manufacturer’s instructions). 100 µl of sample was taken and added to 100 µl 1 M sulphuric 
acid to stop the reaction. Absorbance was read on an Anthos, zenyth 340 rt plate reader at 492 
nm. 
2.2.20  Whole cell expression ELISA 
As above, including a 1 h incubation in 0.1 % (v/v) Triton X-100 in PBS after fixation with 
formaldehyde. 
2.2.21  SDS-PAGE and Western blot 
Samples were run by SDS-PAGE as previously described (Laemmli, 1970). Protein samples 
were incubated at room temperature for 30 min with loading buffer (50 mM Tris, 2 % (w/v) 
SDS, 10 % (v/v) glycerol, 0.004 % (w/v) (bromophenol blue) and 2 % (v/v) β-
mercaptoethanol). Samples were loaded onto a 10 % (w/v) polyacrylamide gel with a 4 % (w/v) 
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polyacrylamide stacking gel. Protein markers were included for identification of protein size. 
200 V was applied for approximately 45 min in denaturing running buffer (25 mM tris, 200 
mM glycine, 0.1 % (w/v) SDS). Gels were washed in transfer buffer (25 mM tris, 200 mM 
glycine, 10 % (v/v) methanol) for 10 min, shaking at room temperature. Proteins were 
transferred to nitrocellulose at 100 V for 1 h in transfer buffer. Nitrocellulose was blocked in 5 
% (w/v) milk in PBS for 1 h. Primary antibody was added to a final dilution of 1:5000 and 
incubated overnight, shaking, at 4 °C. Nitrocellulose was washed twice in wash buffer (PBS 
containing 0.2 % (v/v) TWEEN20) for 5 min, shaking at room temperature. HRP-linked 
secondary antibody was added (1:5000 dilution in 5 % (w/v) milk in PBS) and incubated at 
room temperature, shaking, for 45 min. Nitrocellulose was washed twice, as before, and 
proteins detected using EZ-ECL detection kit (as per manufacturer’s instructions). Image was 
captured using a Uvitec alliance chemiluminescent detection system (Cambridge instruments, 
U.K). 
2.2.22  Data analysis 
All data analysis was performed using the Prism 4.0 (Graphpad, San Diego, U.S.A) computer 
program. All values given as the mean of 3 indiviual replicates ± S.E.M unless otherwise stated. 
Radioligand binding assays were plotted as a percentage of specific binding. Each plot was of 
at least 3 indiviudal replicates, each performed in triplicate. Nonlinear regression was used to 
fit one-site Langmuir binding isotherms to identify IC50 values. IC50 values were corrected for 
the presence of radioligand using the following equations:  
[3𝐻]𝐿𝑖𝑔𝑎𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑀)
=
𝐷𝑃𝑀
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐶𝑖𝑚𝑚𝑜𝑙−1) + 𝑆𝑎𝑚𝑝𝑙𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 (µ𝑙) × 2.22
 
 
𝐾𝑖(𝑛𝑀) = 𝐼𝐶50 − [𝐹𝑟𝑒𝑒 𝑅𝑎𝑑𝑖𝑜𝑙𝑖𝑔𝑎𝑛𝑑](𝑛𝑀) 
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𝐾𝑖 (𝑛𝑀) = 𝐼𝐶50 ×
𝐾𝑑[ 𝐻
3 ]𝐿𝑖𝑔𝑎𝑛𝑑
𝐾𝑑[ 𝐻
3 ]𝐿𝑖𝑔𝑎𝑛𝑑 × [𝐹𝑟𝑒𝑒 𝑅𝑎𝑑𝑖𝑜𝑙𝑖𝑔𝑎𝑛𝑑]
 
 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑜𝑐𝑐𝑢𝑝𝑎𝑛𝑐𝑦 =
[𝐹𝑟𝑒𝑒 𝑅𝑎𝑑𝑖𝑜𝑙𝑖𝑔𝑎𝑛𝑑]
𝐾𝑑[ 𝐻
3 ]𝐿𝑖𝑔𝑎𝑛𝑑 × [𝐹𝑟𝑒𝑒 𝑅𝑎𝑑𝑖𝑜𝑙𝑖𝑔𝑎𝑛𝑑]
 
ELISA data were presented as histograms of percentage expression for at least 3 individual 
replicates, performed in at least triplicate. Internal standards for 100 % expression (wild-type 
(WT) receptor) and 0 % expression (mock transfected cells) were included in all investigations. 
cAMP assays were plotted as a percentage of bound biotinylated-cAMP. Unstimulated WT-
receptor values were taken as 100 % and forskolin stimulated cells 0 %. Each plot was of 3 
individual replicates performed in duplicate. Nonlinear regression was used to fit one-site 
Langmuir binding isotherms for calculation of EC50 values and Emax. 
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3 CHAPTER 3: SMALP-SOLUBILISATION AND 
CHARACTERISATION OF A2aR FROM MAMMALIAN CELLS 
3.1 Introduction 
The study of membrane proteins has lagged behind studies of soluble proteins due to the 
inherent hydrophobicity of membrane proteins preventing their use in certain biophysical 
techniques. The use of detergents to solubilise membrane proteins has allowed some 
biophysical analysis. However, detergents strip away annular lipid (lipid that immediately 
surrounds the protein), and other membrane components, from the protein. The detergent 
micelle then provides only a poor mimic of the plasma membrane and exerts a different lateral 
pressure on proteins. This leads to conformational changes of proteins that can affect their 
behaviour. As a result, detergent-solubilised proteins are often conformationally unstable. 
Methods to stabilise detergent-solubilised proteins includes modifying proteins (a good 
summary has been previously reported (Maeda and Schertler, 2013)). Alternatively, insertion 
of detergent-solubilised proteins into apolipoprotein-stabilised nanodiscs, amphipathic 
polymers, or substitution of detergent for fluorinated surfactants, after detergent-solubilisation, 
can limit the proteins exposure to detergent. Stabilising membrane proteins by any of these 
mechanisms results in conformationally altered proteins that do not behave as in their natural 
envinronment. In order to keep the protein in its native conformation, extraction with its native 
lipid environment would be required. 
Use of styrene maleic acid (SMA) polymer to solubilise membrane proteins into SMA lipid 
particles (SMALPs) appeared an attractive prospect as it allowed extraction of unmodified 
proteins, still with their lipid annulus intact. Solubilisation of membrane proteins, using the 2:1 
(molar ratio of styrene:maleic acid) SMA polymer, has previously been demonstrated from 
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bacterial, yeast and insect cell expression systems (Jamshad et al., 2011, Swainsbury et al., 
2014, Gulati et al., 2014). Although these systems provided a large quantity of protein, they 
lacked the pharmacological relevance of a mammalian expression system. For pharmaceutical 
studies and drug screens, a mammalian cell membrane composition would allow for the most 
physiologically relevant data. 
Differences in membrane composition can lead to a change in receptor behaviour. Yeast 
membranes, for example, do not contain cholesterol, instead containing ergosterol (Finean et 
al., 1978). The importance of cholesterol, present in mammalian plasma membranes, has been 
demonstrated for the correct functioning of some GPCRs such as the oxytocin receptor, galanin 
receptor and β2 adrenergic receptor (Gimpl et al., 1997, Pang et al., 1999, Zocher et al., 2012). 
The structure of β2 adrenergic receptor in complex with cholesterol has been solved, prompting 
the suggestion of a cholesterol binding motif (Hanson et al., 2008). Therefore proteins 
expressed and studied in yeast may lack a key component for their function. Lipid composition 
may also affect protein behaviour and, in some cases, such as the β2 adrenergic receptor and 
rhodopsin, limit protein function (Sixl and Watts, 1983, Gibson and Brown, 1993, Lee, 2004, 
Hanson et al., 2012). This is especially important considering the lipid-stripping action of 
detergents. By using a mammalian expression system to overexpress specific proteins, 
SMALP-solubilisation may be employed to study proteins with their native lipid annulus intact.  
The aims of this part of the study were to establish whether the SMA polymer was able to 
solubilise a GPCR from mammalian cells and to pharmacologically characterise the SMALP-
GPCR. Using a glycosylation deficient A2aR (with N-terminal haemagglutinin (HA) epitope 
tag) as an exemplar GPCR, SMALP-solubilisation conditions were optimised. 
  
46 
 
3.2 Results 
3.2.1 Optimisation of SMALP-extraction from HEK 293T cells 
It was important to determine the optimal conditions for SMALP-solubilisation of A2aR from 
HEK 293T cells. This was determined for a range of conditions which can affect extraction. 
Each condition (SMA concentration, temperature and time) was tested sequentially and optimal 
extraction was taken and used as a standard condition in testing the next parameter. Samples 
were prepared as described in methods but with systematic variation to the condition being 
optimised. Briefly, HEK 293T cells expressing A2aR were incubated with SMA solution. 
Samples were centrifuged at 100,000 x g for 1 h before supernatants were collected and pellets 
resuspended to initial volume. Extraction efficiency was determined by Western blot analysis 
using anti-HA antibody to target the A2aR. 
3.2.1.1 SMA concentration 
Samples were incubated for 1 h at 37 °C in the presence of SMA at concentrations of 1 % to 4 
% (w/v). Samples were centrifuged for 1 h at 100,000 x g and supernatants collected before 
pellet was resuspended to initial volume. Supernatant and pellet fractions were separated by 
SDS-PAGE and transferred to nitrocellulose before probing with anti-HA antibody to reveal 
relative abundances of A2aR (expected MW: ~45790 Da) in each sample, displayed in figure 
3.1. In the absence of SMA, no extraction was observed. 1 % (w/v) SMA was able to extract a 
minor fraction of the total receptor, but the majority was left unsolubilised. SMA at 
concentrations of 2 %, 3 % and 4 % (w/v) extracted similar amounts of A2aR by visual 
inspection, solubilising the majority of A2aR from the cells. Optimal concentration of SMA 
was 2 % (w/v), providing maximum extraction using the minimum amount of polymer.  
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Figure 3.1. Western blot analysis of SMALP-solubilisation of A2aR using different concentrations of SMA. Molecular weight marker (M), 
soluble (S) and pellet (P) fractions of SMALP preparations, prepared with indicated concentrations of SMA, were probed with anti-HA antibody. 
Characteristic gel of three experiments.
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3.2.1.2 Temperature of incubation 
Optimal concentration of SMA, 2 % (w/v), was used to extract A2aR from mammalian cell 
membranes that were then incubated at a range of temperatures, as indicated in figure 3.2, for 
1 h. Samples were then analysed by Western blot to identify the optimal incubation 
temperature. It was observed that at 4 °C SMALP-solubilisation of A2aR was not as efficient 
as at higher temperatures. Although samples incubated at ambient room temperature (14 °C), 
25 °C and 30 °C all extracted the majority of receptor, the A2aR remaining in the pellet 
decreased with increasing temperature, with 37 °C the most efficient temperature employed. 
Therefore, 37 °C was considered optimal as it provided maximum extraction of A2aR. Higher 
temperatures were deemed inappropriate. Although protein would be extracted, higher 
temperatures were thought to be detrimental to the preservation of ligand binding capabilities 
of A2aR. 
3.2.1.3 Time of incubation 
Samples were prepared using 2 % (w/v) SMA and incubated at 37 °C for the lengths of time 
indicated in figure 3.3. Extraction efficiency was determined visually from Western blot 
analysis. It was observed that less than 1 h at 37 °C reduced the efficiency of extraction. 
Obviously at 0 h incubation, pre-centrifugation, only a minor fraction of the receptor was 
extracted to the supernatant. After 1 h the majority of the receptor was extracted to the 
supernatant. Time of incubation was investigated at 3 h, as shown in figure 3.4 where the 
amount of soluble A2aR after 3 h at 37 °C was similar to the amount seen without incubation 
at 37 °C (0 h). This was therefore less efficient than 1 h at 37 °C with 2 % (w/v) SMA (figure 
3.4: incubation temperature 37 °C) which was shown to be the set of conditions that produced 
maximum extraction of A2aR. From figure 3.4 it was also observed that a pre-centrifugation 
incubation time of 0 h provides predominantly monomeric A2aR. The presence of apparent 
dimeric A2aR in SMALP samples was observed to increase when samples were incubated for  
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Figure 3.2. Western blot analysis of SMALP-solubilisation of A2aR at different temperatures. Molecular weight marker (M), soluble (S) and 
pellet (P) fractions of SMALP-A2aR were probed with anti-HA antibody. SMALP-A2aR samples were prepared with 2 % (w/v) SMA and incubated 
at the indicated temperatures for 1 h. Characteristic gel of four experiment
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Figure 3.3. Western blot analysis of SMALP-solubilisation of A2aR incubated for different lengths of time. Molecular weight marker (M), 
soluble (S) and pellet (P) fractions of SMALP-A2aR prepared with 2 % (w/v) SMA and incubated at 37 °C for the indicated time. Samples were 
probed with anti-HA antibody. Characteristic gel of three experiments.
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Figure 3.4. Western blot analysis of SMALP-solubilised A2aR incubated under various conditions. Molecular weight markers (M). Soluble 
fraction of SMALP-A2aR incubated for 3 h with 2 % (w/v) SMA at 37 °C was compared to SMALP-A2aR prepared with different incubation times, 
temperatures and SMA concentrations. Samples were probed with anti-HA antibody. Characteristic gel of two experiment
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longer times during solubilisation or in the presence of greater amounts of SMA. The optimised 
conditions of 1 h at 37 °C with 2 % (w/v) SMA were investigated for the amount of A2aR 
solubilised in comparison the amount that was originally expressed. As seen in figure 3.5, 
compared to the total amount of A2aR expressed, the vast majority, as determined visually, was 
solubilised using optimised SMALP conditions (1 h, 37 °C, 2 % (w/v) SMA). Figure 3.5 also 
demonstrated the specificity of the anti-HA antibody for the HA-tag present on A2aR. HEK 
293T cells were treated with PEI as though being transiently transfected (as in section 2.2.9), 
but no DNA was introduced. SMALP-solubilisation and subsequent Western blot analysis 
demonstrated no reactivity of the anti-HA antibody for these SMALP-mock transfected cell 
samples. All bands observed from other samples were therefore a clear indication of the HA-
tagged receptor being present. As seen during optimisation, the amount remaining in the pellet 
fraction was minimal by comparison to the soluble fraction. 
3.2.2 Pharmacological characterisation of SMALP-A2aR 
Having established optimal conditions for SMALP-solubilising A2aR based on extraction of 
the HA-tagged protein, it was important to determine the functional characteristics of SMALP-
A2aR. Radioligand binding assays were performed on SMALP-A2aR samples solubilised under 
optimised conditions. Using [3H]ZM241385 as a tracer ligand, as described in section 2.2.17, 
and a range of well characterised A2aR ligands, agonists and antagonists, to probe the effect of 
SMALP-solubilisation on the A2aR ligand binding site. The pharmacological profile of 
SMALP-A2aR was compared to membrane preparations of A2aR (mem-A2aR) to determine 
whether SMALP-solubilised A2aR retained wild type (WT)-like pharmacology. 
SMALP-A2aR was able to bind the agonist NECA, as well as antagonists: ZM241385, XAC 
and theophylline with WT-like pKi values (figure 3.6 and table 3.1). The total binding of the 
SMALP-A2aR was 2.0 ± 0.24 pmol/mg of protein (n=3) equivalent to a yield of 23.3 ± 2.7 %  
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Figure 3.5. Western blot analysis of SMALP-A2aR in comparison to the total A2aR 
expressed. Molecular weight markers (M). Total A2aR present in the sample before SMALP-
solubilisation (T), SMALP-solubilised A2aR using optimised conditions (1 h, 37 °C, 2 % (w/v) 
SMA) (S) and A2aR remaining in the pellet fraction (P). SMALP-mock transfected HEK 293T 
cells (MT) run as a negative control. Samples were probed with anti-HA antibody. 
Characteristic gel of three experiments. 
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Figure 3.6. Competition radioligand binding of A2aR in SMALPs and membrane 
preparations with a range of competing ligands. Mem-A2aR (●) and SMALP-A2aR (■) 
competition radioligand binding curves using [3H]ZM241385 as a tracer in all assays. Panel A, 
ZM241385; panel B, theophylline; panel C, XAC and panel D, NECA were competing ligands. 
Data are mean ± s.e.m. of three experiments performed in triplicate. 
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Ligand Mem-A2aR SMALP-A2aR 
ZM241385 8.87 ± 0.1 8.53 ± 0.0 
Theophylline 4.87 ± 0.1 4.97 ± 0.3 
XAC 7.17 ± 0.2 6.38 ± 0.2 
NECA 5.29 ± 0.1 5.39 ± 0.4 
 
Table 3.1. pKi values of [3H]ZM241385 in the presence of competing ligands. Data are 
mean ± s.e.m. of three experiments performed in triplicate 
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compared to the original HEK 293T cell membrane preparation. This was similar to the 
recovery seen from detergent (DDM) solubilisation of A2aR (27.6 ± 11.4 %, n=3). The recovery 
with SMALP-A2aR was less variable than with DDM-A2aR. 
3.2.3 Thermostability of SMALP-A2aR 
It was hypothesised that SMALP encapsulation of receptors with retention of the lipid annulus 
would increase the stability of the receptor over that of detergent-solubilised receptors. To 
investigate this, SMALP-A2aR was investigated for its thermostability in comparison to mem-
A2aR and DDM-A2aR. Thermostability of A2aR in the environment of its membrane, SMALP 
and detergent micelle was determined by exposing the receptor sample to the temperatures 
stated in figure 3.7 for 30 min. After incubation the samples were cooled on ice and ligand 
binding assessed and compared to the 20 °C control values. From data presented in figure 3.7 
and table 3.2, it was observed that SMALP-A2aR displayed an increased thermostability over 
DDM-A2aR of approximately 4 °C. No other sample was as stable as mem-A2aR. SMALP-
A2aR had >90 % binding activity remaining at physiological temperature. DDM-A2aR had lost 
over 50 % of its binding activity by 37 °C. Cholesterol has been linked to increased GPCR 
stability. The original HEK 293T cell would have contained cholesterol that would therefore 
be present in SMALPs. DDM would try to separate cholesterol from GPCRs when forming 
micelles and so additional cholesterol, in the form of cholesteryl hemisuccinate (CHS) is 
routinely added in detergent solubilisation to stabilise the protein. When CHS (0.5 % (w/v)) 
was introduced during SMALP-A2aR preparation, as it was in DDM-A2aR preparation, 
thermostability of SMALP-A2aR was increased a further 9 °C. This was 13 °C more stable than 
DDM-A2aR. 
3.2.3.1 SMALPs as a potential platform for drug discovery assays 
GPCRs are already a major target for the development of drugs. In order to create more specific 
drugs, reducing side-effects, information on how compounds behave at GPCRs under 
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physiological conditions is required. Assays related to drug discovery, such as high-throughput 
assays, are therefore likely to be performed at physiological temperature (37 °C). Observing 
how different compounds behave at the same receptor can be affected by differences in receptor 
activity between preparations. The ability to create a large preparation that could be stored for 
later use without detriment to the proteins activity would be of great advantage. This is not 
possible with unstable detergent-solubilised receptors which require immediate use. To 
investigate the potential use of SMALPs as a platform for drug discovery assays, A2aR was 
prepared in membranes, SMALPs and DDM-micelles. Samples were then incubated at 37 °C 
or 4 °C and aliquots taken for specific binding determination at the time points indicated in 
figure 3.8. Specific binding at time points was then compared to the specific binding observed 
before incubation (0 h). As seen in figure 3.8 and table 3.3, at 37 °C SMALP-A2aR showed 
increased stability of 7-fold over DDM-A2aR. This meant that after 1 h DDM-A2aR had less 
than 25 % of its binding activity remaining, whereas SMALP-A2aR still had over 80 %. 
However, neither method of solubilisation provided stability equal to mem-A2aR which 
retained almost 100 % ligand binding activity after 7 h. At 4 °C the profile of remaining binding 
activity for SMALP-A2aR was indistinguishable from mem-A2aR and after 10 days had ~80 % 
specific binding remaining. However, DDM-A2aR had 80 % specific binding remaining after 
1 day and had only ~3 % ligand binding activity remaining after 3 days. 
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Figure 3.7. Radioligand binding activity of A2aR prepared by different methods following 
incubation at different temperatures. Mem-A2aR (●), SMALP-A2aR (■), DDM-A2aR (▲) 
and SMALP-A2aR + 0.5 % (w/v) CHS (▼) specific binding activities were determined using 
self-competition radioligand binding of ZM241385. Data are expressed as relative to 20 °C 
data point (mean ± s.e.m. of three experiments performed in triplicate). 
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Sample T50 (°C) 
Mem-A2aR >60 
DDM-A2aR 36.2 ± 0.5 
SMALP-A2aR 40.2 ± 0.4 
SMALP-A2aR + CHS 49.0 ± 0.9 
 
Table 3.2. Thermostability of A2aR in different preparations. Thermostability expressed as 
T50 (°C), the temperature at which 50 % ligand binding activity was lost for A2aR prepared in 
membranes (mem-A2aR), DDM detergent micelles (DDM-A2aR), SMALPs (SMALP-A2aR), 
and SMALPs + 0.5 % (w/v) cholesteryl hemisuccinate (SMALP-A2aR + CHS). Data given are 
mean ± s.e.m. of three experiments performed in triplicate. 
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Figure 3.8. Specific binding activity remaining in various A2aR samples over time when 
stored at different temperatures. Mem-A2aR (●), SMALP-A2aR (■) and DDM-A2aR (▲) 
samples were stored at 37 °C (upper panel, A) 4 °C (lower panel, B). Aliquots were taken at 
the times indicated and specific binding was determined. Data are mean ± s.e.m. of three 
experiments performed in triplicate. 
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Sample t1/2 at 37 °C (min) t1/2 at 4 °C (days) 
Mem-A2aR >420 >16 
DDM-A2aR 21 ± 7 1.8 ± 0.3 
SMALP-A2aR 148 ± 13 >16 
 
Table 3.3. Thermostability of A2aR preparations. Thermostability expressed as t1/2, the time 
required for A2aR samples to lose 50 % ligand binding activity, when incubated at 37 °C or 4 
°C. A2aR samples prepared in membranes (mem-A2aR), DDM detergent micelles (DDM-A2aR) 
or SMALPs (SMALP-A2aR) were stored at temperatures indicated. At set time points, aliquots 
were taken and specific binding determined and compared to specific binding before 
incubation. Data are mean ± s.e.m. of three experiments performed in triplicate. 
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SMALP-A2aR was further studied for its ability to be stored by commonly used methods. If 
samples could be stored, it would allow preparation of large sample volumes for prolonged 
use. For this, the ability of SMALP-A2aR to retain ligand binding activity following repeated 
freeze-thaw cycles at -20 °C was investigated as was retention of binding activity following 
lyophilisation and subsequent resuspension in buffer. It was found, as shown in figure 3.9, that 
SMALP-A2aR presented resilience to common storage methods. Samples were stored at -20 °C 
until frozen (minimum 1 h) before thawing at room temperature (~16-18 °C for approximately 
20 min). Aliquots were taken from the thawed SMALP-A2aR sample and radioligand binding 
performed to assess retention of ligand binding capability. After 5 freeze-thaw cycles SMALP-
A2aR showed no decrease in binding capability. Furthermore, even after the extreme process 
of lyophilisation through freeze-drying and re-hydration in buffer, SMALP-A2aR retained ~ 70 
% of its initial binding activity. 
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Figure 3.9. Retention of SMALP-A2aR binding activity following storage by different 
methods. Specific binding was determined for: (A) SMALP-A2aR that underwent repeated 
freeze-thaw cycles; (B) SMALP-A2aR that underwent freeze-drying before resuspending to 
initial volume in buffer. Data are compared to specific binding from before storage (mean ± 
s.e.m. of three experiments performed in triplicate). 
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3.3 Discussion 
The inherent disadvantages of using detergents for protein solubilisation, such as protein 
instability and irreversible aggregation, have led to the search for improved methods of 
stabilising membrane proteins when soluble in aqueous solution. Amphipols, fluorinated 
surfactants and apolipoprotein stabilised nanodiscs have all been investigated. Apart from the 
rare occurrence with certain amphipols, none of these systems can solubilise proteins directly, 
and require an initial detergent solubilisation of the protein. This introduces all the structural 
instability, known to be caused by detergent solubilisation, before the protein is stabilised in 
the chosen system. This is, at least in part, a result of the removal of the lipid annulus from 
around the protein. SMALP-solubilisation has been proven to extract protein directly from 
membranes, with their lipid annulus intact. SMALPs have been increasingly utilised in the 
study of membrane proteins since their first use in 2009 (Knowles et al., 2009). Since then, 
SMALP-solubilisation has been used for membrane proteins expressed in bacteria, yeast, insect 
and mammalian cells. 
The ratio of styrene:maleic acid is known to affect extraction efficiency but has been varied in 
SMA use. This study is the very first GPCR solubilised without detergent from mammalian 
cells. Previous studies using 2:1 (molar ratio styrene:maleic acid) SMA to solubilise membrane 
proteins have largely focused on extraction from yeast and bacterial overexpression systems. 
Extraction of active membrane proteins, ABC transporters, from mammalian cells has only 
been published once (Gulati et al., 2014), and this was not of a pharmaceutically relevant 
GPCR. Other studies have looked at extraction of naturally expressed membrane proteins from 
yeast mitochondria (Long et al., 2013) and extraction from plant cells (Bell et al., 2015) using 
3:1 (molar ratio styrene:maleic acid) SMA. However, after solubilisation the samples were only 
centrifuged at 20,000 x g for 10 min and therefore doubts are raised as to whether only 
solubilised protein was present in these studies. This study has looked at SMALP-solubilisation 
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of overexpressed protein at the plasma membrane of mammalian cells using 2:1 SMA. Before 
functional assays could be performed on SMALP-solubilised protein, optimisation of the 
extraction conditions was necessary. 
3.3.1  Optimisation of SMALP-solubilisation from mammalian cells 
Optimisation was performed sequentially: SMA concentration; temperature of incubation; 
length of incubation. 1 % (w/v) SMA was too little to effectively extract A2aR from the plasma 
membrane. 3 and 4 % (w/v) SMA were unable to extract more protein than 2 % (w/v) SMA. It 
was therefore chosen that 2 % (w/v) SMA would be used. This would limit the amount of free 
SMA (that which did not form nanodiscs) in the sample as free SMA may affect downstream 
analysis. 37 °C is physiological temperature for humans and therefore should have allowed 
extraction of protein while the membrane was in its physiological state. The fluidity of the lipid 
bilayer at 37 °C would also allow for easier insertion of polymer into the membrane. Lower 
temperatures than 37 °C were investigated in the interest of protein preservation. However, at 
lower temperatures, as seen at 4 °C, extraction was reduced. Low temperatures, such as 4 °C, 
are known to reduce the fluidity of the membrane through tighter packing of lipid molecules. 
It has been shown that tighter packing of lipids reduces the extraction capabilities of SMA 
(Scheidelaar et al., 2015). The low temperature therefore would make insertion of SMA into 
the lipid membrane more difficult and extraction less efficient. As the temperature was 
increased, the fluidity of the membrane would increase allowing greater extraction. Generally 
with detergent-solubilisation, samples are maintained at 4 °C throughout use to preserve 
biological function and processes performed in a cold room. This would be detrimental to 
SMALP preparation, so an alternative approach to temperature is required. A 1 h incubation 
(pre-centrifugation) provided optimal extraction of receptor. Less than 1 h incubation reduced 
the extraction efficiency. During the 1 h centrifugation at 4 °C the SMA was still able to extract 
a small amount of receptor. However this was much less than was seen with a 1 h incubation 
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at 37 °C before centrifugation. This correlated well with what was observed with the 4 °C 
incubation for 1 h during the temperature trials. Incubating for 3 h at 37 °C, as seen in the 37 
°C stability investigations, was detrimental to protein function. 
Despite A2aR having a predicted mass of approximately 45790 Da (~45.8 kDa), bands 
attributed to monomeric A2aR were observed at ~40 kDa. This was likely due to the 
hydrophobicity of the A2aR causing it to run ~5 kDa further than expected, a known 
phenomenon amongst hydrophobic proteins. The band present at 80-90 kDa was attributed to 
dimeric A2aR. There is a possibility that this observed dimeric A2aR was merely an artefact of 
the SDS-PAGE, commonly seen with the very hydrophobic 7TM receptors. However, as there 
was an observed increase in levels of dimeric A2aR with increasing incubation times and SMA 
concentrations, SMALP-solubilisation appears to be able to preferentially solubilise GPCRs as 
monomers or monomer/dimer mixtures with varying ratios of monomer:dimer. Without a 
defined mechanism for the formation of SMALP discs, the reasons for increased presence of 
dimers is speculative. However, if SMA forms discs by individual chains of SMA inserting 
into membranes before forming a belt around a section of membrane, increased time and SMA 
concentrations would aid in the formation of larger discs and therefore the encapsulation of 
larger protein complexes. With careful selection of solubilisation conditions, SMALP-
solubilisation may be a useful tool in the future study of GPCR dimers. 
3.3.2  Pharmacological characterisation of SMALP-A2aR 
Radioligand binding assays showed that SMALP-solubilisation had not affected the 
pharmacology of the A2aR. Antagonists (XAC and theophylline), that occupy the receptor but 
elicit no response, and the inverse agonist ZM241385, that stabilises the inactive state of A2aR, 
were able to bind to SMALP-A2aR with no obvious deviation from the membrane-bound A2aR. 
Agonists, such as NECA, interact with a receptor and cause conformational changes resulting 
in intracellular signalling. NECA displayed WT-like binding affinity at SMALP-A2aR. This 
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provided a more stringent study of the pharmacology of SMALP-A2aR as an agonist interacts 
with the receptor differently to antagonists as it induces an active conformation in the receptor. 
The native ligand of A2aR, adenosine, could not be used to investigate radioligand binding of 
A2aR. This is due to the necessary addition of adenosine deaminase to remove endogenous 
adenosine in the samples which would occupy the binding site and compete with other ligands 
(Jenner et al., 2009, Fredholm, 2010). 
The recovery of ligand binding activity calculated for solubilised-A2aR, compared to mem-
A2aR, showed that SMALPs extracted as much active receptor as DDM (23.3 ± 2.75 % in 
SMALPs compared to 27.6 ± 11.4 % for DDM, compared to membrane preparations). 
However, there was much less variability between SMALP samples than between DDM 
samples. Therefore any replicates performed will be able to more accurately calculate the 
amount of active receptor present in SMALPs over DDM. 
3.3.3  Stability of A2aR in SMALPs 
Retention of important membrane components (e.g. cholesterol and annular lipid), in SMALPs 
increased thermostability of A2aR over DDM-A2aR. The 4 °C increase in thermostability was 
approximately the same as was observed in SMALP-A2aR over DDM-A2aR prepared from 
yeast membranes (Jamshad et al., 2015). This would suggest that the SMALP process itself 
infers an element of stability on the receptor, regardless of the initial membrane composition. 
The addition of cholesterol, in the form of CHS, to SMALP-A2aR further increased its 
thermostability. By comparison, even the presence of CHS in all detergent samples, routinely 
used in detergent solubilisation (Toro et al., 2009, Attrill et al., 2009), still did not stabilise 
A2aR to the same level as in SMALPs. The presence of natural cholesterol, possibly other 
stabilising components from the membrane and lateral pressure exerted by the retained bilayer 
structure in SMALPs were possibe reasons for the increased stability at 37 °C. SMALP-A2aR 
retained the native membrane bilayer structure and so was able to stabilise the A2aR at higher 
68 
 
temperatures and for longer. SMALPs were not as stable as native membrane, suggesting there 
was a stabilising factor lost during the SMALP process. However, in comparison to detergent-
solubilised proteins, SMALPs would be a much better platform for drug screens at 37 °C. 
Whether storing SMALPs at 4 °C or -20 °C, there would be no detriment to the sample in 
comparison to mem-A2aR. This infers that the lipid bilayer extracted in the SMALP behaved 
similarly to native membrane, with membrane components acting as cryopreservatives 
resulting in SMALP-A2aR behaving indistinguishably from mem-A2aR at low temperatures. 
This allows for easier handling of samples, large sample preparation and storage without fear 
of protein degradation. 
In summary, presented here is the very first report of a GPCR of any description being 
solubilised in the total absence of detergent from a mammalian cell with retention of 
pharmacological activity. SMALPs were shown to be a method of solubilising functional 
GPCRs from mammalian cells that inferred greater stability than detergent solubilisation. 
Samples could be prepared in advance of their use and stored in different ways without loss of 
binding activity. Finally, SMALPs provided a better platform for drug screens at physiological 
temperature compared to detergent micelles. This work resulted in a joint first author paper 
(Jamshad et al., 2015). 
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4 CHAPTER 4: SMALP-SOLUBILISATION OF 
INTRACELLULAR MEMBRANES 
4.1 Introduction 
Retention of proteins in the endoplasmic reticulum (ER) is the leading cause of several 
diseases. Retinitis pigmentosa is the degeneration, and ultimately loss, of sight and can be 
caused as a result of ER-retention of rhodopsin (Dryja et al., 1990), a cononical family A 
GPCR. Hypogonadotrophic hypogonadism, a condition that can be caused by retention of 
gonadotrophin releasing hormone receptor (de Roux et al., 1997). Some melanocortin 4 
receptor mutations lead to ER-retention and familial obesity (Nijenhuis et al., 2003). 
hypothyroidism (thyroid stimulating hormone receptor (Tonacchera et al., 2004)), familial 
glucocorticoid deficiency (melanocortin 2 receptor (Chung et al., 2008)) and Leydig cell 
hypoplasia leading to infertility (leutinizing hormone receptor (Dickinson et al., 2009)) are all 
diseases caused by mutations in GPCRs which result in ER-retention. ER-retention is not 
restricted to GPCRs, other proteins are known to be retained in the ER as a consequence of 
mutation. These can lead to serious disease states such as: lysosomal storage diseases e.g. 
Gaucher’s disease (mutations in β-glucosidase (Beutler et al., 2004)); and has been well 
documented in many mutations of cystic fibrosis transmembrane conductance regulator in 
cystic fibrosis. 
One of the most studied diseases caused by ER-retention of a protein is nephrogenic diabetes 
insipidus (NDI), a disease characterised by polyuria leading to severe dehydration and 
potentially death. There have been >130 mutations identified in the V2 vasopressin receptor 
(V2R), a family A GPCR, which cause approximately 90 % of all cases of NDI (Knoers, 1993, 
Birnbaumer, 2000). These mutations often lead to ER-retention due to misfolded V2R. As a 
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result, circulating [arginine8]vasopressin (AVP) acts upon far fewer receptors, preventing 
effective reabsorption of water in the kidneys. Attempts to aid correct folding, and thus recover 
cell-surface expression, of V2R through pharmacological chaperones has been attempted 
(Robben et al., 2007) but with limited success. Were there more details known of the 
conformational changes induced through these disease-causing mutations, it may be possible 
to design and develop better chaperones and drugs to aid in recovery of cell surface expression. 
The SMALP method of solubilisation could potentially be used for this purpose. 
SMALP studies to date have predominantly focused on extraction from cell plasma 
membranes. Two reports have investigated the ability of 3:1 (styrene:maleic acid molar ratio) 
SMA to extract proteins from the membranes of organelle preparations (Long et al., 2013, 
Skaar et al., 2015). However, doubts are raised over the samples used in these studies as post-
SMALP-solubilisation samples were centrifuged at only 20,000 x g for 10 min. This may not 
have removed all insoluble material from the supernatant. These, and all other SMALP studies, 
have looked at SMALP-solubilisation from membrane preparations (Knowles et al., 2009, 
Orwick-Rydmark et al., 2012, Gulati et al., 2014, Prabudiansyah et al., 2015). However, here, 
SMALP-solubilisation was performed on whole cells. It was therefore not known whether the 
solubilised membrane fragments were of the plasma membrane only or of intracellular 
membranes as well. 
It has been shown that SMA displays no preference in relation to lipid type when forming 
nanodiscs (Scheidelaar et al., 2015). Lipids possessing negative charge have been SMALP-
solubilised (Prabudiansyah et al., 2015)  demonstrating a lack of ionic interference in nanodisc 
formation. In E.coli, SMA extracted proteins efficiently regardless of the lipid composition 
they were present in (Dorr et al., 2014). It was therefore plausible that SMA would be able to 
extract proteins from intracellular membranes of whole, mammalian cells. 
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In this part of the study, use of SMA to extract protein from intracellular membranes of whole 
mammalian cells was investigated. This would provide a new method of studying diseases 
caused by intracellular retention of proteins. Study of the misfolded proteins, and their 
interactions with known pharmacological chaperones, could open new possibilities for drug 
design, discovery and mechanisms of action for pharmacological chaperones. 
4.1.1  KDEL 
The KDEL sequence (- lysine – aspartate – glutamate – leucine -) is a well-known ER retention 
motif that has proved efficient at retaining proteins in the ER. KDEL is a common sequence at 
the extreme c-terminal tail of 3 proteins known to be retained in the ER; binding 
immunoglobulin protein; heat shock protein 90 kDa beta member 1; protein disulphide-
isomerase (Jackson et al., 1990, Munro and Pelham, 1987). Each of these 3 soluble proteins 
are present in the ER and have roles in the correct folding of nascent polypeptides. Mutagenesis 
studies have concluded that the C-terminal KDEL sequence was essential for their retention in 
the ER, but they must be the final 4 residues to confer ER-retention. However, providing this 
was the case, not even a change in the tertiary structure could prevent their retention (Munro 
and Pelham, 1987). 
Upon engineering the KDEL sequence to the extreme C-terminus of a transmembrane protein 
(CD8), ER retention was observed (Stornaiuolo et al., 2003). This showed that the KDEL 
sequence did not just affect soluble proteins, but membrane-bound proteins as well. However, 
studies of the budding pattern of the KDEL-tagged CD8 showed its leaving from the ER. 
Presence of N-linked glycosylation was proof of processing through the ER, but lack of O-
linked glycosylation suggested the protein had not reached the Golgi apparatus. It was proposed 
that KDEL-receptors act to identify nascent polypeptides that are still marked by ER-
chaperones (Hamada et al., 2004). KDEL-receptors are responsible for binding misfolded 
proteins and returning them to the ER. With knowledge that membrane proteins were retainable 
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in the ER (Jackson et al., 1990), A2aR was engineered with a KDEL, ER-retention motif at the 
C-terminus (A2aR-KDEL) to allow investigation of the ability of SMA to solubilise 
intracellular membranes. 
4.1.2  Glycosylation of A2aR 
The passage of nascent polypeptides through the ER results in correct folding of the protein 
and derivatisation by polysaccharides to appropriate N-linked glycosylation sites (N-X-S/T). 
After processing in the ER, proteins are transported to the Golgi for further (O-linked) 
glycosylation and processing of the N-linked glycosylation before transport to their ultimate 
destination. The vast majority of GPCRs have N-linked glycosylation sites on the N-terminus 
or ECLs. Often multiple glycosylation sites are utilised (Wheatley and Hawtin, 1999). There 
are very few O-linked glycosylation sites on GPCRs, V2R is one of the few that does receive 
O-linked glycosylation (Sadeghi and Birnbaumer, 1999). The precise role of glycosylation is 
not clear for A2aR (Piersen et al., 1994). Since the A2aR construct used in these studies, as 
mentioned in section 3.1, was glycosylation deficient, re-introduction of the glycosylation site 
in A2aR was performed as this may play a role in GPCR trafficking. A2aR was developed with 
the N154Q mutation reversed, reintroducing the sole glycosylation site of A2aR. This construct 
was characterised before introduction into the A2aR-KDEL sequence to investigate A2aR ER-
retention. 
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4.2 Results 
4.2.1  A2aR-KDEL 
Primers, as shown in table 4.1, were designed to introduce the KDEL sequence, in-frame, on 
to the C-terminus of A2aR in one reaction. A Quikchange-like, site-directed mutagenesis 
protocol was employed, as described in section 2.2.1. This reaction required the insertion of 12 
base pairs (bp) rather than the more usual 1-3 bp changes required for a single point mutation. 
Consequently, the complementary sequence at the 5’ and 3’ ends were extended, from the usual 
9-12 to 21, to ensure efficient primer annealing. Once the DNA sample had been prepared and 
correct DNA sequence confirmed by sequencing in both directions, the A2aR-KDEL construct 
generated was characterised. 
Given that KDEL is an established ER-retention sequence, it was anticipated that A2aR-KDEL 
would exhibit reduced cell surface expression in comparison to A2aR lacking the KDEL 
sequence. Cell-surface expression levels of A2aR-KDEL were determined by ELISA, as 
described in section 2.2.19. A2aR-KDEL was compared to A2aR for cell-surface expression 
levels. As was evident from figure 4.1, the KDEL sequence on the C-terminus of A2aR did not 
cause any decrease in cell surface expression as A2aR-KDEL expression levels were WT-like. 
The ability of agonist challenge to drive receptor internalisation was also investigated for A2aR-
KDEL and compared to A2aR. Stimulation with a saturating concentration of NECA (100 μM) 
was employed to study the ability of any A2aR-KDEL expressed at the cell surface to 
internalise. A2aR-KDEL responded to saturating amounts of NECA with the same level of 
internalisation as A2aR (~20 %) 
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Receptor 
construct 
Sense primer Antisense primer 
A2aR-KDEL 
5' – CAG-GAT-GGA-GCA-GGA-
GTG-TCC-AAG-GAT-GAA-
CTG-TAG-GCG-GCC-GCT-
CGA-GTC-TAG - 3' 
5' – CTA-GAC-TCG-AGC-GGC-
CGC-CTA-CAG-TTC-ATC-
CTT-GGA-CAC-TCC-TGC-
TCC-ATC-CTG - 3' 
 
Table 4.1. Oligonucleotide sequences designed to introduce the KDEL ER-retention motif 
to the C-terminus of A2aR. Sequences shown in red denote the bases inserted. Sequence 
shown in black denotes bases complementary to template DNA. 
 
Figure 4.1. Cell surface expression of A2aR-KDEL compared to A2aR and response to 
agonist challenge. Cell-surface expression was determined by ELISA. Data presented 
normalised to untransfected cells (0 %) and unstimulated A2aR (100 %). Internalisation 
following agonist stimulation was determined using NECA (100 μM) for 1 h. Data are mean ± 
s.e.m. of three experiments performed in triplicate.  
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4.2.2  Glycosylation of A2aR-KDEL 
Primers, shown in table 4.2, were designed to re-introduce the glycosylation site of A2aR and 
A2aR-KDEL at residue 154 by mutating Gln back to the native Asn. A one-step mutagenesis 
strategy was employed and the sequence of constructs confirmed by automated fluorescence 
sequencing in both directions, as described in section 2.2.7. Glycosylated A2aR herein referred 
to as glyco-A2aR and glycosylated A2aR-KDEL herein referred to as glyco-A2aR-KDEL 
The effect of re-creating the N-glycosylation site on cell surface expression was investigated. 
It was determined by ELISA, figure 4.2, that there was no notable change in cell-surface 
expression levels, nor ability of agonist stimulation to internalise the receptor construct, upon 
re-introduction of the glycosylation site (glyco-A2aR). Western blot analysis of A2aR and glyco-
A2aR revealed a clear difference. Whereas the A2aR (lacking glycosylation) migrated as a single 
band (~40 kDa), glyco-A2aR generated a series of bands between 40 – 50 kDa coinciding with 
the appearance of not only non-glycosylated A2aR but glycosylated intermediates (figure 4.3). 
Having demonstrated the glycosylation site had resulted in glycosylated A2aR without 
detriment to the cell surface expression levels or the ability to internalise upon agonist binding, 
glycosylation was investigated for the ability to induce ER-retention in A2aR-KDEL. Glyco-
A2aR-KDEL was studied in comparison to A2aR cell surface expression levels. As shown in 
figure 4.4, there was no notable change in cell-surface expression levels for the glyco-A2aR-
KDEL construct in comparison to A2aR. Presence of the N-glycosylation also did not affect the 
levels of A2aR internalisation upon agonist stimulation. 
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Receptor 
construct 
Sense primer Antisense primer 
Glyco-A2aR 
5' –CA-AAG-GAG-GGC-AAG-
AAC-CAC-TCC-CAG-GGC- 3' 
5' –GCC-CTG-GGA-GTG-GTT-
CTT-GCC-CTC-CTT-TG- 3' 
 
Table 4.2. Primers to introduce Asn154 for the native glycosylation site of A2aR. Sequences 
shown in red denote the bases changed to create the [Q154N]A2aR construct. Sequence shown 
in black denotes bases complementary to template DNA. 
 
 
Figure 4.2. Cell-surface expression of glycosylated A2aR (glyco-A2aR) in comparison to 
non-glycosylated A2aR (A2aR) with (+) or without (-) agonist stimulation. Cell-surface 
expression was normalised to untransfected cells (0 %) and unstimulated A2aR (100 %). 
Internalisation under agonist stimulation was determined using NECA (100 μM) for 1 h. Data 
are mean ± s.e.m. of three experiments performed in triplicate.  
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Figure 4.3. Western blot analysis of SMALP-solubilised glycosylated A2aR. SMALP-A2aR 
(A2aR S) compared to glycosylated A2aR T: total receptor present; S: soluble and P: insoluble 
fractions after centrifugation. Probed with anti-HA antibody. Molecular weight marker (M). 
Characteristic gel of two experiments 
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Figure 4.4. Cell-surface expression of glycosylated A2aR-KDEL (glyco-A2aR-KDEL) in 
comparison to non-glycosylated A2aR (A2aR) with (+) or without (-) agonist stimulation. 
Cell-surface expression was normalised to untransfected cells (0 %) and unstimulated A2aR 
(100 %). Internalisation under agonist stimulation was determined using NECA (100 μM) for 
1 h. Data are mean ± s.e.m. of three experiments performed in triplicate. 
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4.2.3  ER-retention sequence from α2c-AR 
As the incorporation of the KDEL ER-retention sequence had failed to prevent the A2aR 
trafficking to the cell surface, an alternative ER-retention sequence was sought. The ER-
retention sequence from the α2c adrenergic receptor (α2c-AR) was selected as it had been 
previously reported to retain α2c-AR in the ER (Schwappach et al., 2000). The α2c-AR and the 
A2aR are both family A GPCRs. Furthermore, it has been reported that engineering the final 14 
residues of α2c-AR onto CXCR1, another family A GPCR, resulted in ER-retention (Milligan 
et al., 2005). It was therefore hypothesised that this ER-retention motif should be able to confer 
ER-retention to the A2aR. The α2c-AR ER-retention motif consists of the final 14 residues at 
the C-terminus (-Lys-His-Ile-Leu-Phe-Arg-Arg-Arg-Arg-Arg-Gly-Phe-Arg-Glu-(-
KHILFRRRRRGFRQ-COOH)) of the α2c-AR. The -KHILFRRRRRGFRQ- motif was 
therefore engineered onto the C-terminus of A2aR (A2aR-KHILFRRRRRGFRQ). 
Initially primers were designed to introduce the full 42 bp ER-retention motif in one step. 
Complementary 5’ and 3’ sequences were extended to 28 bp to assist primer annealing. 
However, this method proved unsuccessful as no product was produced through Quikchange-
like mutagenesis. Primers were then designed to introduce the bases in 2 steps. The first round 
introduced 18 of the 42 bp corresponding to KHILRQ (table 4.3, shown in red). This was 
selected to avoid possible hairpin loop formation within the primers that was identified as a 
possibility from observation of complementary sequences in the primers. Creation of the A2aR 
with the –KHILRQ fragment of the –KHILFRRRRRGFRQ motif provided increased 
complementarity for the primers designed to introduce the full motif. The second round of 
mutagenesis used the product from the first round as a template to introduce the remaining 24 
bp corresponding to FRRRRRGF (table 4.3, shown in purple). The sequence of the final 
product (A2aR-KHILFRRRRRGFRQ) was confirmed by sequencing in both directions. 
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Receptor 
construct 
Sense primer Antisense primer 
HA-A2aR-
KHILRQ 
5' – C-CTG-GCC-CAG-GAT-
GGA-GCA-GGA-GTG-TCC-
AAG-CAC-ATC-CTC-AGG-CAG-
TAG-GCG-GCC-GCT-CGA-GTC-
TAG-AGG-GCC-C - 3' 
5' – G-GGC-CCT-CTA-GAC-TCG-
AGC-GGC-CGC-CTA-CTG-CCT-
GAG-GAT-GTG-CTT-GGA-CAC-
TCC-TGC-TCC-ATC-CTG-GGC-
CAG-G - 3' 
HA-A2aR- 
KHILFRRR
RRGFRQ 
5' – C-CTG-GCC-CAG-GAT-
GGA-GCA-GGA-GTG-TCC-
AAG-CAC-ATC-CTC-TTC-CGA-
CGG-AGG-AGA-AGG-GGC-
TTC-AGG-CAG-TAG-GCG-GCC-
GCT-CGA-GTC-TAG-AGG-GCC-
C - 3' 
5' – G-GGC-CCT-CTA-GAC-TCG-
AGC-GGC-CGC-CTA-CTG-CCT-
GAA-GCC-CCT-TCT-CCT-CCG-
TCG-GAA-GAG-GAT-GTG-CTT-
GGA-CAC-TCC-TGC-TCC-ATC-
CTG-GGC-CAG-G - 3' 
 
Table 4.3. Oligonucleotide sequences designed to introduce the KHILFRRRRRGFRQ 
ER-retention motif from α2c-AR to the C-terminus of A2aR. Sequences in red denote the 
bases inserted in the first reaction. Sequences in purple denote bases introduced during the 
second reaction. Sequences in black denote bases complementary to template DNA. 
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Cell surface expression levels of A2aR-KHILFRRRRRGFRQ were first identified to 
investigate the ability of the –KHILFRRRRRGFRQ motif to prevent A2aR trafficking to the 
cell surface. It was observed by ELISA (figure 4.5) that A2aR-KHILFRRRRRGFRQ had a 
decreased expression level at the cell-surface (51.1 ± 3.9 % compared to A2aR). Agonist 
challenge of receptor expressed at the cell surface, with 100 μM NECA, was performed to 
investigate the ability of A2aR-KHILFRRRRRGFRQ, expressed at the cell surface, to 
internalise. The A2aR-KHILFRRRRRGFRQ that was still expressed at the cell surface was able 
to internalise to WT-like levels (~15 % internalisation) upon agonist stimulation. 
Having observed a reduction in cell surface expression, investigations into whether this was a 
result of ER-retention or of reduced overall expression were performed. This was achieved by 
using low concentration (0.1 %) of the detergent Triton X-100 to permeabilise the plasma 
membrane (Barwell et al., 2011). This allowed anti-HA antibody to access the intracellular 
components in addition to the cell surface. Whole-cell expression ELISA data (figure 4.6) 
revealed that, in comparison to A2aR cell surface expression, there was reduced overall 
expression of A2aR-KHILFRRRRRGFRQ (61.4 ± 9.1 %). This was similar to the 51.1 ± 3.9 % 
decreased expression of A2aR-KHILFRRRRRGFRQ noted above, observed at the cell-surface. 
Whole cell expression of A2aR was also shown to be reduced compared to expression at the 
cell surface (84.4 ± 4.7 %).  
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Figure 4.5. Cell surface expression of A2aR and A2aR-KHILFRRRRRGRFRQ and effect 
of agonist stimulation. Cell-surface expression was determined by ELISA and normalised to 
untransfected cells (0 %) and unstimulated (-) A2aR (100 %). Internalisation following agonist 
stimulation was determined using NECA (100 μM) for 1 h (+). Data are mean ± s.e.m. of three 
experiments performed in triplicate. 
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Figure 4.6. Whole-cell expression data comparing total expression of A2aR-
KHILFRRRRRGRFRQ and A2aR. Data were normalised to untransfected cells (0 %) and 
cell-surface expression of A2aR (100 %). Data are mean ± s.e.m. of three experiments 
performed in triplicate. 
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4.3 Discussion 
Many diseases, including retinitis pigmentosa and nephrogenic diabetes insipidus, can be 
caused by ER-retention of mutated proteins. Characterisation of these ER-retained proteins 
would provide insight into the misfolding of the proteins and potential methods of recovering 
cell surface expression. Already there are pharmacological chaperones that allow recovery of 
cell surface expression, in vitro, for some proteins such as V2R (Hawtin, 2006). Detailed 
information of the retained proteins would help identify and develop new pharmacological 
chaperones that may be used as treatment for some of the diseases mentioned. These mutated 
proteins are not trafficked to the cell surface, therefore solubilisation of ER membranes would 
be required. SMALP-solubilisation has been shown to show no preference for lipid type when 
solubilising membranes (Dorr et al., 2014). It is therefore possible that SMALPs could 
solubilise intracellular membranes but this has not yet been conclusively established. To 
investigate the ability of SMA to solubilise intracellular membranes, A2aR constructs were 
engineered with ER-retention motifs with the view to prevent their trafficking to the cell 
surface. 
Previous studies that have engineered the KDEL motif at the extreme C-terminus of proteins 
have proven successful at retaining the protein in the ER (Munro and Pelham, 1987, Jackson 
et al., 1990). Although a small amount of “leakage” had been observed in some studies, 
receptor progression through the ER and Golgi apparatus was retarded for both soluble and 
membrane-bound proteins (Jackson et al., 1990). However, the lack of any ER-retention in this 
study showed that the KDEL sequence was ineffective at retaining A2aR in the ER. It has been 
shown, (Stornaiuolo et al., 2003), that the KDEL sequence results in retrieval of proteins in 
transit between the ER and Golgi apparatus. There have been reports of transmembrane 
proteins that exit the ER through different mechanisms, bypassing the Golgi altogether (Grieve 
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and Rabouille, 2011). This may have provided an alternative pathway by which glycosylation 
deficient A2aR could reach the cell surface. 
In an attempt to force the A2aR through the Golgi pathway, reintroduction of the glycosylation 
site at residue 154 was performed. The asparagine residue at 154 undergoes N-linked 
glycosylation, originating in the ER before elaboration in Golgi apparatus. Although 
glycosylation has been shown to increase cell-surface expression of proteins (Davidson et al., 
1996), there has been no evidence of saturating the ER-retention mechanism reported, despite 
up to 7-fold increases in receptor expression (Munro and Pelham, 1987). The increased 
expression of glycosylated-A2aR was not expected to be as high as 7-fold as A2aR only contains 
1 glycosylation site, unlike most family A GPCRs which contain 2 or 3. Western blot analysis 
showed the typical banding pattern observed for glycosylated proteins (Wheatley and Hawtin, 
1999). Different sugar moieties of different sizes confer extra mass to a protein, providing a 
thick, undefined banding pattern greater than that of the calculated protein mass. However, 
glycosylation of A2aR-KDEL was still ineffective at conferring ER-retention. As glyco-A2aR 
must have been transported to the Golgi apparatus, the KDEL ER-retention motif must not 
have been able to impart ER-retention on A2aR. This could possibly have been due to the 
tertiary structure adopted by the long (~122 residues) C-terminal tail of A2aR concealing the 
KDEL motif. 
The final 14 residues of the α2c-AR, KHILFRRRRRGFRQ, have been reported to act as an ER-
retention motif at family A GPCRs α2c-AR and CXCR1 (Schwappach et al., 2000, Milligan et 
al., 2005). The increased length of the KHILFRRRRRGFRQ motif and the reported ability to 
retain family A GPCRs in the ER made this motif an exciting prospect after KDEL was unable 
to impart ER-retention on A2aR. The KHILFRRRRRGFRQ motif was engineered to the C-
terminus of A2aR and first investigated for its ability to prevent A2aR expression at the cell 
surface. A2aR-KHILFRRRRRGFRQ displayed reduced expression at the cell surface of 51.1 ± 
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3.9 % compared to A2aR, but this was largely a result of an overall reduced expression level. 
The KHILFRRRRRGFRQ motif was responsible for reducing overall expression of A2aR to 
61.4 ± 9.1 %, although this figure may be slightly misleading. The whole-cell ELISA technique 
employs detergent to permeabilise the cell membrane, allowing antibody access to the 
intracellular membranes of the cell. As a result, the detergent solubilises a fraction of the cell 
surface-expressed receptor. This is likely how overall expression of A2aR appeared to be less 
than A2aR expressed at the cell-surface. This was obviously impossible and therefore most 
likely an artefact of the whole-cell ELISA technique. Total A2aR-KHILFRRRRRGFRQ 
expression was therefore probably higher than the data suggested. However, it appeared the 
majority of A2aR-KHILFRRRRRGFRQ expressed was expressed at the cell surface. Upon 
SMALP-solubilisation of A2aR-KHILFRRRRRGFRQ it would not be possible to state 
definitively whether it had been extracted from the ER or cell surface. 
The KHILFRRRRRGFRQ sequence was substantially longer than KDEL and was able to 
affect some measure of intracellular retention. This suggests that it may have been the length 
of the KDEL sequence in comparison to the length of the A2aR C-terminus (~121 residues) that 
was preventing KDEL from effectively retaining A2aR in the ER. It has been previously 
reported (Singh et al., 2010, Piersen et al., 1994) that the C-terminus of A2aR can be truncated, 
by 96 residues, back to residue 316 without affecting receptor function. KDEL was a short 
(only four residues) sequence at the end of a seemingly superfluous region of A2aR. The –
KHILFRRRRRGFRQ motif, which has been successfully used for ER-retention for α2c-AR 
(Schwappach et al., 2000) and CXCR1 (Milligan et al., 2005) (C-terminal lengths of 21 and 42 
respectively), was a short sequence compared to the 121 residues at the C-terminal tail of A2aR. 
Therefore the tertiary structure adopted by the C-terminal tail of A2aR may have concealed the 
KDEL and KHILFRRRRRGFRQ sequences, preventing retention in the ER. Although it has 
been shown that removal of tertiary structure from the C-terminus has no effect on ER-retention 
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conferred by KDEL (Munro and Pelham, 1987), there has been no indication of possible 
interference to ER-retention from different tertiary structures of extended C-termini. 
The efforts to retain A2aR in the ER were therefore unsuccessful and it is unclear as to why this 
was the case. Future work that may go in to SMALP-solubilisation from intracellular 
membranes may wish to engineer the retention motifs to C-terminally truncated A2aR. This 
would allow for a more accessible motif, increasing the likelihood of being captured in the ER, 
without compromising receptor function. Alternatively, HA-tagged V2R containing an NDI 
mutation, such as I46K (Pasel et al., 2000), resulting in ER-retention could be employed. 
RAMP1 is known to be retained in the ER in the absence of family B GPCR expression 
(Christopoulos et al., 1999). Epitope-tagging of RAMP1 and subsequent SMALP-
solubilisation would provide information on the ability to SMALP-solubilise from intracellular 
membranes. However, no functional studies would be available to study the functional state of 
RAMP1 once SMALP-solubilised. 
In summary, it is still unknown whether SMA can extract proteins from the membranes of 
intracellular organelles in whole mammalian cells. This was due to the difficulties in creating 
a tool to measure such properties. KDEL and KHILFRRRRRGFRQ sequences were unable to 
retain A2aR in the ER. The reasons for this were unclear but may involve concealed C-termini. 
Although these methods did not confer ER-retention, there are still several alternatives that 
could be investigated. 
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5 CHAPTER 5: CYSTEINE-DEPLETED A2aR FOR SMALP 
BIOPHYSICAL STUDIES 
5.1 Introduction 
SMALP technology has proven a useful platform in the study of membrane-bound proteins by 
analytical techniques such as: cryo-electron microscopy (Postis et al., 2015); transmission-
electron microscopy; nuclear magnetic resonance (NMR); circular dichroism (CD) (Knowles 
et al., 2009); electron paramagnetic resonance (Orwick-Rydmark et al., 2012); analytical 
ultracentrifugation and differential scanning calorimetry (Jamshad et al., 2011). In each case, 
SMALPs provided a platform as useful for the technique as alternative solubilisation 
methodologies. In some cases SMALPs proved more useful than alternatives in techniques 
such as CD. When used in CD, SMALPs were able to be studied at lower wavelengths than the 
available membrane-embedded alternative, apolipoprotein stabilised nanodiscs, due to the non-
proteinaceous nature of SMALPs, allowing further studies of protein structure. However, to 
date, no study on the real-time dynamics of protein conformation has been performed in 
SMALPs. 
The real-time study of proteins provides information on conformational rearrangements upon 
ligand interaction and protein-protein interactions. In recent years Förster resonance energy 
transfer (FRET) has been used to study GPCRs upon ligand interaction to view nanometre 
changes in conformations over nanosecond timescales (Lohse et al., 2012). 
5.1.1  Intrinsic tryptophan fluorescence and FRET 
The structure of TM helices in transmembrane proteins has been shown to be dependent on the 
lipid composition of the bilayer (Gibson and Brown, 1993, Caputo and London, 2003). 
Changes to the lipid composition, and change in lateral pressure, through detergent 
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solubilisation can therefore alter the structure and behaviour of the protein studied. By 
maintaining the lipid annulus of proteins, SMALP-solubilisation was hypothesised to be a 
potential platform for studying GPCR ligand-induced conformational changes using intrinsic 
tryptophan fluorescence and FRET. The transparency of SMA has already been shown to allow 
detailed study of proteins at lower wavelengths than other solubilisation systems. Tryptophan 
residues are known to excite at 280 nm and emit photons at approximately 350 nm, at both 
wavelengths SMALPs have been shown not to obscure light. Changes in the local environment 
of the Trp affect the emission spectra; movement of Trp residues from hydrophobic regions 
(e.g. membrane embedded) to be more solvent-exposed displays as a reduced quantum yield in 
fluorescence signalling (and vice versa). This allows real-time study of the conformational 
changes of proteins.  
FRET is another, highly sensitive, fluorescence technique. With longer fluorescence times than 
intrinsic tryptophan fluorescence, FRET allows collection of data over nanosecond timescales. 
This allows determination of rotations and more intermediate conformations adopted upon 
ligand interaction, with fewer artefacts created from surrounding residues. The extrinsic 
fluorophore IAEDANS (5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic acid) 
is commonly used in fluorescence microscopy and FRET. IAEDANS reacts with thiol groups, 
which in proteins allows labelling of non-disulphide-bound cysteines. As the fluorescence 
spectra of IAEDANS are linked to the immediate solvent environment, changes in protein 
conformation can be observed through altered emission spectra. The excitation of IAEDANS 
(336 nm) overlaps well with tryptophan fluorescence emissions, meaning IAEDANS-Trp 
FRET data can be used to observe changes in distance between these two reporters. IAEDANS 
emits at 490 nm, a wavelength not obscured by SMA, allowing the use of SMALPs in FRET 
studies. 
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5.1.2  Loci for reporter group introductions 
For these studies, an A2aR construct was manufactured to contain strategically placed 
tryptophan (intrinsic tryptophan fluorescence) and cysteine residues (IAEDANS derivatisation 
site). These residues would allow for studies of A2aR conformation upon activation by agonist 
compared to binding antagonists. The desired use of IAEDANS as a fluorescent probe, at a 
specific locus, required all other thiol groups (i.e. cysteine residues) to be either invested in 
disulphide-bond formation or inaccessible. Remaining cysteines would require mutation to a 
different, non-reactive, residue to ensure the spectra observed were from the desired cysteine 
only. 
Inspection of the A2aR sequence revealed several residues with potential to report on 
conformational changes associated with activation of the A2aR. Leu78 (3.26 at the top of TM3), 
Ile106 (3.54 in ICL2), Tyr176 (5.37 at the top of TM 5), Leu225 (6.27 in ICL3), Ala231 (6.33 
in ICL3) and Thr256 (6.58 at the top of TM6) were all identified as being suitable candidates 
for mutation to reporter groups tryptophan or cysteine (numbers in brackets are the Ballesteros-
Weinstein numbering system (Ballesteros and Weinstein, 1995)). As seen in figure 5.1, Leu78, 
Tyr176 and Trp256 are all present close to the top of their respective TM helix. Introduction 
of reporter groups at these sites would allow study of how the extracellular face of A2aR 
behaves upon ligand binding. As noticed among crystal structures of family A GPCRs (Dore 
et al., 2011, Xu et al., 2011, Unal and Karnik, 2012), it would be expected that Thr256 and 
Leu78/Tyr176 would move closer together upon agonist binding. At the intracellular face, 
detected signals from residue 106 in relation to residues 225 and 231 would allow study of 
conformational changes at the intracellular face of A2aR. An observed increase in distance 
between TM3 and TM6 upon agonist binding would be expected as a G-protein binding pocket 
becomes exposed. Intracellular residues Ile106 and Ala231 were the A2aR equivalent of β2AR 
residues that were previously successful as reporter groups in fluorescence assays  
91 
 
 
Figure 5.1. 2D representation of the A2aR. An HA-epitope tag at the N-terminus shown in dark blue. Cysteines that form disulphide bridges are shown in 
matching shades of green. Residues mutated for reporter groups are highlighted in red. Two cysteines that were not mutated are shown in cyan. Cysteine residues 
with grey backgrounds were removed. Residues in orange form the ZM241385 binding pocket. Helices are labelled with roman numerals.
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(Yao et al., 2006, Yao et al., 2009). Due to the steric hindrance caused by the bulky Trp 
sidechain, Trp was considered to be the more difficult of the reporter groups to incorporate. 
Residues to be used as IAEDANS derivatisation sites were investigated for their ability to 
incorporate the bulky IAEDANS. These residues were mutated to the bulky tryptophan to 
observe any negative impact on receptor function. 
5.1.3  The “Zhar” construct 
For most biophysical analyses, large quantities of protein are required. Large-scale production 
of proteins most commonly utilises expression systems such as yeast or E.coli, or insect cells 
such as Sf9. Due to relative abundances of tRNAs varying between different systems, it was 
possible for the creation of a “yeast optimised” form of the A2aR to be engineered. The yeast-
optimised A2aR, herein referred to as “Zhar”, coded for the human A2aR protein, but codons 
had been optimised to correspond to the most abundant forms of tRNA present in Pichia 
pastoris (P.pastoris). This generated increased expression levels of the A2aR in the yeast 
expression system P.pastoris and was a kind gift from Prof. Roslyn Bill (Aston University). 
As displayed in figure 5.2, the Zhar construct had several modifications to aid downstream 
purification and analysis. From the N-terminus, Zhar contains: a bovine pancreatic trypsin 
inhibitor (BPTI) signal peptide to allow targeting of the protein to the yeast cell plasma 
membrane; thrombin cleavage site to allow removal of the BPTI signal peptide; 10 x His-tag 
for downstream protein purification; a tobacco etch virus (TEV) cleavage site to remove His-
tag after purification; 5 x GS linker to allow flexibility of the N-terminal tags; A2aR containing 
the mutation N154Q (to remove the sole glycosylation site and provide homogeneity in protein 
samples (Fraser, 2006) and C-terminally truncated after residue 316. This truncation of 96 
residues had been reported previously not to be detrimental in relation to protein function 
(Piersen et al., 1994); flag-tag for downstream identification; 5 x GS linker and biotinylation 
site to provide an alternative purification strategy on a streptavidin column. None of these  
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Figure 5.2. The A2aR “Zhar” construct. Bovine pancreatic trypsin inhibitor signal peptide at the N-terminus shown in dark blue. Light blue shows a thrombin 
cleavage site. 10 x His tag at the N-terminus and FLAG tag at the C-terminus shown in yellow. TEV cleavage site shown in brown. 5 x GS linker at both termini 
shown in black. Biotinylation site shown in purple. Cysteines that form disulphide bridges are shown in matching shades of green. Residues mutated for reporter 
groups are highlighted in red. Two cysteines that were not mutated are shown in cyan. Cysteine residues with grey backgrounds were mutated. Residues in 
orange form the ZM241385 binding pocket. Helices are labelled with roman numerals.
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additions contained cysteine or tryptophan residues that may interfere with fluorescence 
signalling assays. 
Cys-depletion of A2aR was engineered in Zhar as downstream biophysical techniques would 
require large quantities of protein. This would be uneconomical to produce from mammalian 
cell culture but readily achievable in P.pastoris. Pharmacological characterisation of all 
mutations was undertaken in transiently transfected mammalian cells (HEK 293T). 
5.2 Results 
5.2.1  Zhar reporter group mutations 
Tryptophan and cysteine residues can act as reporter groups in fluorescent studies. From their 
introduction at specific loci it is possible to elucidate the conformational changes a receptor 
undergoes upon ligand binding. Tryptophan was introduced at residues 78, 106, 176, 225 and 
231 of Zhar while cysteine was introduced at residues 78 and 256 of Zhar. These loci would 
provide information of the conformational changes of A2aR upon agonist stimulation. 
However, it was important that these mutations should not perturb receptor function. Each 
individual mutant was therefore characterised for expression at the cell surface and ligand 
binding capabilities. It was demonstrated that there was no difference in affinity for 
[3H]ZM241385 between A2aR and Zhar (table 5.1). 
Competition radioligand binding experiments were performed to assess the effect of the 
mutations on the binding capabilities of Zhar. All tryptophan introductions displayed WT-like 
binding profiles, with the exception of [L78W]Zhar which showed a 100-fold reduced affinity 
for ZM241385 (figure 5.3 and table 5.1). [L78C]Zhar bound with WT-like affinity, making it 
better tolerated than [L78W]Zhar, but with a large s.e.m., the results were inconsistent. 
[T256C]Zhar showed a 100-fold reduced affinity for ZM241385. 
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Figure 5.3. Competition radioligand binding of Zhar with individual reporter group 
introductions. Self-competition of [3H]ZM241385 as a tracer at A: tryptophan introductions 
[L78W]Zhar (▲); [I106W]Zhar (▼); [Y176W]Zhar (♦); [L225W]Zhar (□); [A231W]Zhar (Δ) B: 
[L78C]Zhar (▲); [T256C]Zhar (♦). Both panels have A2aR (●) and WT-Zhar (■) for comparison. Data 
are mean ± s.e.m. of three experiments performed in triplicate. 
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Construct pKi ± s.e.m. 
A2aR 8.87 ± 0.1 
WT-Zhar 8.97 ± 0.1 
[L78W]Zhar 6.96 ± 0.2 
[L78C]Zhar 8.64 ± 1.0 
[I106W]Zhar 8.99 ± 0.2 
[Y176W]Zhar 8.46 ± 0.5 
[L225W]Zhar 9.23 ± 0.3 
[A231W]Zhar 9.31 ± 0.3 
[T256C]Zhar 6.85 ± 0.4 
 
Table 5.1. pKi values of [3H]ZM241385 at A2aR compared to Zhar and mutant Zhar 
constructs. Data are mean ± s.e.m. of three experiments performed in triplicate. 
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Cell surface expression of Zhar constructs was determined in relation to WT-Zhar. As seen in 
figure 5.4 and table 5.2, cell surface expression of [L78W]Zhar, [L78C]Zhar  and [T256C]Zhar 
were all markedly reduced compared to WT-Zhar. Expression levels were WT-like for 
[I106W]Zhar; reduced for [Y176W]Zhar; and reduced to around 50 % for [L225W]Zhar and 
[A231W]Zhar. All constructs that expressed >50 % retained the ability to internalise at levels 
comparable to WT-Zhar. Internalisation experiments were not reliable when expression level 
of constructs was < 20 % of WT-Zhar. There was an observed decrease in specific binding for 
all Zhar constructs in relation to WT-Zhar (shown in table 5.2) that correlated with the observed 
decrease in cell surface expression. [I106W]Zhar, [Y176W]Zhar and [A231W]Zhar showed 
reduced levels of specific binding further than the reduced levels of cell surface expression. 
However, the specific binding remaining for these constructs was sufficient to allow acquisition 
of robust ligand binding data. 
[I106W]Zhar was the best tolerated mutation, with WT-like expression levels and binding 
profile, therefore chosen as the introduced Trp reporter at the bottom of TM3. Of the other 
intracellular-side mutations investigated, mutation of [L225]Zhar and [A231]Zhar were 
equally well tolerated. They both displayed WT-like binding profiles and expression levels that 
would allow robust cell signalling data acquisition. [A231]Zhar was chosen to be the site of 
the Cys residue introduction. With I106W, A231C could be used to monitor movement 
between TM3 and TM6. 
5.2.2  Zhar Cys-depletion 
To avoid IAEDANS labelling of undesired thiol groups, cysteine residues in the A2aR had to 
be either contributing to a disulphide-bond or buried in a TM helix and thereby inaccessible to 
a water-soluble reagent. The A2aR has 15 cysteine residues; 8 Cys residues, located in ECL1, 
2 and 3, form disulphide bonds with one another (Cys71-Cys159; Cys74-Cys146; Cys77-
Cys166; Cys259-Cys262). Mutation of these residues results in perturbation of normal function 
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(Wheatley et al., 2012), but as they were disulphide-bound they could not be derivatised as 
there was no free thiol group. As seen in the high resolution crystal structure of A2aR (PDB 
code: 4EIY (Liu et al., 2012)), Cys185 and Cys245 are both located in the middle of their 
respective TMs (5 and 6), pointing away from the ligand binding pocket located in the centre 
of the TM bundle. Cys245 also forms part of the, highly conserved family A, CWxP motif of 
TM6, mutation of which leads to drastically reduced, almost abolished, cell surface expression 
and altered receptor function amongst GPCRs (Lu et al., 2007, Xu et al., 2008). It has been 
previously reported that Cys residues buried deep in TM helices were not tolerant of mutation 
(Yao et al., 2006). However, as these residues were also inaccessible for IAEDANS binding 
and would not interfere with FRET signalling assays, it was described that it may not be 
necessary for Cys185 and Cys245 in A2aR to be mutated. Cys394 is present in the C-terminal 
tail of A2aR, a region of great flexibility and easily accessible due to its hydrophilic nature. 
However, as explained below, Cys394 was removed through a C-terminal truncation in the 
A2aR construct used. It was deemed necessary to mutate Cys28, Cys82, Cys128 and Cys254 as 
they were all close to the top or bottom of their respective TM helices and therefore potentially 
reactive towards thiol-directed derivatisation. 
It was important to select mutations for cysteine residues that would not result in altered 
receptor function. Cysteine to alanine mutations are generally well tolerated amongst GPCRs, 
but this is not necessarily the case. In addition, replacing cysteine with alanine introduces a 
different physical characteristic at that locus which may be detrimental to function. In an effort 
to select residues to replace cysteine that would be less likely to perturb the tertiary structure 
of A2aR, sequences were compared across adenosine receptor subtypes and across species 
within a subtype. Cys82 was found to be conserved as a cysteine across the adenosine receptor 
family; with no obvious alternative, this was mutated to alanine. Cys254 was also a conserved 
cysteine in all but mouse and rat A3R in which it is phenylalanine, a large sidechain was likely  
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Figure 5.4. Cell surface expression of Zhar constructs containing reporter groups +/- 
agonist stimulation. Cell surface expression, determined using anti-His antibody was 
normalised to untransfected cells (0 %) and unstimulated WT-Zhar (100 %). Internalisation 
under agonist stimulation was determined using NECA (100 μM) for 1 h. Data are mean ± 
s.e.m. of three experiments performed in triplicate.  
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Construct 
Cell surface expression  
(% of Zhar ± s.e.m.) 
Specific binding  
(% of Zhar ± s.e.m.) 
WT-Zhar 100.0 ± 0.1 100 ± 0.0 
[L78W]Zhar 1.6 ± 1.5 6.6 ± 0.8 
[L78C]Zhar 13.4 ± 4.2 13.7 ± 2.6 
[I106W]Zhar 92.4 ± 5.1 34.6 ± 11.4 
[Y176W]Zhar 77.7 ± 11.6 27.8 ± 5.4 
[L225W]Zhar 53.1 ± 5.4 53.5 ± 3.8 
[A231W]Zhar 57.6 ± 4.0 36.7 ± 1.5 
[T256C]Zhar 10.8 ± 3.7 7.6 ± 1.8 
 
Table 5.2. Cell surface expression levels compared to specific binding observed for Zhar 
constructs relative to WT-Zhar. Data are mean ± s.e.m. of three experiments performed in 
triplicate. 
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to create steric hindrance, therefore Cys254 was also mutated to the small residue alanine. 
Cys28, as shown in figure 5.5, was isoleucine in A1R which was conserved across species. 
Cys128 was a conserved leucine in A2bR, as shown in figure 5.6. Cys28 and Cys128 were 
therefore mutated to Ile and Leu respectively, as well as to Ala, to identify which mutation 
produced the least disruption to receptor function. 
Due to their presence at the top of their respective helices, Cys82 and Cys254 necessitated 
mutation to prevent labelling by IAEDANS. A double mutant, [C82A/C254A]Zhar was 
created. From data displayed in figure 5.7, it was seen that [C82A/C254A]Zhar bound with 
WT-like affinity for ZM241385 in comparison to A2aR (pKi: 9.33 ± 0.2 in comparison to 8.87 
± 0.1). [C82A/C254A]Zhar expressed at the cell surface at slightly increased levels (119 ± 4.7 
% compared to WT-Zhar) but retained WT-like internalisation of ~19 % upon agonist 
stimulation. 
With the successful construction of the [C82A/C254A]Zhar (herein referred to as [2A]Zhar), 
reporter group mutations were incorporated at ICL2 (I106W) and ICL3 (A231C) to ensure 
[I106W/A231C][2A]Zhar (herein referred to as [Δ4]Zhar) was a viable construct. As seen in 
figure 5.8, [Δ4]Zhar displayed a slight reduction in affinity of ZM241385. [Δ4]Zhar bound 
ZM241385 with a pKi of 8.63 ± 0.4 compared to A2aR with a pKi of 8.87 ± 0.1. [Δ4]Zhar was 
expressed at the cell surface at levels comparable to WT-Zhar (85.5 ± 5 %). [Δ4]Zhar was also 
able to internalise to a similar degree as WT-Zhar following agonist challenge (NECA, 100 
μM, 1 h). 
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Figure 5.5. ClustalW alignment of human A2aR with A1R from different species. 
Highlighted is the Cys28 of A2aR. 
 
 
 
Figure 5.6. ClustalW alignment of human A2aR with A2bR from different species. 
Highlighted is the Cys128 of A2aR. 
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Figure 5.7. Characterisation of [C82A/C254A]Zhar. A: Self-competition radioligand binding of 
[3H]ZM241385 at A2aR (●) or [C82A/C254A]Zhar (■). B: cell surface expression of 
[C82A/C254A]Zhar in comparison to WT-Zhar, in the presence (+) or absence (-) of agonist stimulation 
(NECA, 100 μM, 1 h). Data are mean ± s.e.m. of three experiments performed in triplicate. 
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Figure 5.8. Characterisation of [Δ4]Zhar. A: Self-competition radioligand binding of ZM241385 at 
A2aR (●) or [Δ4]Zhar (■). B: cell surface expression of [Δ4]Zhar in comparison to WT-Zhar, in the 
presence (+) or absence (-) of agonist stimulation (NECA, 100 μM, 1 h). Data are mean ± s.e.m. of three 
experiments performed in triplicate.  
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Individual cysteine mutations at Cys28 and Cys128 were investigated to ensure WT-like 
characteristics of A2aR were maintained. This was performed in the human A2aR as well as 
Zhar to ensure the additional tags present in Zhar were not affecting the mutant constructs 
functionality. From figure 5.9 it can be observed that [C28A]A2aR expressed at a reduced level 
compared to A2aR, whereas [C28I]A2aR was expressed at WT-like levels (63.0 ± 6.0 % and 
108.9 ± 1.9 % respectively, compared to A2aR). Both [C128L]A2aR and [C128A]A2aR were 
expressed at levels comparable to A2aR (114.6 ± 5.2 % and 101.9 ± 6.8 % respectively). 
The construct that the mutations were incorporated into affected the outcome. When the same 
mutations were introduced to Zhar, [C28A]Zhar expressed at WT-like levels at the cell-surface 
(91.3 ± 10.3 % in Zhar, 63.0 ± 6.0 % in A2aR). [C128L] displayed higher expression levels in 
Zhar compared to A2aR with increased expression of 169.4 ± 9.2 % in Zhar (only 114.6 ± 5.2 
% in A2aR). [C28I] and [C128A] also both displayed increased cell surface expression levels 
in Zhar (122.5 ± 9.2 % and 120.5 ±10.3 % respectively). In both A2aR and Zhar, all 4 mutants 
retained the ability to internalise to a similar degree as WT. As [C28I] and [C128L] were both 
well tolerated in A2aR and Zhar, they were chosen as the mutations to remove the Cys residues 
at those positions. As shown in figure 5.10 and table 5.3, [C28I]Zhar and [C128L]Zhar 
demonstrated WT-like binding affinity for ZM241385. 
Figure 5.11 shows that introduction of the [C28I] and [C128L] substitutions to the [Δ4]Zhar 
background showed an increase in cell-surface expression of 153.0 ± 28.2 % and 121.1 ± 22.3 
% respectively in comparison to [Δ4]Zhar. The increased expression was not lost upon 
introduction of both mutations; [C28I/C128L][Δ4]Zhar expressed at 173.5 ± 23.5 % at the cell 
surface in comparison to [Δ4]Zhar. Radioligand binding data, shown in figure 5.12 and table 
5.4, showed an increased affinity for ZM241385 of [C128L][Δ4]Zhar correlating with 
observations from [C128L]Zhar. Increased binding affinity was not lost in 
[C28I/C128L][Δ4]Zhar where introduction of both mutants resulted in approximately 10-fold   
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Figure 5.9. Cell surface expression of A2aR and Zhar mutant constructs +/- agonist stimulation. 
Cell surface expression was determined for cysteine knockdown mutations in A2aR (panel A) and Zhar 
(panel B) and normalised to untransfected cells (0 %) and A: unstimulated A2aR (100 %) or B: 
unstimulated WT-Zhar (100%). Internalisation under agonist stimulation was determined using NECA 
(100 μM, 1 h). Data are mean ± s.e.m. of three experiments performed in triplicate. 
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Figure 5.10. Competition radioligand binding analysis of cysteine mutations in Zhar. Self-
competition of [3H]ZM241385 at WT-Zhar (●), [C28I]Zhar (■) and [C128L]Zhar (▲). Data 
are mean ± s.e.m. of three experiments performed in triplicate. 
Construct pKi ± s.e.m. 
WT-Zhar 8.97 ± 0.1 
[C28I]Zhar 9.42 ± 0.2 
[C128L]Zhar 9.52 ± 0.4 
 
Table 5.3. pKi values of cysteine knockdown mutations in Zhar. Data are mean ± s.e.m. of 
three experiments performed in triplicate.  
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Figure 5.11. Cell surface expression of cysteine mutations in the [Δ4]Zhar background 
+/- agonist stimulation. Cell surface expression was determined for cysteine mutations in 
[Δ4]Zhar, normalised to untransfected cells (0 %) and unstimulated [Δ4]Zhar (100 %). 
Internalisation under agonist stimulation was determined using NECA (100 μM, 1 h). Data are 
mean ± s.e.m. of three experiments performed in triplicate. 
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Figure 5.12. Competition radioligand binding analysis of cysteine mutations in the [Δ4]Zhar 
background. Self-competition binding of [3H]ZM241385 performed on [Δ4]Zhar (●); [C28I][Δ4]Zhar 
(■); [C128L][Δ4]Zhar (▲) and [C28I/C128L][Δ4]Zhar (▼). Data are mean ± s.e.m. of three 
experiments performed in triplicate. 
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Construct pKi ± s.e.m. 
[Δ4]Zhar 8.63 ± 0.4 
[C28I][Δ4]Zhar  8.47 ± 0.5 
[C128L][Δ4]Zhar  9.10 ± 0.8 
[C28I/C128L][Δ4]Zhar  9.64 ± 0.0 
 
Table 5.4. pKi values of cysteine mutant constructs in the [Δ4]Zhar background. Data are 
mean ± s.e.m. of three experiments performed in triplicate. 
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increase in affinity. In addition to establishing that the ligand binding capabilities of the 
depleted Cys A2aR was not greatly perturbed, it was also necessary to establish that the 
signalling capability was also retained. A2aR signals via activation of Gs for stimulating 
adenylyl cyclase. Consequently, cAMP was assayed in response to increasing concentrations 
of the agonist NECA (figure 5.13 and table 5.5). It was observed that pEC50 values of 
[C28I/C128L][Δ4]Zhar were comparable to [Δ4]Zhar, and in turn comparable to A2aR. 
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Figure 5.13. cAMP dose-response curves of cysteine-depleted A2aR. Alphascreen 
determined NECA dose-response curves of cAMP accumulation in HEK 293T cells transiently 
transfected with A2aR (●); [Δ4]Zhar (■) and [C28I/C128L][Δ4]Zhar (▲). Data are mean ± 
s.e.m. of three experiments performed in triplicate. 
Construct pEC50 ± s.e.m. 
A2aR 9.93 ± 0.2 
[Δ4]Zhar 9.26 ± 0.0 
[C28I/C128L][Δ4]Zhar 9.12 ± 0.2 
 
Table 5.5. pEC50 values for cysteine-depleted A2aR. All data are mean ± s.e.m. of three 
experiments performed in triplicate.  
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5.3 Discussion 
GPCRs are of great interest to the pharmaceutical industry. Their presence on the cell surface 
allows their targeting with drugs to transduce signals down a plethora of signalling pathways. 
The ability to develop better, more specific drugs requires more information on the 
conformational changes a GPCR undergoes upon ligand binding. In the case of A2aR, this 
would aid in development of drugs to treat diseases such as Parkinson’s disease, Alzheimer’s 
disease and graft versus host disease. Biophysical techniques such as FRET can provide 
information on the conformational states of GPCRs. However, this requires specific sites of 
fluorescent probe attachment. IAEDANS is a fluorescent probe that can attach to the thiol 
groups of cysteine residues. By introducing cysteine residues at specific locations on A2aR it 
may be possible to study the conformational states of A2aR in SMALPs. 
Identification of suitable sites for reporter group introduction, at the intracellular side, was 
based on previous studies in β2 adrenergic receptor (β2-AR) (Yao et al., 2009, Yao et al., 2006). 
Upon GPCR activation, the movement of TM6 away from TM3 on the intracellular side is 
reported to be one of the largest conformational changes (Rasmussen et al., 2011a, Rasmussen 
et al., 2011b, Kobilka, 2011). Introduction of reporter groups around these helices would 
provide the clearest observations of conformational changes in A2aR.  
At the extracellular side of A2aR, the movement of TM6 towards TM3 upon agonist binding 
would also provide valuable insight into GPCR conformational changes upon ligand binding. 
However, in A2aR ECL1 and ECL3, at the top of TM3 and TM6 respectively, contain few 
residues and are locked in place through disulphide bonds. Reporter groups located in these 
areas would not provide significant insight into conformational changes due to their restricted 
movement. Leu78 and Thr256 are located at the top of TM3 and TM6 respectively, while 
Tyr176 is located at the top of TM5, a midpoint between Leu78 and Thr256. Reporter groups 
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located at these locations would have allowed information on the movement of extracellular 
domains upon ligand binding.  
Of the 15 cysteine residues present in A2aR, 8 were involved in the formation of disulphide-
bonds, 2 were structurally/functionally important and inaccessible. The remaining 5 required 
mutation to a non-derivatisable residue to allow robust analysis through use of intrinsic 
tryptophan fluorescence and IAEDANS-Trp FRET. C-terminal truncation and mutation to 
alanine, leucine or isoleucine, based on sequence homologies and previous work (Yao et al., 
2006), were employed to remove these derivatisable sites. 
5.3.1  Introduction of reporter groups 
Mutation of residues in the TM helices, areas of conserved structural composition, were not 
well tolerated (Unal and Karnik, 2012). Disruption to the structure of a TM with the bulky 
sidechain of tryptophan, or introduction of nucleophilic cysteine residues to the hydrophobic 
TM region was not well tolerated. This was apparent at Leu78 where mutation to either Cys or 
Trp resulted in reduced binding affinity and reduced cell surface expression. [L78W]Zhar 
showed the lowest cell surface expression of any of the constructs investigated. This may have 
been due to retention of misfolded proteins. The presence of the large Trp sidechain 
neighbouring Cys77 could have caused a steric hindrance in the formation of a disulphide bond. 
Preventing protein disulphide isomerase from creating the appropriate disulphide bridge would 
probably lead to the retention of the protein in the ER (Shi and Javitch, 2002). The small 
amount of receptor that was expressed at the cell surface demonstrated lower affinity binding 
for ZM241385. This would suggest that even when disulphide bonds have been correctly 
formed, the steric hindrance created by the Trp sidechain was either blocking the binding site 
or preventing key interactions with other residues. [L78C]Zhar also displayed a decreased cell 
surface expression, likely due to ER-retention resulting from misplaced disulphide bonds. As 
Leu78 does not form part of any recognised binding pockets in A2aR, for agonists or antagonists 
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(Xu et al., 2011, Jaakola et al., 2010), subtle shifts in binding affinity were likely due to 
conformational change, not loss of a direct binding site. It has been previously reported that 
disulphide bonds introduced to the ECLs of GPCRs can inhibit orthosteric binding of agonists 
and antagonists (Avlani et al., 2007). A change in where ECL2 was restrained may have 
prevented ZM241385 from accessing the binding site. This could also be a result of imposed 
conformational changes to ECL2 which is believed to act as a lid over the binding pocket (Shi 
and Javitch, 2004, Wheatley et al., 2012). This may have increased the time taken for binding 
assays to reach equilibrium, presenting as the reduced affinity observed from radioligand 
binding. [L78C]Zhar displayed reduced cell surface expression while retaining WT-like 
binding affinity. Despite a reduction in specific binding that correlated with reduced cell 
surface expression levels, it was possible to produce a full ligand binding curve with robust 
data. It is possible that the L78C mutation resulted in ER-retention of A2aR. Further studies 
would be required to show the reduction in cell surface expression was not a result of a 
reduction in overall expression levels, utilising the whole cell ELISA technique. Furthermore, 
identification of where the construct was retained within the cell would be required. However, 
this construct could potentially be used to study the ability of SMA to extract functionally 
active receptor from intracellular membranes. 
[T256C]Zhar resulted in low cell surface expression and reduced binding affinity. The position 
of Thr256 at the top of TM6 places it in close proximity to the internal disulphide bridge of 
ECL3. Mutation to cysteine may have resulted in misplaced disulphide bonds, preventing 
release from the ER. Reduced binding affinity was unlikely to occur from misplaced 
disulphide-bonds as ECL3 forms an intra-loop disulphide-bond and does not tether ECL2 to 
the TM bundle. However, Asn253 is a key binding point for ZM241385, revealed by the crystal 
structures of A2aR (Liu et al., 2012, Jaakola et al., 2010) and is present just below Thr256 in 
TM6. It is therefore possible that the increased carbon-sulphur bond length of the thiol group, 
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in comparison to carbon-carbon bond length, in the [T256C]Zhar construct, extended further 
into the binding pocket and inhibited ligand binding, resulting in the observed decreased 
binding affinity.  
Tyr176 was the only residue at the extracellular side to tolerate mutation and maintain high 
levels of cell surface expression. WT-like binding affinity of ZM241385 for [Y176W]Zhar 
correlates with the recognised ligand binding pocket for ZM241385 not involving Tyr176. 
Mutation from one bulky aromatic side-group to another did not disrupt antagonist binding. 
Unfortunately, with the investigated mutations on other helices resulting in greatly reduced cell 
surface expression and altered binding affinities, there was no appropriate site identified for 
the correlated Cys residue to allow study of conformational changes at the extracellular side of 
A2aR. 
Ile106, Leu225 and Ala231 had previously been shown to tolerate mutation in the correlating 
residues of β2-AR. In this study it was found that although there was a reduced cell surface 
expression of [L225W]Zhar and [A231W]Zhar, expression levels were high enough to be used 
for cell signalling assays and provide clear data in radioligand binding assays. The lack of 
disruption to ligand binding was expected; these residues would not interact directly with the 
ligand binding pocket, nor do they form any of the interactions known to maintain an inactive 
state in GPCRs. [I106W]Zhar presented WT-like expression levels and binding affinity so was 
chosen as the Trp reporter residue. [L225W]Zhar and [A231W]Zhar were both equally well 
tolerated, however as the β2-AR equivalent of Ala231 had been the site of the Cys reporter 
residue in previous reports (Yao et al., 2006, Yao et al., 2009), this was chosen for mutation to 
cysteine. 
117 
 
5.3.2  Cys-depletion 
The two cysteine residues buried in the middle of TM5 and TM6 (Cys185 and Cys245 of the 
A2aR, respectively) were deemed unreactive in previous studies on β2-AR (Yao et al., 2006). 
However, four cysteine residues existed at the ends of helices which would probably be 
exposed to IAEDANS labelling (Liu et al., 2012). These exposed cysteines were mutated to 
either alanine (well tolerated in most GPCRs) or a residue identified as conserved among other 
adenosine receptor subtypes.  
Cys82 and Cys254 are present at the top of TM3 and 6, respectively, placing them in close 
proximity to the ligand binding pocket and making them more accessible to IAEDANS 
labelling than Cys28 and Cys128. Across the adenosine family these residues are conserved 
cysteines, suggesting an important role. However, there was no observable change in binding 
to ZM241385, nor cell signalling assays under stimulation from the agonist NECA. Therefore, 
although conserved across the adenosine receptor family, Cys82 and Cys254 play no role in 
ligand binding or receptor activation. The observed increase in cell surface expression suggests 
that mutation of the nucleophilic cysteine to the small sidechain of alanine stabilises the α-
helical conformation of their respective helices. Introduction of the reporter residues ([I106W] 
and [A231C]) was well tolerated in the [2A]Zhar backbone, displaying WT-like binding 
affinities and cell surface expression levels. This proved that Ala231 was able to retain WT-
like function when mutated to cysteine, as it could in the β2-AR (Yao et al., 2006). 
Although Cys28 and Cys128 were concealed within the TM bundle, and theoretically should 
also be shielded from IAEDANS by the SMA belt and lipid bilayer surrounding A2aR in 
SMALPs, access from the “intracellular” side may have been possible. [C128L]A2aR showed 
a minor increase in expression levels, still within WT-like range. However, for the C-terminally 
truncated Zhar construct, the [C128L]Zhar produced a much more noticeable increase in cell 
surface expression. By mutating the nucleophilic cysteine to a hydrophobic leucine, the 
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stability of TM4, and the whole TM-bundle, seems to have been increased. From the increased 
affinity for the inverse agonist, ZM241385, it is suggested that [C128L]Zhar has been stabilised 
in an inactive state. However, this has not affected the ability to internalise or signal upon 
agonist stimulation. [C28I]Zhar demonstrated increased cell surface expression, but [C28I] did 
not produce any change in expression levels of A2aR. As before, the mutation of a nucleophile 
to a hydrophobic residue is likely to have increased stability of TM1. However, as TM1 is not 
known to be heavily involved in receptor activation, stabilising TM1 has only a minor effect 
on expression levels and no notable effect on ligand binding. [C28I] and [C128L] were chosen 
to replace these two cysteines as there was no detrimental effect upon incorporation into A2aR 
or Zhar. 
[Δ4]Zhar was expressed at levels comparable to WT-Zhar, despite containing [C82A/C254A] 
mutations (shown to increase cell surface expression in Zhar). This was likely due to the 
incorporation of [A231C]; mutation of Ala231 had been shown to reduce cell surface 
expression. Introduction of [C28I] and [C128L] into the [Δ4]Zhar backbone displayed similar 
trends as in A2aR and Zhar backbones. The reduced increase in cell surface expression observed 
in [C128L][Δ4]Zhar, compared to [C128L]Zhar, was likely due to the already increased 
stability conferred by [C82A/C254A]. However, [C28I][Δ4]Zhar presented increased cell 
surface expression compared to [C28I]Zhar. As TM1 is not part of the main TM bundle, 
stability conferred by [C82A/C254A] had no effect on the stability conferred by [C28I]. 
Despite the changes in relative cell surface expression levels, no differences were observed in 
binding affinity of [C28I][Δ4]Zhar. [C128L] conferred a subtle increase in affinity for 
ZM241385 in [Δ4]Zhar. This was further apparent in [C28I/C128L][Δ4]Zhar which was 
expressed at levels comparable to [C28I][Δ4]Zhar and bound ZM241385 with increased 
affinity. 
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The presence of [I106W] and [A231C] reporter groups at the intracellular face of A2aR, and 
the same mutations in the corresponding residues of β2-AR, show the utility of this technique 
for GPCR studies. Two family A GPCRs have had residues incorporated which will facilitate 
FRET studies in a receptor with a Cys-depleted background. This suggests this may be a 
common method to study family A GPCRs through fluorescence techniques. 
In summary; presented here is [C28I/C128L][Δ4]Zhar, a Cys-depleted A2aR construct 
displaying WT-like characteristics for an A2aR. [C28I/C128L][Δ4]Zhar is a construct ready to 
be over-expressed in yeast before SMALP-solubilisation, derivatisation with IAEDANS and 
the effects of ligand binding studied by FRET and intrinsic tryptophan fluorescence. This will 
allow elucidation of the conformational changes A2aR undergoes upon ligand binding, 
potentially aiding drug design for this pharmaceutically relevant protein. Also, this will further 
the understanding of potential uses of the SMALP technique. 
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6 CHAPTER 6: DETERGENT-FREE EXTRACTION OF OTHER 
GPCRS 
6.1 Introduction 
A2aR was a useful tool to study the characteristics and stability of SMALP-GPCRs. Information 
obtained on the pharmacological profile and stability of the SMALP-solubilised A2aR allowed 
an understanding of the limitations and potential uses of the SMALP technique. However, it 
was important to understand the versatility of SMALP-solubilisation. Previous reports have 
demonstrated extraction of membrane proteins not of the GPCR superfamily: 
bacteriorhodopsin and PagP (Knowles et al., 2009), the tetrameric potassium channel KcsA 
(Dorr et al., 2014), AcrB (Postis et al., 2015) and ABC transporter proteins (Gulati et al., 2014). 
However, before this study there was no report of SMALP-solubilised GPCRs. The GPCR 
superfamily, despite sharing a 7 transmembrane (7TM) bundle, shares very little sequence 
homology within GPCR sub-families, and even less homology between sub-families (Ji et al., 
1998). Although the presence of a 7TM domain is conserved across the GPCR superfamily, 
detailed protein structure, ligands and ligand binding mechanisms differ between sub-families 
(Harmar, 2001, Wu et al., 2014). Family B GPCRs possess a much larger N-terminus than 
family A GPCRs (100-160 residues) as this is a key site of ligand recognition and interaction 
in family B GPCRs. Ligands for family A GPCRs usually bind deep in the TM core, with the 
peptide ligands often forming interactions with the ECLs (Strader et al., 1995). Family B GPCR 
ligands are usually large peptides (~30-40 residues) that bind their C-terminus to the N-
terminus of the GPCR. This orientates the N-terminus of the ligand to the TM-core of the 
GPCR where it interacts predominantly on the periphery of the TM bundle (Dautzenberg et al., 
1999, Hoare et al., 2004, Siu et al., 2013). Family C GPCRs possess N-termini larger than the 
whole of a family A GPCR (~581 residues in the metabotropic glutamate receptor 1). These 
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are structured for a Venus-fly trap model of ligand interaction (Jingami et al., 2003). With such 
diversity in structure and mechanism of ligand binding within the GPCR superfamily, it was 
not known whether the SMALP-solubilisation technique would be able to extract other GPCRs 
in an active form. 
Other than protein structure, one of the key differences between GPCR sub-families is the 
difference in their endogenous ligands. The A2aR is a receptor for small molecule ligands (MW: 
~270 Da), with a library of well-characterised small molecule ligands that were utilised to study 
SMALP-A2aR. Other members of family A have been as equally well-characterised as A2aR, 
such as the neurohypophysial receptor family of GPCRs: vasopressin 1a receptor (V1aR); 
vasopressin 1b receptor (V1bR); vasopressin 2 receptor (V2R) and the oxytocin receptor (OTR), 
as well as the muscarinic acetylcholine receptor family (including muscarinic acetylcholine 
receptor M1 (M1R)). These receptor were chosen to investigate if the SMALP technique could 
be a general method to study family A GPCRs or if it was restricted to A2aR. These receptors 
were chosen as they have all been well characterised with a range of small molecule and peptide 
ligands. However, the endogenous ligands for the neurohypophysial receptors are peptides (9 
residues in length), and acetylcholine is a small amine ligand at the M1R. These ligands differ 
from adenosine, a small molecule ligand that is smaller than the peptide ligands for the 
neurohypophysial receptors. The presence of a sugar moiety on the adenosine adds bulk to the 
molecule that is not present on small amine ligands such as acetylcholine and its stable 
analogue carbachol (ligands at the M1R) (Piersen et al., 1994). The difference in ligand size 
from small amines to peptides would allow the study of SMALP-solubilised receptors that bind 
different types of ligands in different ways. Small molecule ligands have been shown to bind 
deep in the binding pocket of GPCRs (Palczewski et al., 2000, Xu et al., 2011). Whereas the 
much larger peptide ligands tend to bind more on the periphery of the TM bundle, where they 
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can form interactions with the ECLs as well as the 7TM bundle (Fong et al., 1992, Hawtin et 
al., 2006, Conner et al., 2007, Wheatley et al., 2012) (reviewed in (Strader et al., 1995)).  
Successful use of the SMALP technique to extract and study other functional GPCRs could 
provide detailed and accurate data on the neurohypophysial receptor family. This could lead to 
development of drugs to aid in conditions such as: nephrogenic diabetes insipidus (NDI) caused 
by mutation of V2R (Knoers, 1993); adrenocorticotropin-independent macromodular adrenal 
hyperplasia and, potentially, autism linked with V1aR (Mune et al., 2002, Yirmiya et al., 2006); 
depression and anxiety linked to V1bR (Griebel et al., 2002) and problems with childbirth such 
as premature labour related to OTR (Akerlund et al., 1985). The M1R is linked with seizures 
(Hamilton et al., 1997) and breathing difficulties arising from bronchoconstriction 
(Struckmann et al., 2003) amongst other conditions. SMALP-solubilisation would allow 
biophysical analysis of these receptors in their native conformation and lipid environment. This 
would lead to better understanding of the mechanism of action of different ligands upon 
binding, providing insight into how ligands induce their response. From this, drugs with greater 
specificity for individual receptors might be designed to induce the effect required with reduced 
side-effects. 
6.1.1  Family B GPCRs 
The characteristic GPCR 7TM bundle is preserved in family B GPCRs. However, there is very 
little sequence homology with family A and the TM bundle has been shown to adopt a chalice-
like conformation (Hollenstein et al., 2013, Siu et al., 2013). Family B GPCRs also possess an 
extended N-terminus compared to family A GPCRs. The importance of the N-terminus for 
ligand binding in family B GPCRs provided a different structural component of the receptor to 
be maintained throughout SMALP-solubilisation. The variety of available ligands for family 
B GPCRs is more limited than for family A GPCRs. Those that are commercially available are 
predominantly large peptides of 27-141 residues (Harmar, 2001). This is much larger than the 
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nonapeptides that target neurohypophysial receptors, providing another useful tool to study the 
utility of the SMALP technique. 
Some family B GPCRs, such as the calcitonin receptor (CTR), have the ability to interact with 
a small family of three single membrane-spanning proteins called receptor activity modifying 
proteins (RAMPs 1-3 (McLatchie et al., 1998)). RAMPs interact with family B GPCRs through 
their N-terminus to produce pharmacologically distinct receptors (Christopoulos et al., 1999, 
Fraser et al., 1999). The CTR is a family B GPCR that interacts with RAMPs to produce 
pharmacologically different amylin receptors named AMY1-3 in correlation with the 
complexed RAMP (Christopoulos et al., 1999). Figure 6.1 provides a graphic representation of 
the ability of CTR to express at the cell surface independently or as a heterodimer with the 3 
different RAMPs (Christopoulos et al., 2003). 
Interaction with RAMPs is not necessary for CTR transport to the cell surface (Morfis et al., 
2008), resulting in the CTR. Expression at the cell surface as the CTR:RAMP1 complex results 
in the AMY1 receptor that has high affinity for the ligand amylin, which CTR does not. These 
two distinct pharmacological profiles provides the opportunity to investigate the ability of 
SMALPs to solubilise functional heterodimeric complexes. Studies of family B GPCRs have 
been hindered by the endogenous expression of RAMPs in cells introducing mixed 
pharmacological profiles to samples. If it was possible to extract GPCR:RAMP complexes in 
a functional state and purify samples through affinity chromatography with a specific epitope-
tagged RAMP subtype, the study of specific GPCR:RAMP complexes would be possible. This 
would further the understanding of these complexes, potentially aiding drug design targeting 
family B GPCRs involved in diabetes (AMY1-3 (Younk et al., 2011)) and osteoporosis (CTR 
(Henriksen et al., 2010)) among others (reviewed in (Bortolato et al., 2014)). 
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Figure 6.1. The ability of CTR to express at the cell surface as four pharmacologically distinct receptors. CTR is able to express at the cell 
surface as the calcitonin receptor, independent of RAMPs. Alternatively it may dimerise with any of the 3 RAMPs (R1, R2 or R3) in the ER, to 
produce the 3 amylin receptors. Adapted from (Purdue et al., 2002). 
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6.2 Results 
6.2.1  SMALP-solubilisation of other family A GPCRs 
To investigate whether extraction of other family A GPCRs in binding competent states was 
possible, pre-labelling of V1aR, V1bR and V2R with [
3H]AVP as a tracer, OTR with [3H]OT as 
a tracer, M1R with [3H]NMS as a tracer and A2aR (for comparison) with [
3H]ZM241385 as a 
tracer was performed. Before solubilisation, samples were incubated with approximately 1 nM 
of the appropriate [3H]ligand. This was performed in the presence or absence of a saturating 
concentration of competing ligand. Unbound radioligand was removed by aspiration before 
samples were SMALP-solubilised using the conditions optimised for SMALP-A2aR (as 
determined in chapter 3). After centrifugation (100,000 x g, 1 h), 50 μl aliquots of supernatant 
were taken for liquid scintillation analysis to determine the specific binding in each SMALP-
GPCR sample. Observation of specific binding would indicate SMALP-solubilisation does not 
perturb the receptors ability to bind ligand, and therefore is present in a functional state in the 
SMALP. 
Specific binding was observed for each of the GPCRs investigated, shown in figure 6.2. In each 
case specific binding was observed at around 50 % of total binding, except at OTR where it 
was ~25 %. Specific binding recorded was (in descending order): 23660.7 ± 2401.9 d.p.m. at 
A2aR; 8114 ± 462.8 d.p.m. at V2R; 6502.3 ± 2246.7 d.p.m. at M1R; 5923.7 ± 1516.4 d.p.m. at 
V1aR; 4622.7 ± 996.2 d.p.m. at V1bR and 3132.7 ± 352.7 d.p.m. at OTR (mean ± s.e.m. of three 
experiments performed in triplicate). 
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Figure 6.2. Pre-labelled radioligand binding observed for SMALP-solubilised family A GPCRs. 
Specific binding was determined for the GPCRs indicated using approximately 1 nM of appropriate 
[3H]ligand in the absence (total) and presence (non-specific) of saturating amounts of competing ligand. 
Non-specific binding was defined by: 1 μM AVP at V1aR, V1bR and V2R; 1 μM OT at OTR; 1μM 
ZM241385 at A2aR and 100 μM atropine at M1R. Data are of three experiments performed in triplicate 
(mean ± s.e.m.).  
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SMALP-solubilisation was not detrimental to the ligand binding capabilities of the GPCRs 
investigated. It was important, for their use in downstream analyses, to assess the ability of 
GPCRs to bind ligand after SMALP-solubilisation. This would allow study of SMALP-GPCRs 
in biophysical techniques such as Förster resonance energy transfer (FRET) that require ligand 
binding to induce conformational changes in a receptor. To investigate this, ligand binding was 
assayed following SMALP-solubilisation of an unoccupied receptor. Initially however, it was 
important to be able to effectively separate bound from free radioligand.  
To separate bound from free radioligand in the SMALP-solubilised samples, size affinity 
chromatography was employed as the SMALP is substantially larger than the free ligand (MW 
of AVP: ~1090 Da compared to ~113 kDa for SMALP containing only lipid (Lee and Dafforn, 
personal correspondence). Sephadex G-50 (MW cut-off of >30,000 Da), Sephadex G-25 (MW 
cut-off of >5,000 Da) and Sephadex G-15 (MW cut-off: >1500 Da) were investigated for 
efficient removal of free ligand from solution. [3H]ZM241385 was investigated first and diluted 
to approximately 1 nM in buffer (20 mM HEPES, 1 mM EGTA, 1 mM magnesium acetate, pH 
7.4) corresponding to the concentration used in assay. As in radioligand binding assays, 50 μl 
of the radioligand sample was loaded onto spin columns containing 500 μl bed volume of the 
indicated size exclusion resin. Samples were centrifuged for 4 min at 1,000 x g. 1 ml of Hisafe3 
scintillation cocktail was added to void volumes before samples were analysed by liquid 
scintillation analysis. 
It was observed, as seen in figure 6.3, that although all size-exclusion resins investigated were 
able to remove [3H]ZM241385 (MW: ~337 Da) from the sample, Sephadex G-15 was the most 
efficient with only 1.74 ± 0.3 % (mean ± s.e.m. of three experiments performed in triplicate) 
of the loaded [3H]ZM241385 present in the void volume. However, similar investigation into 
removal of [3H]AVP from a sample found that Sephadex G-15 was not the most suitable resin   
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Figure 6.3. Removal of [3H]ZM241385 from a sample using size exclusion 
chromatography. Sephadex G-50 (MW cut-off >30,000 Da), Sephadex G-25 (MW cut-off 
>5,000 Da) and Sephadex G-15 (MW cut-off >1,500 Da) were investigated for their ability to 
effectively remove [3H]ZM241385 from sample. Data show proportion (% of total d.p.m. 
loaded) of sample eluted in void volume in each case. Data are mean ± s.e.m. of three 
experiments performed in triplicate. 
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for use with [3H]AVP. Despite AVP having a calculated MW of ~1090 Da, this was not well 
retarded in Sephadex G-15, with 79.6 ± 0.9 % (mean + s.e.m. of three experiments performed 
in triplicate) eluting in the void volume (figure 6.4). Sephadex G-50 was shown to retard the 
elution of [3H]AVP with only 17.1 ± 5.3 % (mean + s.e.m. of three experiments performed in 
triplicate) eluting in the void volume. As size-exclusion resins separate molecules based on 
size, [3H]NMS (MW: ~320 Da) and [
3H]OT (MW: 1010 Da) were deemed likely to behave 
similarly to [3H]ZM241385 and [3H]AVP respectively due to similar molecular weights. 
Although it was possible to SMALP-solubilise functional receptor when it was pre-labelled 
with [3H]ligand, no specific binding could be detected when an unoccupied receptor was 
SMALP-solubilised other than A2aR (SMALP-A2aR ligand binding presented in section 3.2.2). 
As it had been established that SMALP-solubilisation did not prevent the receptor binding their 
respective ligands, it was hypothesised that there was an interaction between [3H]NMS, [3H]OT 
and [3H]AVP and the SMA polymer. To investigate this, [3H]ligands were investigated for 
their elution from size-exclusion spin columns in the presence of SMA. [3H]ZM241385 and 
[3H]NMS, tracer ligands, used for studying A2aR and M1R respectively, were applied to 
Sephadex G-15 spin columns. [3H]OT and [3H]AVP, tracer ligands, used in the study of the 
neurohypophysial receptors, were applied to Sephadex G-50 spin columns. This was performed 
in the presence and absence of 2 % (w/v) free SMA (SMA that has not formed discs). The 
presence of SMA allowed observation of any interactions with the radioligand. Free SMA has 
a minimum MW of 3000 Da, therefore interaction of [
3H]NMS or [3H]ZM241385 with SMA 
polymer would result in an increased presence in the void volume following gel filtration on 
Sephadex G-15 resin. However, Sephadex G-50 would still allow elution in the void volume 
of a single peptide chain of AVP or OT interacting with a monomeric free SMA chain. As a 
result, [3H]AVP and [3H]OT were investigated for their interaction with 2 % (w/v) free SMA 
as well as with SMALP-mock-transfected cells (MT cells). 
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Figure 6.4. Removal of [3H]AVP from a sample using size exclusion chromatography. 
Sephadex G-50 (MW cut-off >30,000 Da) and Sephadex G-15 (MW cut-off >1,500 Da) were 
investigated for their ability to effectively remove [3H]AVP from sample. Data show 
proportion (% of total d.p.m. loaded) of sample eluted in void volume in each case Data are 
mean ± s.e.m. of three experiments performed in triplicate. 
 
  
H
]A
VP
 lo
ad
ed
3
[ S
ep
ha
de
x 
G
-1
5
Se
ph
ad
ex
 G
-5
0
0
25
50
75
100
125
[3
H
]A
V
P
 i
n
 v
o
id
 v
o
lu
m
e
(%
 o
f 
to
ta
l 
d
.p
.m
. 
lo
a
d
e
d
)
131 
 
MT cells were HEK 293T cells that were treated the same as transiently transfected HEK 293T 
cells, but no plasmid was introduced for protein expression. SMALP-MT cells were predicted 
to have a MW of at ~113 kDa as they would predominantly contain only lipids. Any interaction 
of [3H]AVP or [3H]OT with a SMALP-MT cell disc would result in increased elution in the 
void volume after gel filtration on Sephadex G-50 resin. 
As shown in figure 6.5, [3H]ZM241385 was present in the void volume at ~1.5 fold over basal 
in the [3H]ZM241385 + 2 % (w/v) SMA sample compared to [3H]ZM241385 alone. This was 
similar for [3H]OT where an increase of [3H]OT in the void volume to ~1.7 was observed in 
the presence of 2 % (w/v) SMA and also SMALP-MT cells. [3H]NMS and [3H]AVP however, 
were present in their respective void volumes at greatly increased amounts in the presence of 
2 % (w/v) SMA (~3.7 and ~6 fold over basal respectively). Interestingly, presence of free SMA 
was enough to increase [3H]OT and [3H]AVP presence in void volume with SMALP-MT cells 
showing no substantial increase over free SMA alone. 
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Figure 6.5. Elution profiles of [3H]ligands in the absence and presence of SMA and SMALP-MT 
cells. [3H]ligand samples, at concentrations used in assay, were applied to appropriate size-exclusion 
spin columns in the presence of 2 % (w/v) SMA (+ SMA) and presence of SMALP-MT cells (+ 
SMALP-MT cells). Observed d.p.m. for basal were: ~700 for [3H]ZM241385; ~2000 for [3H]NMS; 
~650 for [3H]AVP and ~ 700 for [3H]OT. Data are mean ± s.e.m. of three experiments performed in 
triplicate.  
H
]Z
M
24
13
85
 +
 S
M
A
3
[
H
]N
M
S 
+ 
S
M
A
3
[
H
]A
V
P 
+ 
S
M
A
3
[
H
]A
V
P 
+ 
S
M
A
LP
-M
T 
ce
lls
3
[
H
]O
T 
+ 
S
M
A
3
[
H
]O
T 
+ 
S
M
A
LP
-M
T 
ce
lls
3
[
0
1
2
3
4
5
6
7
8
[3
H
]l
ig
a
n
d
 i
n
 v
o
id
 v
o
lu
m
e
(f
o
ld
 o
v
e
r 
[3
H
]l
ig
a
n
d
 o
n
ly
133 
 
It was hypothesised that the negative charge of the SMA was creating ionic interactions with 
[3H]AVP, [3H]NMS and, to a lesser extent, [3H]ZM241385 and [3H]OT. To investigate this, 
[3H]ligand samples with 2 % (w/v) SMA in the presence of 500 mM NaCl were applied to size-
exclusion columns. As seen in figure 6.6, 500 mM NaCl was unable to affect the elution in 
void volume of [3H]ZM241385, [3H]AVP and [3H]OT in the presence of free SMA. However, 
500 mM NaCl was able to reduce the levels of [3H]NMS in the void volume by approximately 
50 % in the presence of 2 % (w/v) SMA. [3H]NMS is present in the void volume at ~3.7 fold 
over basal in the presence of 2 % (w/v) SMA, a 50 % reduction of this with 500 mM NaCl 
reduces the overall presence in the void volume to ~1.85 over basal. This was similar to the 
level observed with [3H]ZM241385 (~1.5 fold over basal). 0.1 mM L-arginine and 1 % (w/v) 
BSA were also investigated for their ability to reduce non-specific binding of [3H]AVP in 
SMALP samples. No improvements on non-specific binding were observed. 
To increase the concentration of NaCl higher than 500 mM was known to be detrimental to 
ligand binding function (New and Wheatley, unpublished data). As an alternative to increased 
NaCl concentrations, reducing the amount of free SMA in the samples was investigated to 
reduce non-specific binding of [3H]AVP. Removal of free SMA, by gel filtration of SMALP 
samples, was first performed on SMALP-A2aR to allow radioligand binding analysis of 
samples. It was important to determine that gel filtration of SMALP-samples did not 
compromise the integrity of the protein. Size-exclusion chromatography was employed with 
Mw cut-offs at >30,000 Da (Sephadex G-50) and >80,000 Da (Sephadex G-75). SMALP-
GPCRs would elute in the void volume of both Sephadex resins as GPCRs possess a MW of 
~45 kDa even without the additional mass of the SMALP disc and annular lipid.  
Preliminary self-competition radioligand binding assays, with [3H]ZM241385 as tracer at 
SMALP-A2aR, displayed increased total binding ( increased by ~200 d.p.m.) and reduced non-   
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Figure 6.6. Elution profiles of [3H]ligand samples with 2 % (w/v) SMA in the presence of 
500 mM NaCl. [3H]ligand samples, at concentrations used in assay, were applied to 
appropriate size exclusion spin columns in the presence of 2 % (w/v) SMA and 500 mM NaCl. 
Presence of [3H]ligand in the void volume is presented as fold over [3H]ligand + 2 % (w/v) 
SMA. Observed d.p.m. for basal were: ~1000 for [3H]ZM241385; ~7500 for [3H]NMS; ~3900 for 
[3H]AVP and ~1200 for [3H]OT Data are mean ± s.e.m. of three experiments performed in 
triplicate  
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specific (reduced by ~300 d.p.m.) using Sephadex G-75 compared to Sephadex G-50 (figure 
6.7, data of one experiment performed in triplicate). This increased the observable specific 
binding from Sephadex G-75 in comparison to G-50 to ~50 % of total binding (similar to that 
seen for SMALP-A2aR not gel filtered). It was observed that there was a small increase of 5-
10 μl (~10 % of volume loaded) in sample volume after gel filtration. This was also observed 
in Western blot analysis (figure 6.8) in which SMALP-A2aR (MW: ~45790 Da) gel filtered 
using Sephadex G-75 was observed as a band of reduced intensity for the same volume loaded 
(53.8 %, mean of two experiments, calculated using ImageJ densitometry software). 
Specific binding observed in SMALP-A2aR samples, after gel filtration using Sephadex G-75, 
demonstrated that functional receptor was still present. However, as no direct assay was 
available for investigating the concentration of SMA in a sample, it was only assumed that gel 
filtration had removed free SMA from the sample. Sephadex G-75 was employed to gel filtrate 
SMALP-V1aR samples. A reduction in non-specific binding of [
3H]AVP observed in SMALP-
V1aR samples after gel filtration would indicate a reduced concentration of SMA. As with 
SMALP-A2aR, Western blot analysis of gel filtrated SMALP-V1aR (expected MW: ~47,890 Da) 
displayed at a reduced intensity compared to the original sample (79.8 %, mean of two 
experiments), as seen in figure 6.9. Radioligand binding analysis demonstrated decreased non-
specific binding after gel filtration of SMALP-V1aR samples (~920 d.p.m. compared to ~3900 
d.p.m. before gel filtration). Size exclusion chromatography can therefore be used to remove 
SMA from a SMALP sample. Furthermore, this allowed observation, for the first time, of 
specific binding for SMALP-V1aR (figure 6.10). 
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Figure 6.7. Competition radioligand binding performed on gel filtrated SMALP-A2aR 
from two different size-exclusion resins. Retention of specific binding in SMALP-A2aR 
eluted from Sephadex G-50 and G-75 resins was performed using 1 nM [3H]ZM241385 in the 
absence (total) and presence (non-specific) of a saturating concentration of ZM241385 (1 μM). 
Data are mean ± s.e.m. of one experiment performed in triplicate.  
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Figure 6.8. Western blot analysis of SMALP-A2aR before and after elution from size 
exclusion spin columns. Gel filtrated SMALP-A2aR (GF) was compared to SMALP-A2aR 
before gel filtration (S) on size-exclusion spin columns to remove excess SMA from the 
sample. Characteristic gel of two experiments.  
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Figure 6.9. Western blot analysis of SMALP-V1aR before and after elution from Sephadex 
G-75 size-exclusion spin columns. SMALP-V1aR before gel filtration (S) was compared to 
gel filtrated SMALP-V1aR (GF) on size-exclusion spin columns to remove excess SMA from 
the sample. Characteristic gel of two experiments.  
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Figure 6.10. Competition radioligand binding performed on SMALP-V1aR following 
elution from Sephadex G-75 size-exclusion spin columns. Determination of specific binding 
in SMALP-V1aR after elution from Sephadex G-75 spin columns. Self-competition radioligand 
binding was performed using 1 nM [3H]AVP in the absence (total) and presence (non-specific) 
of a saturating concentration of AVP (1 μM). Data are mean ± s.e.m. of one experiment 
performed in triplicate. 
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6.2.2  Family B GPCRs 
Some family B GPCRs interact with receptor activity modifying proteins (RAMPs), 
endogenously expressed in mammalian cells (Sexton et al., 2001). GPCR-RAMP complexes 
display altered pharmacological profiles compared to the GPCR alone. Altered pharmacology 
of family B GPCRs provides a tool to explore the ability of SMALP-solubilisation to extract 
GPCRs in complex with other proteins. The size of commercially available family B ligands 
(~30-40 residues) and the different mode of ligand interaction, in comparison to family A 
GPCRs, would also allow the study of GPCRs with different characteristics from different 
GPCR subfamilies. The calcitonin receptor (CTR) is a family B GPCR that expresses at the 
cell surface independently of RAMPs, but can also associate with RAMPs to form CTR:RAMP 
complexes. Two forms of calcitonin, salmon and human, are commercially available in 
unlabelled and [125I]labelled forms, allowing radioligand binding analysis of an active CTR. 
Due to the accessibility of high affinity radioligands, and its ability to be expressed at the cell 
surface in the presence or absence of RAMPs, CTR was chosen as an exemplar family B GPCR 
to be used in the study of the SMALP-solubilisation technique. 
HEK 293T cells are known to express RAMPs at relatively high levels. For the purpose of this 
investigation CTR was therefore transiently transfected into COS-7 cells, which express 
RAMP1 at much lower levels (Christopoulos et al., 1999). SMALP-solubilisation of COS-7 
cells transiently transfected with CTR alone or co-transfected with RAMP1 (producing amylin 
receptor 1 (AMY1)) would allow the study of two pharmacologically distinct receptors. CTR 
displays high affinity for human calcitonin only when not complexed with RAMPs (Hay et al., 
2005). Both CTR and AMY1 display high affinity binding for salmon calcitonin, but of CTR 
and AMY1 only AMY1 binds amylin with high affinity. 
SMALP-solubilisation from whole mammalian cells had only ever been performed from HEK 
293T cells. To ensure efficient extraction from COS-7 cells, A2aR was expressed, SMALP-
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solubilised and compared to membrane preparations from COS-7 and HEK 293T cells. From 
data expressed in figure 6.11 and table 6.1, it was observed that A2aR expressed in COS-7 cells 
displayed similar binding affinities for ZM241385 in comparison to A2aR expressed in HEK 
293T cells in both membrane and SMALP samples. 
Application of the HEK 293T cell-optimised SMALP-solubilisation technique yielded 
functional, soluble A2aR from COS-7 cells. Although no change to the SMALP technique was 
needed for solubilisation of COS-7 cells, it was not known whether a fully intact family B 
GPCR could be SMALP-solubilised in a functional state. SMALP-solubilisation of an HA-
epitope tagged CTR (herein referred to as CTR) from COS-7 cells was performed before 
Western blot analysis. This would allow identification of solubilised CTR and the relative 
amount remaining unsolubilised. Samples were separated using a 4-20 % (w/v) Tris-glycine 
gel (Bio-Rad, U.K.) before transfer to nitrocellulose, anti-HA antibody was used to probe for 
the HA-tag present on CTR. As shown in figure 6.12, SMALP-solubilisation from COS-7 cells 
was efficient, with the vast majority of receptor being present in the soluble fraction after 
SMALP-solubilisation (85.6 %, mean of two experiments, determined using ImageJ 
densitometry software). The bands present ~115 kDa were attributed to dimeric CTR 
(theoretical monomeric MW: ~60,400 Da). Higher bands, such as that observed ~175 kDa, were 
attributed to trimeric CTR and further higher order oligomers. 
Having shown SMALP-solubilisation of CTR was possible from COS-7 cells, the ability to 
SMALP-solubilise CTR in a functionally active state was determined through pre-labelling 
with radioligand. CTR was expressed in COS-7 cells before prelabelling with approximately 
50 pM [125I]salmon calcitonin ([125I]sCT) in the presence or absence of 1 μM sCT. Samples 
were incubated for 1 h, 37 °C, before free ligand was removed by aspiration. Samples were 
then SMALP-solubilised before bound [125I]sCT was quantitated by liquid scintillation 
counting.  
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Figure 6.11. Self-competition radioligand binding of A2aR expressed in COS-7 cells and 
HEK 293T cells. Radioligand binding performed on A2aR expressed in COS-7 cells and 
prepared as membranes (▲) and SMALPs (▼) compared to membrane A2aR (●) and SMALP-
A2aR (■) from HEK 293T cells. Data are mean ± s.e.m. of three experiments performed in 
triplicate. 
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 pKi ± s.e.m. 
Sample HEK 293T COS-7 
Membrane-A2aR 8.87 ± 0.1 9.39 ± 0.1 
SMALP-A2aR 8.53 ± 0.0 8.99 ± 0.1 
 
Table 6.1. pKi values of [3H]ZM241385 at A2aR prepared from HEK 293T and COS-7 
cells as membrane and SMALP samples. Data are mean ± s.e.m. of three experiments 
performed in triplicate. 
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Figure 6.12. Western blot analysis of SMALP-solubilised CTR from COS-7 cells. CTR 
present in the insoluble pellet fraction (P) and SMALP-solubilised fraction (S) were compared 
to initial CTR amounts (T) through use of an anti-HA probe. Typical of two experiments. 
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Non-specific binding was very low, only ~400 d.p.m., in comparison to total binding of ~2400 
d.p.m. Specific binding was 80.5 % of total binding (figure 6.13) and ~ 68 % of specific binding 
observed in membrane preparations of CTR from COS-7 cells, demonstrating the ability of 
SMALPs to solubilise CTR in a functional state. This preliminary study provided proof of 
concept for further investigation into use of SMALP-solubilisation to study family B GPCRs. 
6.2.3  Styrene maleimide lipid particles 
The ionic interactions observed between SMA and [3H]NMS, and possibly [3H]AVP, 
highlighted a possible limitation of the SMALP technique. It would appear that the negative 
charge surrounding the SMALP could interact with positively charged ligands to produce 
increased non-specific binding. Reversal of the charge on the outside of the SMALP could 
prevent the ionic interaction with positively charged molecules. For this, an SMA analogue 
possessing a positively charged moiety instead of maleic acid was investigated. Styrene 
maleimide (SMI) is a polymer that has been used in the past for: pigment dispersion in inks 
and paints, a clarifying agent (for use in flocculation) and paper/wood coating. Despite its use 
as a surfactant in the majority of its applications, there is no reported use of SMI in 
solubilisation of membrane proteins. The structure of SMI is similar to that of SMA (as 
displayed in figure 6.14). At a ratio of 2:1 (styrene:maleimide molar ratio) the structure differs 
only in the size and charge of the maleic side chain. Whereas in SMA the maleic acid group is 
small and displaying a negative charge, in SMI the maleimide group is bulkier and presents a 
positive charge. As there was no reported use of SMI to solubilise membrane proteins, it was 
unknown whether SMI would behave the same as SMA in solubilisation of GPCRs.  
Should SMI be able to solubilise functional GPCRs, it would provide an alternative polymer 
that could bypass charge interactions with positively charged ligands. To investigate whether 
SMI polymer interacts with ligand, analysis using size-exclusion chromatography was  
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Figure 6.13. Specific binding determination of SMALP-CTR through pre-labelling. 
Specific binding of SMALP-CTR was determined through pre-labelling with [125I]sCT in the 
absence (total) or presence (non-specific) of a saturating concentration of salmon calcitonin (1 
μM). Data are mean ± s.e.m. of one experiment performed in triplicate. 
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Figure 6.14. Structure of the monomeric subunits of SMA and SMI. The chemical structure of the repeating subunits of SMA (left) and SMI 
(right). For the 2:1 (styrene:maleic group molar ratio) form of each polymer, as used in this study, n=2 and x=1. 
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employed as before (section 6.2.1). As it was unknown whether SMI would solubilise 
membrane proteins in a similar way to SMA, increased concentrations of SMI were to be used 
for initial experiments. This would provide the best chance for maximum extraction of GPCR 
from membranes. As a result, 5 % (w/v) SMI was investigated for its interaction with 
[3H]ligands. [3H]ligand samples in the presence of 5 % (w/v) SMI and 5 % (w/v) SMI + 500 
mM NaCl were applied to spin columns containing size exclusion resin; Sephadex G-15 
([3H]ZM241385 and [3H]NMS) or Sephadex G-50 ([3H]AVP and [3H]OT). Presence of 
[3H]ligand in the void volume was measured by liquid scintillation counting. 
As shown in figure 6.15, more [3H]ZM241385 eluted in the void volume in the presence of 
SMI than in the absence of SMI. At ~2 fold over basal [3H]ZM241385 presence in the void 
volume with SMI was increased in comparison to SMA (~1.5 fold over basal) and inclusion of 
500 mM NaCl displayed no ability to reduce this. [3H]OT, as with SMA, showed only slightly 
increased quantities in the void volume in the presence of SMI (~1.2 fold over basal compared 
to ~1.5 fold over basal with SMA). [3H]AVP and [3H]NMS both showed increased quantities 
in void volumes in the presence of SMI (1.8 and 2.2 fold over basal respectively). However, 
these levels were not as high as those observed with SMA (~6 and ~3.7 fold over basal for 
AVP and NMS respectively) and in both cases inclusion of NaCl was able to produce a subtle 
decrease in [3H]ligand elution (from ~1.8 to ~1.4 fold over basal for [3H]AVP and from ~2.2 
to ~1.7 fold over basal for [3H]NMS). 
There was therefore a reduction in polymer interaction observed with [3H]AVP, [3H]OT and 
[3H]NMS. This indicated that SMI could potentially be used as an alternative to SMA to reduce 
non-specific binding of these ligands. However, this all depended on the ability of SMI to 
solubilise GPCR in a functional state. As solubilisation of proteins into styrene maleimide lipid 
particles (SMILPs) had never been previously reported, proof of concept was investigated. This   
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Figure 6.15. Elution profiles of [3H]ligands with SMI resolved by size exclusion 
chromatography. [3H]ligand samples, at concentrations used in assay, were run through 
appropriate size-exclusion spin columns in the presence of 5 % (w/v) SMI (+ SMI) and 
presence of 5 % (w/v) SMI + 500 mM NaCl (+ SMI + NaCl). Observed d.p.m. for basal were: 
~700 for [3H]ZM241385; ~2000 for [3H]NMS; ~650 for [3H]AVP and ~700 for [3H]OT. Data 
are mean ± s.e.m. of three experiments performed in triplicate.  
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was achieved through transient transfection into HEK 293T cells and subsequent pre-labelling 
of A2aR and V1aR with [
3H]ZM241385 and [3H]AVP respectively (~1 nM). This was performed 
in the presence or absence of a saturating concentration of competing ligand (1 μM ZM241385 
or 1 μM AVP). Samples were incubated at 30 °C for 30 min (A2aR) or 90 min (V1aR) before 
free ligand was removed by aspiration. As there was not an optimised protocol for SMILP-
solubilisation from mammalian cells, more polymer was used than in SMALP-solubilisation 
to increase the chance of maximum extraction. Pre-labelled A2aR and V1aR were incubated at 
37 °C, 1 h, before centrifugation at 100,000 x g for 1 h. Bound ligand in the supernatant was 
quantitated by liquid scintillation counting. As seen in figure 6.16, extraction of functional 
A2aR and V1aR into SMILPs was possible. Specific binding observed was 21941.3 ± 1871.4 
d.p.m. at SMILP-A2aR and 5667.3 ± 1655.4 d.p.m. for SMILP-V1aR (mean ± s.e.m. of three 
experiments performed in triplicate). These data were comparable to those observed with pre-
labelled SMALP-solubilisation (23660.7 ± 2401.9 d.p.m. at A2aR and 5923.7 ± 1516.4 d.p.m. 
at V1aR). 
As pre-labelling of SMILP samples produced specific binding equivalent to SMALP samples, 
radioligand binding was attempted of V1aR having been SMILP-solubilised in the absence of 
ligand. Even in the presence of 500 mM NaCl, the specific binding was only 11.1 ± 2.4 % (n=3, 
mean ± s.e.m.) of the total binding (~120 d.p.m. compared to ~1000 d.p.m.), as displayed in 
figure 6.17. This translates to approximately 5.5 % binding recovery in comparison to 
membrane preparations of V1aR from HEK 293T cells. These data were collected from V1aR 
solubilised using non-optimised conditions. It may have been possible to improve SMILP-
solubilisation of V1aR through optimisation of the SMILP-solubilisation protocol. 
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Figure 6.16. Pre-labelled radioligand binding observed for SMILP-A2aR and SMILP-V1aR. 
Panel A: specific binding was determined for A2aR using [
3H]ZM241385 in the absence (total) 
and presence (non-specific binding) of a saturating concentration (1 μM) of ZM241385. Panel 
B: specific binding was determined for V1aR using [
3H]AVP in the absence (total) and presence 
(non-specific binding) of a saturating concentration (1 μM) of AVP. Data are mean ± s.e.m. of 
three experiments performed in triplicate.  
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Figure 6.17. Radioligand binding of SMILP-V1aR performed after SMILP-solubilisation. 
Specific binding of SMILP-V1aR was determined through incubation with [
3H]AVP (~1 nM) 
in the absence (total) and presence (non-specific) of a saturating concentration of AVP (1 μM). 
Observed d.p.m. was ~1000 for total binding. Data are mean ± s.e.m. of three experiments 
performed in triplicate. 
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6.2.3.1 SMILP optimisation 
As with SMALP-solubilisation optimisation, parameters of SMI concentration, incubation 
temperature and incubation time were to be investigated sequentially. Initial parameters were 
based around optimised SMALP-solubilisation for mammalian cells. It had been shown that 5 
% (w/v) was able to extract V1aR and A2aR in a functional state. However, it was noticed that 
there was a large amount of white precipitate present in the insoluble fraction of SMILP 
samples (figure 6.18). This large amount of precipitate had never been observed with SMALP 
samples, even when using 4 % (w/v) SMA. Common pellet size of SMALP samples is shown 
in figure 6.18, and is characteristic of all SMALP samples created with >1 % (w/v) SMA. 
Although pre-labelling of A2aR and V1aR produced data equivalent to those produced from 
SMALP samples, radioligand binding performed on SMILP-V1aR, after solubilisation, 
demonstrated very little specific binding. The amount of precipitate observed was more than 
the amount of membrane present in the sample. It was therefore hypothesised that the white 
precipitate present after SMILP-solubilisation was, in part, the result of SMI precipitation and 
that this was preventing efficient extraction of V1aR. 
BCA assays were performed on SMILP samples created with 5 % (w/v) SMI. Total protein 
content of the precipitate was determined to be 12.9 ± 0.9 % (mean ± s.e.m. of three 
experiments performed in triplicate) of the total protein present before SMILP-sample 
centrifugation at 100,000 x g, 1 h. This was comparable to data obtained from SMALP samples 
(~17 % of total protein remained in the pellet). However, this was performed on crude 
preparations and therefore all soluble proteins from within the cell contributed to the protein 
concentration of the soluble samples. As there was no specific binding observed from SMILP 
pellet samples, Western blot analysis was employed to observe V1aR presence in SMILPs. 
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Figure 6.18. Pellet fractions of V1aR when solubilised with SMA or SMI. Left panel displays the un-doctored image. Right panel has 
highlighted, in red, the pellets of SMALP-V1aR (top) and SMILP-V1aR (bottom), from the same amount of starting material. SMALP-V1aR was 
prepared using the conditions optimised for SMALP-solubilisation from mammalian cells and this image is characteristic of all SMALP samples 
prepared using >1 % (w/v) SMA. SMILP-V1aR samples were prepared using 5 % (w/v) SMI and incubated at 37 °C for 1 h. The SMILP pellet is 
characteristic of SMILP samples prepared using 5 % (w/v) SMI.  
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6.2.3.2 Use of Western blots in the study of SMILP-solubilisation 
Western blot analysis was used to probe for the presence of the HA-tagged V1aR in SMILP 
samples. Unfortunately, sample migration from the stacking gel to the separating gel was poor. 
V1aR that did migrate into the separating gel produced ill-defined, high molecular weight bands 
(figure 6.19). Ionic interactions between SDS and SMI were hypothesised to have prevented 
sufficient denaturing and charge coating of proteins by SDS. Increased SDS concentrations up 
to 10 % (w/v) were employed, allowing observation of bands as seen in figure 6.20. Although 
the band observed at ~60 kDa was faint and not of the expected size (HA-V1aR predicted Mw: 
47,890 Da), the specificity of anti-HA antibody for the HA-tag provided evidence that there 
was some extraction of V1aR using the SMI polymer. Precipitation of samples had been 
observed at the interface of the stacking gel with the separating gel. It was hypothesised that 
there was precipitation of SMI upon reaching the pH 8.8 separating gel of SDS-PAGE as SMI 
precipitates from solution at pH >7.5. This may have resulted in a blockage of the acrylamide 
mesh, preventing and retarding the movement of proteins through the separating gel. However, 
Bis-Tris gels and buffers, providing pH ranges of 6.4 to 7.2, were equally ineffective for use 
with SMILP-V1aR samples. Bis-Tris gels also produced precipitation of samples at the gel 
interface and, as shown in figure 6.21, lower pH ranges still resulted in aggregation of protein 
samples at the gel interface. 
With the great difficulties encountered using SDS-PAGE and Bis-Tris gels, dot blot analysis 
of samples was employed. By applying SMILP samples directly to nitrocellulose before 
immuno-detection using anti-HA antibody, pH and ionic interaction issues were bypassed. This 
meant sacrificing identification of specific band sizes of the target protein containing the HA-
tag. However, it allowed investigation of relative protein amounts under various SMILP-
solubilisation conditions. 
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Figure 6.19. Western blot analysis of SMILP-V1aR prepared with 5 % (w/v) SMI. SMILP-
V1aR soluble samples (S) were compared to initial V1aR concentrations (T) when prepared with 
5 % (w/v) SMI. Samples were separated by SDS-PAGE before transfer to nitrocellulose and 
probed with anti-HA antibody. Typical of six experiments. 
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Figure 6.20. Western blot analysis of the soluble fraction of SMILP-V1aR using increased 
SDS concentrations in loading buffers. Molecular weight markers (M). SMILP V1aR (V) 
soluble sample was probed with anti-HA antibody for the engineered HA-tag once separated 
by SDS-PAGE using 10 % SDS in loading buffer. Characteristic gel of two experiments.  
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Figure 6.21. Western blot analysis from Bis-Tris gel separation of proteins in SMILP-
V1aR samples. Anti-HA antibody used to probe for SMILP-V1aR pellet (P) and soluble (S) 
fractions prepared using 5 % (w/v) SMI. Samples were separated on Bis-Tris gels before 
transfer to nitrocellulose. Representative of five experiments. 
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SMI concentration used in solubilisation of V1aR was the first condition to be optimised for the 
SMILP-solubilisation protocol. SMI at 5 % (w/v) had been shown to extract V1aR. SMI at 2 % 
(w/v) was also investigated as this was the optimum concentration of SMA for use in 
solubilisation of GPCRs from mammalian cells. SMI at 1 % (w/v) was investigated to further 
explore the efficiency of SMILP-solubilisation at low SMI concentrations. SMI at 10 % (w/v) 
was investigated as it appeared SMI precipitated from solution during solubilisation of 
mammalian cells, it was likely that more SMI would be required than SMA for efficient 
solubilisation. As seen in figure 6.22, although protein size could not be observed, SMILP-
solubilised mock-transfected cells did not produce a signal using anti-HA antibody. All 
samples that did produce a signal were therefore a result of the HA-tagged V1aR. 1 % (w/v), 2 
% (w/v) and 5 % (w/v) SMI were able to extract small amounts of V1aR (14 %, 14.6 % and 
12.5 %, mean of two experiments, determined using ImageJ densitometry software), in 
comparison to SMALP-V1aR samples. SMI at 10 % (w/v) extracted the largest amount of 
protein in the SMILP-solubilised samples (34.2 % of SMALP-V1aR, mean of two experiments). 
However, this was still not as efficient as 2 % (w/v) SMA.  
It has been shown that the SMILP-solubilisation protocol has not yet been fully optimised and 
that there is the possibility to improve SMILP extraction of GPCRs. However, despite not being 
optimised, SMILP-solubilisation of V1aR has been shown to extract functional receptor. 
Thereby establishing for the first time that a second polymer is capable of detergent-free 
solubilisation of functional GPCRs.  
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Figure 6.22. Dot blot analysis of SMILP V1aR samples prepared with different concentrations of SMI in comparison to SMALP-V1aR. 
Soluble fractions of SMILP-mock-transfected cells (1) and two separate SMALP-V1aR samples (2 and 3) prepared using conditions optimised for 
SMALP-solubilisation from mammalian cells (determined in chapter 3). SMILP-V1aR prepared with: 1 % (w/v) SMI (4); 2 % (w/v) SMI (5); 5 % 
(w/v) SMI (6) and 10 % (w/v) SMI (7). Samples were applied directly to nitrocellulose and probed using anti-HA antibody. Representative of two 
experiments. 
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6.3 Discussion 
6.3.1  SMALP-solubilisation of family A GPCRs 
The neurohypophysial family of GPCRs has been extensively studied in the laboratory of Prof. 
Mark Wheatley. The muscarinic acetylcholine receptor M1 had also been used for previous studies 
in the laboratory of Prof. Mark Wheatley. With such a rich vein of knowledge behind these 
receptors, they made the obvious choice for further SMALP-studies. Initial SMALP-solubilisation 
of pre-labelled receptors was promising. Extraction of functional receptors was established for a 
range of family A GPCRs, demonstrating specific binding with a range of different ligands. 
SMALP-solubilisation is therefore not detrimental to the ligand binding capabilities of the GPCRs 
studied (V1aR, V1bR, V2R, OTR and M1R) and is compatible with a range of different receptors 
with both amine and peptide ligands. Detailed analysis of SMALP-solubilised GPCRs will require 
the observation of the effect of ligand binding to the receptor. Therefore it was important to 
determine ligand binding capabilities for receptors SMALP-solubilised while unoccupied by 
ligand.  
For their use in radioligand binding assays, soluble SMALP-GPCR samples required a method of 
separating bound from free radioligand. This was achieved by identifying and employing 
appropriate size exclusion chromatography resins. Sephadex G-15 was proven to be optimal for 
use in SMALP-A2aR studies using [
3H]ZM241385. [3H]NMS (MW: ~320 Da) has a similar 
molecular weight to [3H]ZM241385 (MW: ~337 Da) and so was likely to behave in a similar way 
in size-exclusion chromatography. Despite [3H]AVP (MW: ~1090) having a molecular weight less 
than the stated cut-off for Sephadex G-15 (>1500 Da), it’s elution was not effectively retarded by 
Sephadex G-15 resin. This may have been a result of some aggregation of the AVP, increasing its 
molecular weight and causing elution in the void volume. There was no such complication when 
162 
 
using Sephadex G-50 however, which provided a much more efficient size-exclusion medium 
than Sephadex G-15.  
Radioligand binding assays, performed using the appropriate size exclusion resin, were unable to 
identify specific binding of SMALP-GPCRs solubilised in the absence of ligand, other than 
SMALP-A2aR. However, it was known from pre-labelling experiments that the SMALP could 
support these same receptors with ligand binding capability. [3H]ligands were investigated for 
possible interactions with SMA polymer that preventing the radioligand binding analysis. Samples 
were created containing [3H]ligand and SMA (either in the form of free SMA (2 % (w/v)) or as 
SMALP MT-cells) and eluted from size exclusion columns in the presence or absence of 500 mM 
NaCl. Increased presence in the void volume indicated that there was an ionic interaction between 
SMA polymer and [3H]NMS, likely a result of the positively charged quaternary nitrogen group 
of NMS and the negatively charged maleic acid of SMA. This ionic interaction could be 
interrupted by the presence of 500 mM NaCl.  
[3H]AVP formed an interaction with SMA polymer whereas [3H]OT did not interact with SMA 
polymer. As OT differs from AVP in only 2 positions, including non-polar Leu8 in OT being a 
basic residue Arg8 in AVP, it was probable that this positively charged residue in AVP was 
creating strong charge interactions with negatively charged maleic acid groups in SMA. Although 
[3H]OT did not interact with SMA, increased presence of all [3H]ligands studied was observed in 
the void volumes when 2 % (w/v) free SMA was present. When 5 % (w/v) SMI was investigated 
this effect was increased, suggesting a possible blocking of the pores in the resin by the free 
polymer. This reduced the efficiency of the resin to retard elution of free ligand. This was the only 
increase observed for [3H]OT in the void volume. It has therefore been demonstrated that [3H]OT 
does not interact, to any noticeable level, with SMA. SMALP-OTR was proven to be capable of 
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ligand binding, but the low specific binding observed in pre-labelling experiments may suggest 
the occupancy of OTR by [3H]OT needs to be increased to observe specific binding of SMALP-
OTR. 
The presence of similar levels of [3H]AVP in the void volume when eluted in the presence of free 
SMA or SMALP-MT cells, suggests [3H]AVP formed complexes with more than just one SMA 
chain. Free SMA (typical MW: 9500 Da (Knowles et al., 2009)) and a single [
3H]AVP peptide 
chain (MW: ~1090 Da), in a 1:1 complex, would be expected to be absent from the void volume 
when using Sephadex G-50 resin (MW cut-off: >30,000). This suggests one or more [
3H]AVP 
molecules interacts with more than one SMA chain to create a complex of MW greater than 30,000 
Da. The large complexes formed through these ionic interactions were resistant to disruption by 
500 mM NaCl. For the further study of SMALP-V1aR, as well as other proteins with positively 
charged ligands, it was important to limit the formation of these complexes. Gel filtration was 
investigated as a method to remove free SMA from SMALP samples. 
6.3.1.1 Gel filtration of SMALP samples 
Mammalian cell expression systems have relatively low expression levels of receptors compared 
to other expression systems such as bacterial (E.coli) and yeast (P.pastoris). High non-specific 
binding, as a result of SMA presence, could prevent detection of specific binding in SMALP 
samples prepared from mammalian cells. It was therefore important to reduce non-specific 
binding in SMALP samples as much as possible. SMA at 2 % (w/v) was found to be optimal for 
extraction of proteins from mammalian cells. However, this may have excess polymer that does 
not form discs. Free polymer is approximately 9.5 kDa (Knowles et al., 2009), whereas SMALPs 
containing only lipid are predicted to be ~113 kDa, which will increase with the presence of a 
164 
 
GPCR in the SMALP. Size exclusion chromatography could therefore be employed to remove 
free SMA from SMALP samples.  
With molecular weight cut-offs of >30 kDa and >80 kDa, Sephadex G-50 and G-75 (respectively) 
were able to remove free SMA from SMALP-A2aR and SMALP-V1aR samples. Elution of free 
SMA polymer in a sample was retarded while the SMALP-GPCRs were able to elute in the void 
volume. Gel filtration of SMALP-A2aR using Sephadex G-75 retained binding comparable to non-
gel filtered SMALP-A2aR. This was despite a sample volume increase of ~10 %, commonly 
observed after gel filtration. Gel filtration allowed specific binding to be observed, for the first 
time, in SMALP-V1aR due to reduced non-specific binding. As there is a proven interaction 
between AVP with SMA increasing non-specific binding, this provides proof of concept for the 
gel filtration of SMALP samples to remove free SMA from samples without loss of GPCR ligand 
binding capability. This could aid in the study of GPCRs as potential therapeutic targets. It has 
already been established in chapter 3 that SMALPs would provide a suitable platform for drug 
screens. Potential problems that may have arisen from charge interaction between ligand and SMA 
polymer could now be limited. Further study on removal of free SMA to reduce non-specific 
binding of other ligands would need to be performed to assess the general utility of this technique. 
6.3.2  Family B GPCRs and SMALP-solubilisation from COS-7 cells 
Initial investigations into the SMALP-solubilisation of COS-7 cells provided the first information 
on the utility of SMA to extract GPCRs from different mammalian cell types without diminished 
efficiency. A2aR expressed in COS-7 cells displayed binding activity in SMALPs comparable to 
that in membranes from COS-7 cells. This facilitated SMALP-solubilisation in the study of family 
B GPCRs, where mammalian cell lines with reduced endogenous RAMP expression levels have 
often been employed (Christopoulos et al., 1999, Hay et al., 2006).  
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The CTR has proven clinical relevance due to implication in diseases such as: osteoclastic bone 
resorption (Turner et al., 2011). In combination with RAMPs, forming amylin receptors, CTR is 
implicated in diabetes and Alzheimer’s disease (Leighton and Cooper, 1988, Fu et al., 2012). 
Study of SMALP-CTR could therefore aid in the understanding of, and subsequent development 
of improved drugs for, this therapeutically important receptor. Use of SMALP technology was 
shown to be applicable for the study of CTR, suggesting the utility of SMALPs in the future study 
of family B GPCRs. 
Family B GPCRs are notoriously difficult to separate by gel electrophoresis for use in Western 
blots as they are prone to forming aggregates. However, it was found that through the use of 
gradient gels, separation of protein bands was possible, although only as oligomers. The 
theoretical MW of CTR is ~60 kDa, the expected observed band size was ~55 kDa (Pham et al., 
2005). Bands were clearly visible at ~115 kDa, ~175 kDa and >190 kDa, attributed to dimeric and 
higher order oligomers of CTR. As with family A GPCRs, these observed oligomers were not 
necessarily present in SMALPs but may have been artefacts of the Western blot technique. 
SMALP-solubilisation of functionally active receptor was confirmed by radioligand binding. Pre-
labelled CTR was extracted and demonstrated specific binding, presenting for the first time that 
the SMALP-solubilisation technique is applicable to other subfamilies of the GPCR superfamily. 
Although only preliminary data, these findings suggest that SMA is capable of extracting 
functional family B GPCRs. Further studies on ligand binding using SMALP-CTR will require 
removal of free SMA if endogenous, large peptide, ligands are to be studied. The human form of 
the endogenous ligand for CTR, calcitonin, contains lysine and histidine residues (Riniker et al., 
1969). As seen with AVP, positively charged residues will tend form ionic interactions with SMA 
and increase non-specific binding in functional assays. Gel filtration of SMALP-CTR samples 
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could therefore aid in the study of SMALP-CTR, alternatively the few small molecule ligands 
commercially available for family B GPCRs could be employed. 
6.3.3  SMILP-solubilisation of membrane proteins 
6.3.3.1 Use of SMI in functional activity assays 
Use of SMI to extract receptors such as V1aR seemed a promising prospect. The reversal of the 
charge on the outside of the SMILP-solubilised sample, in comparison to SMALP, would prevent 
strong ionic interactions between positively charged residues, such as arginine of AVP, and the 
polymer. The ability to successfully remove [3H]AVP from samples containing SMI through gel 
filtration was more successful than with SMA. In gel filtration experiments [3H]AVP and 
[3H]NMS were present in the void volume at levels comparable to [3H]ZM241385 in the presence 
of SMI, instead of the greatly increased levels observed with SMA. The increased levels present 
in the void volume observed with all [3H]ligands in the presence of SMI, compared to SMA, can 
be explained by the increased concentration of SMI polymer. This was possibly due to the polymer 
blocking the pores of the size exclusion resin. If this was the case, then use of 5 % (w/v) SMI 
compared to 2 % (w/v) SMA would produce an increase in this effect of polymer on the size 
exclusion resin. These data give further evidence of the ionic interaction between [3H]AVP and 
[3H]NMS. Replacing the negative charge of SMA with the positive charge of SMI resulted in no 
apparent interaction between these ligands and the polymer. 
SMILP-solubilisation of pre-labelled receptors with 5 % (w/v) SMI demonstrated for the very first 
time that SMI could be used to extract GPCRs with retention of binding capability. Furthermore, 
the specific binding observed through SMILP-solubilisation of pre-labelled A2aR and V1aR 
demonstrated comparable specific binding to pre-labelled SMALP-A2aR and SMALP-V1aR. This 
suggested SMILPs were as efficient as SMALPs at extracting GPCRs with retention of binding 
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capability. The lack of an interaction between AVP and SMI allowed for specific binding to be 
determined using post-solubilisation radioligand binding on SMILP-V1aR. However, the specific 
binding determined with post-solubilisation radioligand binding was small. Specific binding of 
only ~120 d.p.m. would not be suitable to perform full pharmacological characterisation of 
SMILP-V1aR. This may have been due to low occupancy of V1aR by [
3H]AVP and increasing the 
concentration of tracer ligand may improve this. However, it was more likely due to the amount 
of receptor that had been SMILP-solubilised. 
From dot-blot analysis of SMILP-V1aR samples it appeared that SMILP-solubilisation was much 
less efficient at extracting large amounts of V1aR than SMALPs were. This could mean one of two 
things, either there is much less V1aR present in SMILP samples than in SMALP samples or SMI 
prevents anti-HA antibody binding to the HA-tag of V1aR. If the former is true, then pre-labelling 
experiments on A2aR and V1aR producing equivalent specific binding in SMILPs and SMALPs 
suggests the GPCR was extracted with increased recovery in binding capability in SMILPs than 
SMALPs. This may be explained by the bulky hydrophilic maleimide group of SMI slowing the 
insertion of SMI into the lipid bilayer of membranes. It has been demonstrated that tighter lipid 
packing slows SMA insertion into membranes because it is more difficult for the entire polymer 
to insert into the membrane (Scheidelaar et al., 2015). Increased stability of membrane proteins 
has been reported in detergent solubilisation when detergent solubilisation is slow (de Foresta et 
al., 1989, Kragh-Hansen et al., 1998, Stuart and Boekema, 2007), seemingly due to a large amount 
of detergent entering the membrane rapidly (Pantaler et al., 2000). Slower insertion of SMI into 
the membrane compared to SMA may result in less perturbation of the membrane as fragments 
are solubilised slower. This could allow the membrane to reorganise around proteins, preserving 
their structure before they are solubilised. Alternatively, SMI has extracted equivalent amounts of 
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V1aR but SMI is preventing anti-HA antibody detection of the HA-tagged V1aR. However, if this 
was true then use of 10 % (w/v) SMI to solubilise V1aR would have resulted in an apparent 
reduction in extraction, not increase as was observed by dot-blot analysis. 
6.3.3.2 Optimisation of SMILP-solubilisation 
SMI had never before been investigated for its use as a solubilisation agent. It had been proven 
that 5 % (w/v) SMI could be used to extract V1aR and A2aR, from mammalian cells, with retention 
of ligand binding capability. However, it was still not clear whether SMI behaved in the same way 
as SMA. Therefore it was necessary to optimise the conditions for GPCR extraction from 
mammalian cells with SMI. Identification of a method to compare the amount of V1aR extracted 
with SMI was difficult. BCA assays were of no use as solubilisation was performed on whole 
cells. Therefore, upon membrane solubilisation with SMI, all intracellular soluble proteins would 
be released. Naturally soluble proteins are not differentiated from solubilised membrane proteins 
in BCA assays and so would always show ~85 % extraction efficiency. For SMALP-
solubilisation, Western blots performed on transfers from SDS-PAGE gels were used to observe 
the relative amounts of epitope-tagged proteins. Unfortunately, the negatively charged SDS, used 
to denature proteins and coat them in a negative charge allowing protein separation based almost 
entirely on size, bound to, and precipitated with, positively charged SMI. This prevented 
denaturing of V1aR in SMILP samples, leading to sample aggregation and anomalous migration 
through the gel. Increased SDS concentrations allowed the visualisation of SMILP-solubilised 
V1aR, although not at the expected molecular weight. This may have been due to incomplete 
coating of V1aR with SDS preventing full denaturing of the structure of V1aR or incomplete coating 
with negative charge, both would have resulted in retarded migration through the gel of V1aR. 
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An alternative explanation for the anomalous migration of SMILP-solubilised V1aR in SDS-PAGE 
may be the precipitation of SMI due to unfavourable pH. In SDS-PAGE the stacking gel is pH 6.8 
and the separating gel is pH 8.8. For SMALPs these two gels were within the SMA functional 
range (pH >6.5), but not SMI. At pH >7.5 SMI precipitates, in SDS-PAGE this would result in 
precipitation at the interface between the two gels. This may have created a blockage in the 
acrylamide mesh, preventing proteins from running into the gel. To overcome this, Bis-Tris gels, 
which separate proteins at pH 7.2, were employed. However, the problem of incomplete sample 
denaturation through SDS presented itself, causing sample aggregation and preventing migration 
through the separating gel. Dot-blot analysis was therefore attempted. Although not allowing 
identification of protein size, dot-blots may allow for visual comparison of total V1aR solubilised 
using SMI. Preliminary investigations suggested that 5 % (w/v) SMI was only marginally more 
efficient at V1aR extraction than 1 % (w/v) and 2 % (w/v) SMI. Extraction of V1aR was greatly 
improved through use of 10 % (w/v) SMI. This is likely because there was more SMI available 
for solubilisation following precipitation of some SMI upon cell solubilisation. However, it is not 
yet clear whether this is the optimal concentration of SMI to be used as no higher concentrations 
have yet been investigated.  
Presented here was the first use of the SMA analogue SMI as a means of solubilising GPCRs with 
retention of ligand binding capability. However, although 5 % (w/v) SMI was able to extract 
GPCRs with retention of their binding capabilities, SMI concentration requires optimisation for 
efficient extraction of V1aR from mammalian cells. However, before optimisation is performed it 
would be recommended that interference of anti-HA antibody binding to HA-tagged V1aR be 
investigated. Should SMI interfere in anti-HA antibody binding, an alternative epitope tag may be 
required for robust determination of relative protein amounts extracted with SMI of different 
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concentrations. Use of SMI could enable the study of a wider range of ligands and drugs at 
therapeutic targets such as GPCRs. By swapping the inherent negative charge of SMA for the 
positive charge of SMI, study of peptides with positive charges is possible, as demonstrated with 
the V1aR. 
6.3.4  Summary 
Presented here was: the first use of SMA to SMALP-solubilise V1aR with retention of ligand 
binding capability; the first use of SMALPs to solubilise a family B GPCR with retention of ligand 
binding capability and the first use of SMI to extract GPCRs with retention of ligand binding 
capability. Although study of some SMALP-GPCRs presented some issues relating to ionic 
interactions between ligand and polymer, these could be overcome through the use of NaCl or 
from removal of free SMA. SMI also provided an alternative to SMA in cases where ligand 
interaction with SMA was too strong to be prevented by NaCl. Together, these data provide proof 
of the utility of the SMALP and SMILP techniques for the detergent-free solubilisation of GPCRs, 
from across the GPCR superfamily, with retention of their ligand binding capabilities.  
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7 CHAPTER 7: SUMMARY AND FUTURE WORK 
GPCRs are of great interest to the pharmaceutical industry. Understanding of these membrane 
proteins has been hindered due to their inherent hydrophobicity and the imperfect methods of 
solubilisation that result in unstable receptors. The data presented here assessed the possible use 
of SMA to solubilise and study proteins, from across the GPCR superfamily, expressed in 
mammalian cells. Furthermore, GPCR constructs to research the potential utility of SMALPs in 
intracellular membrane solubilisation and fluorescence studies were developed and characterised. 
Presented in chapter 3 was the very first use of SMALPs to solubilise a GPCR from mammalian 
cells. The successful SMALP-solubilisation of A2aR with retention of ligand binding capability 
could have great implications for pharmaceutical companies developing drugs to treat diseases 
such as Alzheimer’s disease and Parkinson’s disease. To be able to solubilise GPCRs, from their 
native membrane environment in mammalian cells, retaining annular lipid that is important for 
stability and function, could provide reliable data on GPCR behaviour upon drug binding. This is 
not possible with techniques such as apolipoprotein stabilised nanodiscs, which require detergent 
solubilisation of GPCRs, removing their lipid annulus, before insertion into a non-native lipid 
bilayer. The increased thermostability of SMALP-A2aR over DDM-A2aR, particularly at human 
physiological temperature, demonstrates the possible use of SMALPs as a platform in receptor-
based assays and drug screens. The stability of SMALP-solubilised A2aR under standard 
laboratory conditions, and extreme conditions such as freeze-thawing and lyophilisation, was 
greatly increased over DDM-solubilised A2aR. SMALP-GPCR preparations can therefore be made 
in large batches and aliquots stored under standard conditions. This allows study of the same 
sample under many conditions, preventing batch variation between experiments. 
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Chapter 4 attempted to investigate the ability of SMA to solubilise proteins from intracellular 
membranes. Several diseases can be caused by mutated proteins that are retained in intracellular 
compartments such as the ER. Study of these mutated proteins could provide useful information 
on why they were retained and potential sites of pharmacological chaperone interaction that could 
aid in refolding and trafficking to the cell surface. SMALP-solubilisation of these proteins from 
the ER would allow their study despite not being present at the cell surface. C-terminal ER-
retention motifs were engineered onto A2aR and characterised for their ability to retain A2aR in 
the ER. The two retention motifs employed, despite previous reports demonstrating their ER-
retention capability in membrane proteins, were unable to prevent A2aR trafficking to the cell 
surface. It was unclear as to why A2aR was not retained in the ER with these two well characterised 
ER-retention motifs. It is possible that the tertiary structure of the A2aR C-terminus concealed the 
motifs. 
Future studies into the ability of SMA to solubilise intracellular membranes could employ longer, 
or repeated, ER-retention motifs at the C-terminus of A2aR. Alternatively, an ER-retention motif 
applied to a C-terminally truncated A2aR could be employed. The A2aR is known to function if the 
C-terminus is truncated at residue 316, removing the potential for elaborate tertiary structure in 
the C-terminal region. Efforts were made to retain A2aR as there was a functional radioligand 
binding assay that could be used to assess the binding capabilities of SMALP-A2aR extracted from 
the ER. However, Western blot analysis could be used to purely observe whether SMALP-
solubilisation from the ER is possible. To this end, epitope-tagged RAMP1, known to be retained 
in the ER in the absence of family B GPCRs could be employed. Alternatively an ER retained 
V2R construct could be engineered with an NDI-inducing mutation. 
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Chapter 5 presented the development of a Cys-depleted A2aR construct with derivatisable sites 
that could be used in fluorescence studies. SMALPs have proven to be a useful platform for the 
biophysical study of membrane proteins in several different techniques, including spectroscopic 
techniques not available to nanodisc-stabilised proteins. However, study of proteins using 
fluorescence-based techniques have not yet been performed in SMALPs. These techniques 
provide useful information on the local environment of the fluorescent probe and can be used to 
elucidate the conformational rearrangements of proteins upon ligand interaction. The development 
of a Cys-depleted A2aR, which behaves with WT-like characteristics, could provide information 
on the conformational rearrangements that lead to the specific pathways involved in biased 
agonism. This would be of great interest to pharmaceutical companies that could design drugs that 
are highly specific to one receptor conformation and signalling pathway, creating safer drugs with 
fewer side-effects. Furthermore, this would be the second Cys-depleted family A GPCR that 
would have been developed in this way, implicating a possible routine method for developing 
GPCRs that can be studied through fluorescence techniques. This would of course all depend on 
the ability of SMALPs to be used in fluorescence spectroscopy. The next steps in this investigation 
would be large-scale expression and SMALP-solubilisation of the Cys-depleted A2aR. This could 
then be derivatised with a fluorescent probe and studied in fluorescence assays to determine the 
utility of SMALPs in fluorescence-based techniques. 
Chapter 6 explored the possibility of SMALPs to be a general method for GPCR solubilisation. 
Other GPCRs of pharmaceutical relevance, from family A and B, were SMALP-solubilised and 
studied for their ligand binding ability. The vasopressin receptors and M1R were very promising 
in prelabelling experiments. For post-solubilisation ligand binding studies, issues of ligand:SMA 
charge interactions for AVP and NMS could possibly be overcome through gel filtration of 
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SMALP samples to remove excess SMA. Further investigations into this would want to explore 
free SMA removal from samples, by gel filtration, and the effect this has on the ligand binding 
capability of different receptors with different ligands, such as the large peptide ligands of family 
B GPCRs. Study of SMALP-OTR was not affected by OT:SMA interactions making it a prime 
candidate for further SMALP studies. However, further study of SMALP-OTR should use higher 
concentrations of tracer ligand as this may provide greater receptor occupancy. SMALPs have 
demonstrated to be useable in the study of GPCRs with a range of different ligands from small 
amines to peptides. This provides further evidence for the utility of SMALPs in receptor-based 
assays and drug screens. 
The large N-terminus of family B GPCRs did not prevent the SMALP-solubilisation of CTR with 
retention of the ability to bind large peptide ligands. Studies into the ability of SMALP-CTR to 
bind ligands after solubilisation will need to be performed. This will likely require the gel filtration 
of SMALP-CTR, to remove free SMA, as the large peptide ligands will probably interact with 
SMA to increase the non-specific binding. However, these data present the possible use of 
SMALPs in further studies of family B GPCRs. This could allow the study of RAMP:GPCR 
interactions, the binding mechanisms of small molecule ligands and the different conformational 
changes upon ligand binding, and how they are regulated, in family B GPCRs compared to family 
A. SMALPs may be a useful platform for the detailed study of family B GPCRs, furthering the 
understanding of this therapeutically relevant family of GPCRs and potentially aiding in drug 
discovery and design. 
Another first presented here was the use of the SMA analogue SMI as a means to solubilise 
GPCRs, with retention of ligand binding capabilities, from mammalian cells. The positive charge 
imparted on the SMILP by the imide group prevented the interaction with AVP observed with 
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SMA. This presents the potential for SMI use as an alternative to SMA in situations where ionic 
interactions prevent the use of SMALP-GPCRs. Further research into this polymer needs to be 
performed, with optimisation of the SMILP-solubilisation technique required. Identification of 
whether SMI affects antibody binding will be required before immunoblotting techniques can be 
used to observe the efficiency of SMILP-solubilisation. However, there is potential for SMI to be 
used as a means to solubilise membrane proteins while displaying different characteristics to 
SMA. This may be of benefit to research and pharmaceutical industries when studying positively 
charged compounds that may interact with SMA. 
Presented here was the very first use of SMA to solubilise a GPCR from mammalian cells. 
SMALPs were able to extract several GPCRs from mammalian cells, with retention of ligand 
binding capabilities, from different GPCR subfamilies and with different ligand types. There was 
the first demonstration of the SMA analogue SMI also possessing the ability to solubilise GPCRs 
in a functional state. Finally, the development of a Cys-depleted A2aR construct will allow the 
study of SMALP-A2aR using fluorescence spectroscopy. Use of the SMALP and SMILP 
techniques as a detergent free method of GPCR solubilisation could lead to new, more specific 
drugs being identified and designed. This should make SMALP technology of great interest and 
use to the pharmaceutical industry. 
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